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Summary 
 
Antibiotics have been an effective weapon against bacterial infections for over 50 years. However, 
bacterial resistance towards conventional antibiotics has increased considerably within the last 
decades and the number of antibacterial agents available for treating complicated bacterial infections 
is becoming increasingly limited. In the search for alternatives therapies, antimicrobial peptides 
(AMPs) have received considerable attention since they target the bacterial Achilles’ heel i.e. their 
distinct membrane structure. These host defence molecules are ubiquitous in nature by forming part 
of the immune system among all classes of life. Several of these compounds have therefore been 
characterised and developed into future antibacterials. Furthermore, in an attempt to improve the 
antibacterial activity, synthetic analogues i.e. peptidomimetics have been designed based on the 
structural properties of natural AMPs. 
 
The purpose of this PhD study was to establish the potential correlation between structure and 
antibacterial activity for a series of α-peptides/β-peptoid peptidomimetics and additionally to 
determine if mechanistic differences could explain observed variations in activity. We determined 
the activity of the peptidomimetics against a range food borne and nosocomial pathogenic bacteria. 
These structure-activity studies demonstrated that peptide length was important for high antibacterial 
activity since analogues with a length shorter than 12 residues were virtually inactive. In the present 
design, with a 1:1 ratio between cationic α-amino acids and hydrophobic β-peptoids, amino acid 
composition and chirality in the β-peptoid unit only had a minor influence on antibacterial activity.    
 
By using an ATP leakage assay we determined that the mechanism of action of the chimeras was 
permeabilization or disruption of the bacterial cell membrane. The resulting changes to the cell 
surface were visualised with Scanning Electron Microscopy (SEM). Importantly, our leakage studies 
were performed with viable bacterial cells and using a concentration that was close to the Minimum 
Inhibitory Concentration (MIC). The findings show that all of the chimeras included in the study 
have a similar mechanism of action that was independent on bacterial species. However, the study 
showed that the detailed interaction with the cell membrane may be different, since there were large 
variations in the amount of leaked ATP and subsequent loss of viability. A series of three peptides 
differing only in length all caused ATP leakage but only the longest of the three caused complete 
depletion of intracellular ATP, which correlated with a substantial loss in the number of viable cells.  
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In a continuous selection protocol encompassing 500 generations, 10 out of 10 lineages of 
Escherichia coli developed resistance towards the chimera they had been exposed to. This was the 
first time resistance was successfully developed towards peptidomimetics, though several studies 
have reported resistance towards AMPs. Resistance was specific to compounds within the 
peptidomimetics library, since we were unable to demonstrate cross-resistance to other AMPs. We 
sequenced the entire genome of six highly resistant isolates from two separate lineages, and 
identified a single-nucleotide-polymorphism (SNP) in the gene encoding the MltD protein. This 
protein functions in the reorganization of the peptidoglycan layer, and we consider it likely that a 
change in this protein is the cause of resistance, since the SNP was found exclusively in isolates with 
high levels of resistance.  
Conversely, these resistant isolates displayed increased sensitivity towards human blood plasma 
possibly due to immune effector compounds present in this. The addition of 50 % blood plasma also 
increased the activity of the chimeras against wild type bacteria by up to 32 times. This effect was 
abolished by heat-treatment, which is a method known to inactivate the complement system.  
 
The findings in this thesis have elucidated how central structural determinants influence antibacterial 
activity. Peptidomimetics can be regarded as promising future antibiotics since the possibility to 
optimize their properties through structural modification allows for continuous variation. This thesis 
concludes that antibacterial activity can be improved further and that in the future resistance may be 
circumvented by optimizing the existing scaffold.  
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Resumé (in Danish) 
 
Antibiotika har været brugt til behandling af bakterieinfektioner gennem mere end 50 år. Bakterie-
resistens overfor konventionelle antibiotika er dog steget drastisk de seneste årtier, hvilket begrænser 
antallet af behandlingsmuligheder mod komplicerede bakterieinfektioner. I jagten på alternative 
antibakterielle stoffer har de antimikrobielle peptider (AMPer) fået meget opmærksomhed eftersom 
deres aktivitet er rettet mod bakteriernes akilleshæl dvs. deres særlige membranstruktur. Disse 
forsvarsstoffer findes overalt i det naturlige miljø, da de udgør en del af immunforsvaret hos alle 
livsformer. Adskillige af disse stoffer er derfor blevet karakteriseret og udviklet som fremtidens 
antibiotika. Derudover er syntetiske analoger, peptidomimetics, blevet designet ud fra strukturen af 
naturlige AMPer, hvilket giver mulighed for at forbedre den antibakterielle aktivitet.  
 
Formålet med dette ph.d. projekt var at etablere en sammenhæng mellem struktur og antibakteriel 
aktivitet i en række α-peptid/β-peptoid peptidomimetics, og derudover at klarlægge hvilke 
mekanismer, der kunne forklare eventuelle forskelle i aktivitet. Vi bestemte aktiviteten af disse 
peptidomimetics mod en række fødevarebårne og hospitals-erhvervede patogene bakterier. Dette 
studie af forholdet mellem struktur og aktivitet viste, at en vis peptid-længde var nødvendig for at 
opnå høj antibakteriel aktivitet, da analoger med en længde på mindre end 12 enheder var næsten 
ineffektive. I det indeværende design, hvor der er en 1:1 ratio mellem de kationiske α-aminosyrer og 
hydrofobiske β-peptoider, havde aminosyre-komposition og chiralitet i β-peptoid enheden kun ringe 
indflydelse på den antibakterielle aktivitet.  
 
Vi brugte et ATP lækage assay til at vise, at den antibakterielle aktivitet skyldtes permeabilisering 
eller ødelæggelse af bakteriens cellemembran. Dette forårsagede ændringer af celleoverfladen, som 
blev visualiseret gennem Skanning Elektron Mikroskopi (SEM). Det er vigtigt at understrege, at 
lækage studierne blev lavet med levende bakterier og at vi brugte en koncentration, som var tæt på 
den Minimum Inhibitoriske Koncentration (MIC). Vores undersøgelser viste, at alle analogerne har 
den samme virkningsmekanisme og at denne er uafhængig af bakterien. Resultaterne viste dog også, 
at den præcise interaktion med membranen kan variere eftersom der var store variationer i mængden 
af lækket ATP og det efterfølgende fald i antallet af levende celler. En serie på tre peptider, som kun 
varierede i længden, forårsagede alle ATP lækage, men kun den længste bevirkede, at cellen blev 
tømt for ATP. Dette korrelerede med et markant fald i antallet af levende celler. 
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Kontinuerlig selektion gennem 500 generationer resulterede i, at 10 ud af 10 linjer af Escherichia 
coli udviklede resistens mod den benyttede analog. Dette var det første bevis på udvikling af 
resistens mod peptidomimetics, selvom adskillige studier har vist, at AMP resistens kan udvikles. Vi 
anser resistensen for at være specifik for analogerne i indeværende peptid-bibliotek, da vi ikke fandt 
tilfælde af kryds-resistens til en række andre AMPer. Vi sekventerede hele genomet fra seks høj-
resistente isolater fra to forskellige linjer, og identificerede en enkeltmutation (SNP) i genet, der 
koder for MltD proteinet. Dette protein er involveret i reorganiseringen af peptidoglycan laget og 
eftersom denne mutation kun forekom i isolater, som var meget resistente, anser vi det for 
sandsynligt, at en ændring i dette protein er årsagen til resistens.  
Disse resistente isolater havde forøget sensitivitet overfor humant blodplasma, hvilket kunne skyldes 
tilstedeværelsen af innate effektormolekyler. Tilsætning af 50 % blodplasma forøgede samtidig 
aktiviteten af analogerne op til 32 gange. Denne effekt forsvandt efter varme-behandling, som er en 
metode, der benyttes til at inaktivere komplementsystemet.  
 
Arbejdet i denne afhandling har medvirket til en øget forståelse for hvordan centrale strukturelle 
egenskaber påvirker den antibakterielle aktivitet. Peptidomimetics kan betragtes som et godt bud på 
fremtidens antibiotika, fordi det er muligt at optimere deres egenskaber gennem ændringer i deres 
struktur, hvilket betyder uanede muligheder for variation. Denne afhandling konkluderer, at den 
antibakterielle aktivitet kan forbedres yderligere, og at fremtidig resistens måske kan afværges ved 
optimering af den nuværende design.  
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1. Introduction and scope of the PhD project 
 
Since the discovery of penicillin in 1928 and the market introduction a decade later, antibiotics has 
been part of the standard arsenal for treating infectious diseases. In the antibiotic era of the 40’s and 
50’s several novel classes of antibiotics were discovered. This gave hope for a future where all 
infections could be controlled. Indeed, today it is difficult to imagine infectious medicine where 
treatment with antibiotics is not an option. However, bacterial resistance to conventional antibiotics 
has increased considerably within the last decades (Agersø et al., 2010; Jensen et al., 2009). Thus, 
the number of antibacterial agents available for treating complicated bacterial infections is becoming 
increasingly limited. Particular problematic bacteria include Pseudomonas aeruginosa, methicillin-
resistant Staphylococcus aureus and extended-spectrum Lactamase (ESBL)-producing Escherichia 
coli and Klebsiella pneumoniae (Boucher et al., 2009). Importantly, the increased proportion of 
resistant isolates seems to be correlated with an increased consumption of “broad-spectrum” 
antibiotics (Jensen et al., 2009). Novel antibiotics are urgently needed but due to the large R&D 
expenses and modest gain (Projan, 2003), the pipeline of many pharmaceutical companies is 
unacceptably lean and very few novel antibiotic classes are marketed (Jabes, 2011) (Figure 1.1). 
 
 
Figure 1.1. Number of new systematic 
antibiotics approved by the FDA 
(United States) from 1983 through 
March 2011. From (Kuehn, 2011). 
 
Consequently, antibacterial drug development relies on modifying already existing drugs (Fischbach 
and Walsh, 2009), which may accelerate the development of resistance as the mechanism of action 
resembles that of the parent drug (Livermore, 2011). 
 
This has lead to an intensified search for alternative antibacterial therapies. Antimicrobial peptides 
(AMPs) constitute one of the most promising novel classes of novel antibacterial drugs (Yeung et al., 
2011). These compounds form part of the antimicrobial defence among all classes of life including 
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humans (Maroti et al., 2011), and has received considerable attention because they target the 
Achilles’ heel of bacteria i.e. their distinct membrane structure (Zasloff, 2002). Hence, immense 
effort has been put into characterising and developing these compounds into future therapeutics. 
Currently, the biggest obstacles for the AMPs to fulfil their therapeutic promise are poor 
pharmacokinetics due to their sensitivity to proteases, unknown in vivo toxicity profiles and high 
manufacturing cost associated with chemical synthesis (Hancock and Sahl, 2006). Additionally, the 
approval of AMPs for systemic use relies on their ability to show superior efficacy compared to 
conventional already marketed antibiotics, which trials up until now have failed to demonstrate.  
 
Synthetic modification of natural AMPs or mimicking their structural properties for developing 
novel antimicrobials constitute promising approaches for optimizing the activity while limiting the 
level of toxicity (Palermo and Kuroda, 2010). Indeed, new tools for rapid chemical synthesis has 
made it possible to assess the effect of small structural modifications in libraries of synthetic 
analogues i.e. peptidomimetics.  Consequently, structure-activity studies of a variety of 
peptidomimetics have been reported by several research groups.  
 
A library of such peptidomimetics were designed and synthesized by the Natural Products Research 
group at the Faculty of Pharmaceutical Sciences (now Health Sciences), University of Copenhagen. 
These compounds consist of alternating units of cationic α-amino acids and hydrophobic β-peptoids 
and possess structural properties similar to that of AMPs and other peptidomimetics. The α-
peptide/β-peptoid chimeras display limited hemolytic activity and are resistant towards proteases 
(Olsen et al., 2007). They are hence being characterised and optimised for future therapeutic use. 
This involves testing their activity on microbial biofilms (DTU Systems biology) and determining 
their activity in vivo using animal models (Statens Serum Institut). Additionally, these 
peptidomimetics have been investigated for their capabilities to assist in intracellular drug delivery. 
 
Novel peptidomimetics exhibit considerable antibacterial activity similar to natural AMPs, and it is 
hypothesized that it is possible to further improve this by structural modifications of the existing 
scaffold. The central purpose of this project has been to establish a possible correlation between 
peptidomimetic structure and antibacterial activity. Consequently, we hypothesized that substitutions 
with different types of α-amino acids or β-peptoids or modifications of peptide length would alter the 
activity against a range of food borne and nosocomial bacterial pathogens, since such modifications 
have been reported to alter the activity of other peptidomimetics. Most AMPs and peptidomimetics 
target the bacterial cell membrane leading to formation of pores, cell lysis and cell death. We 
Introduction 
3 
 
hypothesised that the same would be the case for the present peptidomimetics, and as an essential 
part of the characterisation, we therefore wanted to determine the mechanism of action of the most 
active compounds. Furthermore, since resistance to AMPs is considered unlikely or very difficult to 
select for, we were interested in investigating if this was also the case for the peptidomimetics. Here, 
it would be particular interesting to study if potential resistance would also confer resistance to other 
groups of AMPs and thereby potentially hamper the human innate immune defence.  
 
This thesis consists of an overview section and three papers. The overview section describes the 
nature of AMPs and the approaches for using their properties to develop novel antimicrobials i.e. 
peptidomimetics (Chapter 2). The overview also includes a review of the activity and mechanism of 
action of AMPs/peptidomimetics (Chapter 3) and describes the mechanisms bacteria have evolved 
circumvent these activities (Chapter 4). Finally, the potential effects the immune system may have on 
activity of these compounds in vivo will be described (Chapter 5). The experimental work and the 
results obtained during the PhD will be described in the three papers although selected results will 
also be covered in relevant chapters of the overview section. 
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2. Natural antimicrobial peptides and novel peptidomimetics 
 
Antimicrobial peptides (AMPs) have the potential for developing into future therapeutic agents for 
treatment of infections caused by human pathogenic bacteria. Hence understanding how, when and 
where they function has become of considerable interest. In the next chapters I will review how these 
compounds affect bacteria both in vivo and in vitro, and the mechanisms bacteria have developed to 
counteract the activities of AMPs. This chapter will give an introduction to antimicrobial peptides in 
nature, and the synthetic approaches for developing new compounds that mimic natural AMPSs i.e. 
peptidomimetics. Several different classes of peptidomimetics have been developed and the α-
peptide/β-peptoids chimeras that are the focus of this thesis constitute one of these groups. 
Accordingly, the library of peptidomimetics and how this was designed will be reviewed in detail.  
 
2.1. Cationic antimicrobial peptides 
Antimicrobial peptides (AMP) constitute a structurally diverse group of compounds. They are 
characterised by having a net negative (cationic) charge and an ability to assume an amphipathic 
structure enabling insertion into bacterial membranes (Chapter 3). As this does not demand a 
stringent organization of their sequence or structure, several diverse architectures have evolved 
(Giangaspero et al., 2001). The diversity in sequence and structure of natural AMPs will be reviewed 
in this section. Human AMPs will be covered in Chapter 5, where they will be discussed as part of 
their role in the innate immune defence in humans. 
 
2.1.1. The nature of antimicrobial peptides 
Cationic AMP are defined as peptides of less than 50 residues with a net positive charge, conferred 
by cationic amino acid residues, and a substantial portion (above 30 %) of hydrophobic residues 
(Hancock and Sahl, 2006). AMPs form part of the immune defence among all classes of life and are 
hence ubiquitous in nature (Maroti et al., 2011). Consequently, more than 1000 natural AMPs have 
been identified to date (Godballe et al., 2011; Wang et al., 2009). These fall into two classes: the 
non-ribosomally synthesized produced only by bacteria and the ribosomally synthesized produced by 
all species of life including bacteria (Hancock and Chapple, 1999). The former include among others 
the polymyxins and are made on multi-enzyme complexes formed by a series of peptide synthetases 
performing the peptide synthesis in an ordered fashion (Hancock and Sahl, 2006). Most AMPs are 
however transcribed from specific genes and synthesized on ribosomes (Zasloff, 2002). In 
invertebrates, AMPs serve as the primary defence against bacterial infections (McPhee et al., 2005), 
Natural antimicrobial peptides and novel peptidomimetics 
5 
 
whereas they in higher animals and plants constitute part of the generic defence response known as 
the innate immune system (Maroti et al., 2011). The expression profiles of genes encoding AMPs 
differ depending  on the organism: local or systemic, constitutive or induced by infectious or 
inflammatory stimuli (Andres, 2011). In the majority of cases the response is local as that produced 
by phagocytic cells and epithelium in animals (Chapter 5). However, intruding bacteria induce a 
systemic response in insects (Andres, 2011). The diversity of sequences is such that the same peptide 
sequence is rarely recovered from two different species (Zasloff, 2002). This suggests that each AMP 
have evolved to act optimally in the environment in which it is produced and against local 
microorganisms (Hancock and Chapple, 1999). Diversification of the AMP repertoire will enable the 
host to better cope with microbial challenges (Patil et al., 2004). Intriguingly, it has been proposed 
that bacterial resistance mechanisms (Chapter 4) direct and shape the diverse repertoire of AMPs 
(Peschel and Sahl, 2006). 
 
2.1.2. Peptide secondary structures 
Due to the large variations in amino acid sequence, AMPs are classified based on their secondary 
structure of which there are four main classes: β-sheet, α-helical, extended and loop peptides, with 
the first two classes being the most common in nature (Powers and Hancock, 2003) (Figure 2.1). 
 
 
Figure 2.1. Structural classes of antimicrobial peptides displayed by one representative AMP of each group: 
A) β-sheet, tachyplesin I; B) α-helical, magainin 2; C) extended, indolicidin; D) loop, thanatin. Disulfide 
bonds are indated in yellow. From (Powers and Hancock, 2003). 
 
Peptide structures are frequently determined when AMPs are interacting with model membranes or 
are in a membrane-mimetic environment (McPhee et al., 2005). The AMPs typically display 
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unordered structures in aqueous solutions (Friedrich et al., 1999; Javadpour et al., 1996). Methods 
for determining the structural characteristic of a given compound will be described in the next 
section. In addition to natural AMPs, a range of synthetic variants (peptidomimetics) have been 
produced which also fall into one of these structural classes (Powers and Hancock, 2003), with the 
large majority of these designed to form an α-helical structure.  
 
The α-helical peptides are the most abundant class of natural peptides. These peptides will upon 
interaction with target membranes fold into an amphipathic α-helix with one face of the helix 
predominantly containing the hydrophobic amino acids and the opposite face the charged amino 
acids (McPhee et al., 2005). Of note, though there within this group also is little conservatism in the 
amino acid sequence, there is a pronounced trend when it comes to the distribution of different types 
of residue i.e. charged, polar etc. (Tossi et al., 2000) (Figure 2.2). 
 
 
Figure 2.2. Helical wheel projection of 
the residue distribution in the 20 residue 
N-terminal stretch of 150 α-helical 
AMPs from natural sources. Residue 
numbers are indicated. The analysis 
indicates considerable positional 
conservatism in terms of residue type 
within the secondary structure of the 
helix. From (Tossi et al., 2000).  
 
β-sheet peptides are classified by the presence of an antiparallel β-sheet stabilized by two or more 
disulfide bonds (Powers and Hancock, 2003) (Figure 2.2a), and include among others the defensins 
of vertebrates, plant and insects (Andres, 2011). Other AMPs contain high proportions of certain 
amino acids such as tryptophan, histidine and proline (Hancock and Patrzykat, 2002). For instance 
the bovine indolicidin contain high amounts of tryptophan (Ando et al., 2010). Most of these 
peptides adopt extended structures upon interaction with the membrane and this is stabilized by 
hydrogen bonds and van der Waals forces with lipids rather than interresidue hydrogen bonds 
Natural antimicrobial peptides and novel peptidomimetics 
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(McPhee et al., 2005). Lastly, the structure of loop peptides is imparted by the presence of a single 
bond i.e. disulfide, amide or isopeptide (Powers and Hancock, 2003) (Figure 2.1d). 
 
2.2. Approaches for developing novel antimicrobial structures 
The potential of AMPs as therapeutic agents shows great promise with a variety of natural and 
synthetic compounds currently in development (Yeung et al., 2011). Novel AMPs can be developed 
in one of three ways; i) discovery and characterization of previously unknown natural AMPs, ii) 
synthetic optimization of natural AMP or iii) using the properties of natural AMPs as templates for 
designing synthetic AMPs i.e. peptidomimetics. In this section I will describe each of these 
approaches for gaining new compounds. The antibacterial activity of specific structures and the 
effect optimization may have on this will be covered in Chapter 3. 
 
2.2.1. Discovery and optimization of natural antimicrobial peptides 
Traditionally, novel antimicrobial compounds were isolated from natural sources (Livermore, 2011). 
This process frequently starts with confirmed biological activity e.g. direct inhibition of bacterial 
growth either using crude natural extracts or biological peptides libraries (Silva et al., 2011). 
Alternatively, organisms may be screened for secretory proteins using transposon assisted signal 
trapping (Mygind et al., 2005) or unknown cDNA sequences identified through amplification using 
specific primers as in the case of novel cathelicidins (Tossi et al., 1997a). Genome mining constitutes 
another promising tool for discovering novel antimicrobial compounds (Velasquez and van der 
Donk, 2011). The production of antimicrobial compounds is often an unstable trait e.g. due to 
regulatory systems making it difficult to define optimal growth conditions in screening systems (Nes 
and Johnsborg, 2004). The increasing availability of genome sequences and rapid developments in 
bioinformatics means that it is now possible to use in silico screening to identify novel members of 
antimicrobial compound groups (de Jong et al., 2010). This approach has been used for identification 
of antimicrobials from both prokaryotic (Begley et al., 2009; Wang et al., 2011b) and eukaryotic 
(Tian et al., 2010) sources. 
 
Primary antibacterial evaluation forms the starting point for precipitation, purification and structural 
characterisation of the potential compound (Silva et al., 2011). After the identification of promising 
compounds, lead candidates may be optimized to further increase their antibacterial activity or 
spectrum of activity. Peptide libraries containing millions of AMP variants are subjected to high-
throughput-screening (HTS) computational or in vitro-based methods for determining activity 
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(Blondelle and Lohner, 2000; Raventos et al., 2005; Silva et al., 2011). Alternatively, high-
throughput-synthesis on cellulose support membranes followed by screening against microbes 
expressing the luciferase gene cassette can elucidate effective amino acid substitutions of a parent 
peptide (Hilpert and Hancock, 2007). 
 
Several modified variants of natural AMPs are now in clinical development (Andres, 2011; 
Brandenburg et al., 2011). AMP congeners are chemical compounds that are closely related to each 
other in composition and prepared by relaxing the structure, replacing specific amino acids within 
the parent AMP sequence or truncating the N-terminus and/or the C-terminus ends of the parent 
peptide (Brogden and Brogden, 2011). Primary sequence modifications of natural AMPs are 
employed to increase the net charge, overall amphipathicity or improve their predicted folding 
patterns (Giangaspero et al., 2001; Kondejewski et al., 1996). For instance, variants based on the 
membranolytic protegrin I contained loop sequence related to the parent compound but was linked to 
a proline template which stabilized the β-hairpin conformation (Srinivas et al., 2010). 
 
Hybrid AMPs are constructed from the active regions of two or three natural AMPs to combine the 
benefits of each individual fragment (Brogden and Brogden, 2011). They are constructed through 
chemical synthesis or expressed as a fusion protein in a recombinant system (Jung et al., 2011). The 
cecropin-bee melittin hybrid peptide CEME contains the N-terminal domain of cecropin and the C-
terminal domain from melittin and has now additionally been further developed into amino acid-
replaced analogues (Friedrich et al., 1999). Similarly, chimeric peptides containing the N-terminal 
region of the human β-defensin 3 and the middle region of human β-defensin 2 were more potent 
than their parent peptides (Jung et al., 2011). Very recently, the design of hybrid peptides based on 
cecropin A, LL-37 and magainin II was described (Fox et al., 2012) (Figure 2.3). 
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Figure 2.3. Helical wheel models of a) cecropin A, b) LL-37, c) magainin II and two hybrid peptides d) CaLL 
(cecropin A residues 1-8 followed by LL-37 residues 17-29 and e) LLaMa (LL-37 residues 17-29 followed by 
magainin II residues 1-12). Residues coloured by type (hydrophobic, charged etc.). The predicted angle 
subtended by the positively charged residues on the formation of the α-helix is shown. From (Fox et al., 2012). 
 
For this, fragments of the parent peptides were selected if they made up the core helix structure 
and/or were responsible for antibacterial activity. Fragments were then combined in silico to 
determine which hybrid peptides would form the best amphipathic α-helixes. This yielded four 
hybrid peptides that were more potent than their parent peptides (Fox et al., 2012). 
 
Comparison and extraction of sequence patterns of natural AMPs is an alternative method for 
optimizing the antimicrobial activity. The most frequent amino acids in the first 20 position of 
natural α-helical AMPs have been determined (Figure 2.2). This sequence analogy reveals the 
distribution of residue types in the archetypal α-helical AMP and can thus be used to create a 
sequence template useful in guiding the design of novel peptides (Tossi et al., 1997b). 
 
2.2.2. De novo synthesis of peptidomimetics 
Several natural AMPs have been associated with high levels of toxicity and additionally these 
compounds may suffer from a variety of pharmacokinetic shortcomings including poor bio-
availability, low metabolic stability and formulation difficulties (Findlay et al., 2010). A variety of 
novel and structurally diverse cationic compounds that mimic the amphiphilic topology have been 
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developed to overcome these problems, the classes of which will be reviewed in the next section. 
Chemical synthesis is the main method for production of peptidomimetics though it is a both time-
consuming and costly process particularly for longer peptides (Silva et al., 2011).  
Peptidomimetics are created by using solid-phase peptide synthesis (SPPS), where the molecule is 
bound to a resin bead and synthesized in a step-by-step process by adding reagents in a consecutive 
fashion. As a standard Fmoc (fluorenylmethoxy-carbonyl) active ester chemistry is applied (Fields 
and Noble, 1990). Due to the complexity of these reactions it will not be reviewed in detail here; for 
details of the chemical reactions involved in synthesizing the α-peptide/β-peptoid chimera I refer to 
Olsen et.al (2007). In short, the C-terminal Fmoc amino acid (or in the case of the chimeras, a 
peptide/peptoid dimer) is attached to the resin bead (Chou et al., 2008; Olsen et al., 2007). Thereafter 
Fmoc building blocks are attached in a consecutive manner to the growing chain for the number of 
cycles needed to obtain the desired length. After synthesis is complete the compound is cleaved from 
the resin bead and Fmoc removed from the N-terminal amino acid (Radzishevsky et al., 2008).  
A variant of solid-phase synthesis enables mixtures of compounds to be synthesized in separate 
groups each being defined by individual residues or building blocks at one or more given positions 
(Blondelle et al., 1996). This form of semi-random synthesis creates synthetic combinatorial 
libraries, which subsequently can be screened for inhibitory activity. 
 
2.2.3. Purification and structural characterisation 
After synthesis samples are purified using reversed-phase high-performance liquid chromatography 
(RP-HPLC) and subjected to matrix-assisted laser desorption ionization (MALDI) mass spectroscopy 
to verify correct mass (da Silva et al., 2008; Junkes et al., 2011; Park et al., 2011; Yeaman et al., 
2002).  
 
HPLC is used to purify the finished product from by-products giving final products that are > 95 % 
pure (Dathe et al., 2001; Olsen et al., 2007; Wu et al., 1999). The compounds are separated based on 
their affinity for a stationary hydrophobic phase and a mobile polar phase, respectively (Schmitt et 
al., 2007). Retention times indicate how strongly the compound will interact with the hydrophobic 
phase, and will be unique for each compound based on its structural and chemical properties 
(Blondelle and Houghten, 1992). HPLC may also be used analytically to determine if the specific 
compound can be degraded by proteolytic enzymes (Porter et al., 2002; Schmitt et al., 2007). where 
compound cleavage will be evident as extra peaks in the chromatogram (Schmitt et al., 2007). 
Peptoids are protease resistant compared to their homologous peptide counterparts (Rotem and Mor, 
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2009). The chimeras used in this thesis are resistant to enzyme degradation, which is believed to be 
due to the inclusion of this unit (Olsen et al., 2007). 
 
The secondary structure of peptidomimetics, which is induced when the compound binds to the 
hydrophobic stationary phase, may influence the retention time (Blondelle and Houghten, 1992). 
Hence, the level of amphipathicity (segregation of hydrophilic and hydrophobic residues) may be 
determined using HPLC (Chen et al., 2005b; Schmitt et al., 2007) (Figure 2.4). 
 
 
Figure 2.4. Overlay of HPLC 
traces for a series of nine peptides 
with different conformations.  The 
longest retention times were seen 
for compounds that adopt a 
globally amphipathic helical 
structure and are extremely 
hemolytic. From (Schmitt et al., 
2007). 
 
A preliminary indication of peptide secondary structure is obtained from analysis of a circular 
dichroism spectrum (CD). In order to predict the structure both outside and within the cytoplasmic 
membrane the analysis is commonly performed in both a hydrophilic and a hydrophobic 
environment (Chen et al., 2005b). The pattern for α-helical peptides is very distinctive since these 
produce large negative bands at ~222 nm and ~208 nm and a large positive band at ~193 nm (Azad 
et al., 2011) (Figure 2.5a). CD spectra of some of the early α-peptide/β-peptoid chimeras revealed 
that lack of chirality (see next section) leads to a lower degree of secondary structure in these 
compounds (Olsen et al., 2007) (Figure 2.5b).   
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Figure 2.5. Peptide CD spectra: a) CD spectra of a series of CEME analogues in the presence of liposomes 
or buffer (dashes, random coil); all peptides except one (solid line, random coil) had the characteristic 
spectrum of α-helixes (Friedrich et al., 1999), b) CD spectra of a series of α-peptide/β-peptoid chimeras; a 
substantial drop was seen in the ellipicity amplitudes at 219nm for peptides 15-17 which had a non-chiral β-
peptoid unit. This indicates a lower degree of secondary structure for these compounds (Olsen et al., 2007). 
 
An amphipathic helical conformation is not expected for the chimeras since these have a design of 
alternating hydrophobic and cationic residues, though it is likely, based on the CD spectrum and 
antibacterial activity, that these compounds have another type of amphipathic conformation. 
Though CD spectroscopy is often used to elucidate the peptide secondary structure, it may not 
always be accurate since two peptides expected to differ in secondary can actually have a similar CD 
spectrum (Glattli et al., 2002). Alternative and more accurate methods for determining structure are 
crystallography or nuclear magnetic resonance (NMR) (Hicks et al., 2007; Mandal et al., 2009; Yu et 
al., 2002), which also makes it possible to define the peptid tertiary structure. 
 
2.3. Classes of antibacterial peptidomimetics 
Mimics of natural AMPs are collectively called peptidomimetics (Godballe et al., 2011). These 
mimics are often based on a different backbone i.e. they are not solely based on α-amino acids 
(Rotem and Mor, 2009). These modifications often render the compounds protease-resistant and 
additionally they may have improved bioavailability compared to peptide analogues (Patch and 
Barron, 2002). All peptidomimetics are modelled after the structural requirements known to be 
important for antibacterial activity (section 3.3.3), and hence all contain elements of positively 
charged and hydrophobic residues resulting in a compound with amphipathic properties (Godballe et 
Natural antimicrobial peptides and novel peptidomimetics 
13 
 
al., 2011). In this section I will outline selected representative classes of peptidomimetics, which 
have received increased focus over the last decade (Figure 2.6). 
 
 
Figure 2.6. Selected types of antimicrobial peptidomimetics. a) oligo acyl lysines (OAKs) (Findlay et al., 
2010; Radzishevsky et al., 2007); b) β-peptides (Porter et al., 2002); c) peptoids (Patch and Barron, 2003). 
 
Oligo acyl lysines (Figure 2.6a) were designed by Mor’s group and are composed of repeats of an 
acyl (fatty acid) chain of variable length and a charged amino acid i.e. lysine (Radzishevsky et al., 
2007). Hence, it is possible to dissect the relative roles of charge and hydrophobicity by modifying 
the number of lysine-acyl subunits and the acyl length, respectively (Radzishevsky et al., 2008). 
Interestingly, this design prevents the formation of stable secondary structures because of the 
rotational freedom of the carbon atoms in the acyl chain (Rotem and Mor, 2009). Conversely, these 
compounds tend to aggregate thereby organizing themselves into a stable amphipathic supra-
molecular structure (Radzishevsky et al., 2008). 
 
In nature, most peptides are composed of α-amino acids and hence β-peptides containing an extra 
methylene group (Figure 2.7) are rare (Godballe et al., 2011). Because of this extra methylene group 
they are not recognised by traditional proteases and are therefore intrinsically resistant to enzymatic 
degradation (Porter et al., 2002). In fact, a design of alternating α- and β-amino acids also increase 
proteolytic stability (Schmitt et al., 2007), thereby making peptidomimetics containing β-amino acids 
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promising antibacterial candidates. These compounds adopt helical structures with greater 
conformational freedom than α-peptides because of the additional methylene unit present in the 
backbone (Porter et al., 2002). Consequently, whereas sequences of natural α-peptides most 
commonly adopt an α-helix conformation, β-peptides sequences adopt distinct helical conformations 
(Patch and Barron, 2002). Several groups have designed β-peptides that adopt different helical 
conformations. The example given in Figure 2.6b is by Gellman’s group, which includes an intra-
residue five-membered ring which restrict the conformational freedom compared to other β-peptides 
(Porter et al., 2002). Analogues differ in their number of cationic and hydrophobic residues and in 
the predicted distribution of positive charges around the helix i.e. scrambled (Porter et al., 2002). 
 
Incorporating unnatural D-amino acids into the peptide structure is an alternative approach for 
increasing resistance towards proteolysis (Hancock and Sahl, 2006). In nature, most peptides are 
composed of L-amino acids, and peptides containing D-amino acids (i.e. the mirror image of L-amino 
acids) are rare (Papo et al., 2002). Hence, incorporation of D-amino acids could lead to lack of 
protease sequence recognition. Replacing natural amino acids with D-amino acid disrupts the 
structure of α-helical peptides (Chen et al., 2005b), and this may also abolish the cytotoxic effects on 
mammalian cells (Vooturi and Firestine, 2010). However, if peptide activity does not depend on the 
stereospecific recognition of a cellular target (Fehlbaum et al., 1996), activity is retained (Merrifield 
et al., 1995). Since most peptide target the bacterial membrane, D-peptides analogues will generally 
be as active as L-peptides (Tossi et al., 2000). 
 
Peptoids share the same structure as amino acids, with the exception that the side chain has been 
removed from the α-carbon to the amide nitrogen (Findlay et al., 2010) (Figure 2.7). Oligomers of 
these building blocks are called α-peptoids. The backbone structure renders the compound protease 
resistant (Vooturi and Firestine, 2010), and decreases the level of hemolysis (Patch and Barron, 
2003). Peptoids are unable to form intra-molecular hydrogen bonds that help to stabilizes α-helical 
and β-sheet structures, but incorporation of bulky aromatic side chains can lead to the formation of 
helices (Wu et al., 2001). This knowledge leads to the formation of a library of ampeptoids 
(antimicrobial peptide oligomers) with peptoid analogous composed of both charged and 
hydrophobic peptoid monomers (Chongsiriwatana et al., 2008) (Figure 2.6c). As for other 
peptidomimetics the design is modified by changing the number of cationic and hydrophobic 
residues or by increasing the number of subunits (Figure 2.6c). 
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Inspired by the heterogeneous backbone structures of α/β-peptides (Schmitt et al., 2004) and the 
structural features of peptoids, the present α-peptide/β-peptoid chimeras were developed (Olsen et 
al., 2007). β-peptoids combine the structural features of β-peptides and peptoids, and hence add to 
the existing repertoire of peptidomimetics (Bonke et al., 2008) (Figure 2.7). 
 
Figure 2.7. Backbone 
structures of natural α-
peptides and novel 
peptidomimetic residues. 
From (Olsen et al., 2007). 
 
 
Dimeric building blocks composed of β-peptoid units and amino acid moieties were designed for use 
in SPPS (Olsen et al., 2007). The advantage of novel heteromers over homomers composed only of 
β-peptoids is the possibility of diversification of side-chains functionalities via inclusion of various 
commercially available α-amino acids (Bonke et al., 2008). Lysine and homoarginine have been used 
as the α-amino acid residues in most of the chimeras; the use of homoarginine over arginine makes it 
possible to construct both homoarginine and lysine containing building blocks using the same 
intermediate. The structure of guanidino-group containing amino acids such as arginine facilitate 
stronger interaction with the bacterial membrane (section 3.3.3) compared to amino-group containing 
amino acids (e.g. lysine). Additional diversity can be created by using a combination of the two types 
of amino acids (Chimeras 45-49, Figure 2.8). For the β-peptoid residues a chiral and a non-chiral 
residue have been designed (Figure 2.8). These form the hydrophobic part of the chimeras. The six 
chimeras that have been used for the experimental work in this thesis are given in Figure 2.8. 
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Figure 2.8. Chemical structures of the six α-peptide/β-peptoid chimeras that have been the primary focus of 
this thesis. The structures of compounds 30 and 34 include a homoarginine residue, whereas compound 36 
have lysine as the α-amino acid. Chimeras 34 and 36, as well as 45-49, contain a chiral β-peptoid, whereas 
the β-peptoid in 30 is non-chiral. Additionally, length varies in chimeras 45-49. Modified from Paper I. 
 
Also, it is possible modify length by increasing the number of subunits (chimeras 45-49) though the 
maximally feasible limit to this is around 16 residues. Lastly, chimeras with a palmitoyl end group 
and fluorescent-coupled oligomers has been synthesized. The peptidomimetic library now comprises 
close to 100 α-peptide/β-peptoid chimeras, and hence allows for ample investigation of the effect 
structural modifications may have on activity.  
 
2.4. Conclusions from chapter 2 
Antimicrobial peptides (AMPs) are defined as peptides less than 50 residues in length with a net 
positive charge and a substantial portion of hydrophobic residues. Natural AMPs are a diverse group 
of compounds and due to large variations in amino acid sequence they are often classified based on 
their secondary structures i.e. α-helical, β-sheet, extended or loop. Several novel antibacterial 
structures have been developed by optimizing natural AMPs or by using the properties of natural 
AMPs as templates i.e. peptidomimetics. The latter is prepared using solid-phase synthesis and the 
level of secondary structure elucidated using circular dichroism. The present chimeras contain 
cationic α-amino acids and hydrophobic β-peptoids, and small modifications in the type and/or 
number of residues has resulted in the development of a peptidomimetic library.  
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3. Activity and mechanism of action of antimicrobial peptides 
 
The immense diversity of natural antimicrobial peptides (AMPs) and peptidomimetics have led to a 
vast number of structure-activity studies in an effort to elucidate their mechanisms of action (MoA). 
Though a few comprehensive studies have revealed the exact activity of selected AMPs, the 
complexity of the AMP-bacteria interaction means that it can be difficult to elucidate the detailed 
mechanisms behind the activity of natural AMPs or mimetics thereof (Hale and Hancock, 2007). In 
this chapter I will first define some commonly used terms and concepts for determining AMP 
activity before I review the MoA of natural AMPs and peptidomimetics. Particular focus will be on 
the structural determinants of peptidomimetic activity and how this relates to their interaction with 
the bacterial membrane. Finally, I will describe the parameters essential for high selectivity towards 
prokaryotic membranes whereby damage of eukaryotic cells is prevented.   
 
3.1. Spectrum of activity of antimicrobial peptides and peptidomimetics 
Most AMPs have a wide spectrum of antimicrobial activity. Hence, though studies often focus on 
their antibacterial properties, some are also effective against pathogenic fungi (Fehlbaum et al., 1996; 
Ryge et al., 2008) or possess anti-viral activities (Hancock and Rozek, 2002). Additionally, natural 
AMPs also have immune-modulatory actions and can thus enhance the host defence against 
pathogens as reviewed by others (Brown and Hancock, 2006). Therefore, synthetic AMPs though 
designed for optimal antimicrobial activity may also possess such activities (Easton et al., 2009). The 
immune-modulatory properties of AMPs will not be covered in this thesis, however, it is interesting 
that the immune-modulatory and antibacterial activity of natural AMPs is associated with different 
structural moieties of the parent molecule (Braff et al., 2005; Jung et al., 2011).  
 
Determination of the Minimum Inhibitory Concentration (MIC) is considered the “golden standard” 
for assessing the activity of an antimicrobial drug (Andrews, 2001). The MIC is defined as the lowest 
concentration of a given compound that inhibits visible growth of bacteria after overnight incubation. 
In addition, determination of the Minimum Bactericidal Concentration (MBC), the concentration that 
kills an arbitrary 99.9 % of bacteria, is a useful measure (Pearson et al., 1980). It follows from this 
that if the MIC=MBC then a compound has a bactericidal effect, whereas if MBC>MIC then a 
compound is bacteriostatic i.e. at MIC it only inhibits. Since AMPs predominantly target the 
bacterial plasma membrane, the majority of them are bactericidal. The MIC value of natural AMPs is 
typically in the range of 1-10 µg/mL, which is somewhat lower than the very high in vitro activities 
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seen for the smaller conventional antibiotics (Hancock, 1997b; Maloy and Kari, 1995; Piers et al., 
1994). Due to large differences in the size of the antimicrobial molecule (Chapter 2) it is better to 
express activity in µmol/L units instead µg/mL (Paper I), but unfortunately this is neglected in most 
structure-activity studies. Hence, when the activity of AMPs is expressed in molar terms it becomes 
closer to that of conventional antibiotics (Hancock and Patrzykat, 2002). 
 
AMPs have been described as “dirty drugs” that disturb many bacterial functions with low potency 
rather than having a single high-affinity target (Peschel and Sahl, 2006), which is especially apparent 
at very low concentrations (section 3.5). However, in general the mechanisms behind the activity of 
AMPs can be divided into two functional classes; membrane-active and non-membrane-active (Hale 
and Hancock, 2007). Several models have been proposed for explaining the AMP MoA (section 
3.3.1), and summarized in the Shai-Matsuzaki-Huang model (Zasloff, 2002) named after the authors 
of three different models (Figure 3.1).  
 
 
Figure 3.1. The Shai-Matsuzaki-Huang model of AMP activity. The model proposes the interaction of 
AMP with the membrane, followed by displacement of lipids, alterations of membrane structure, and in 
some cases internalisation. This model is based on individual models that propose non-receptor mediated 
AMP-lipid interactions (for details of these models see section 3.1.1). From (Zasloff, 2002). 
 
Some AMPs are active against both Gram-positive and –negative bacteria, as we saw with our 
peptidomimetics (Paper I), or only active against one group (Fehlbaum et al., 1996; Giangaspero et 
al., 2001). There are some controversies as to which bacterial group the AMPs are most effective 
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against (Epand et al., 2010; Hancock and Rozek, 2002), however it appears that the more hydrophil 
(polar) an AMP is the more ineffective it will be against Gram-negative bacteria (Epand et al., 2010). 
The AMP MoA is generally similar in Gram-positive and –negative bacteria, but as explained in the 
subsequent sections the precise interaction will vary due to differences in the outer cell layers 
(teichoic acids vs. LPS). Indeed, gram-selectivity appears to be primarily influenced by the initial 
interaction between the AMP and the outer cell surface, which has been extensively studied for 
peptidomimetics (Dathe et al., 1997; Giangaspero et al., 2001).  
 
The design of peptidomimetics is based on the optimization of the structural properties (i.e. 
hydrophobicity, charge, secondary structure etc.) of natural AMPs that favour interaction with 
bacterial cell membranes. Hence, since they are designed for optimal membrane interaction, the cell 
membrane is their primary target (Godballe et al., 2011; Palermo and Kuroda, 2010), though they 
may also display other activities at lower concentrations (Hong et al., 2003). Semi-synthetic AMPs 
i.e. optimized variants of natural AMPs (Chapter 2), will predominantly exert the same mechanism 
as its parent peptide with most of the studied cases being membrane-active (Dathe et al., 2001; 
Kasetty et al., 2011; Maloy and Kari, 1995). One interesting exception from this is a series of 
protegrin peptidomimetics, which has a different target than the membrane-active parent peptide 
(Srinivas et al., 2010). I will use the phrases “natural AMPs and peptidomimetics” when discerning 
the differences in their mechanism of action, but otherwise continue to use the term “AMP” to cover 
both natural and synthetic AMPs. 
 
3.2. Initial peptide interaction with the bacterial cell surface 
Irrespective of which of the two functional  classes a given compound belongs to, the initial 
interaction of a AMPs with a bacterial cell happens through similar mechanisms (Hale and Hancock, 
2007). The cationic AMPs are first attracted to the negative charge of the bacterial cell surface, 
which  in Gram-negative bacteria is due to the lipopolysaccharide (LPS) layer and in Gram-positive 
the presence of teichoic acids  and carboxyl groups in the multilayered peptidoglycan that they have 
to traverse (Tossi et al., 2000). Some AMPs effectively bind and neutralize LPS (endotoxin) 
(Chapple et al., 1998; Junkes et al., 2011; Piers et al., 1994; Wu and Hancock, 1999) or teichoic 
acids (Scott et al., 1999a), potentially making these compound useful to prevent bacterial sepsis and 
inflammation caused by both Gram-positive and –negative bacteria (Brandenburg et al., 2011).  
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The process by which AMPs gain entry to the plasma membrane has been more extensively studied 
for Gram-negative bacteria due to the focus on the barrier properties of the outer membrane (Powers 
and Hancock, 2003). The outer membrane of Gram-negative bacteria is asymmetric with the inner 
leaflet composed of phospholipids and the outer leaflet composed of the polyanionic glycolipid LPS 
(Hancock, 1997c). The negative charges of LPS are due to phosphates and acidic sugars, which are 
bridged by divalent cations that partially neutralize the negative charge and stabilize the outer 
membrane (McPhee et al., 2005). After being attracted to Gram-negative bacteria, AMPs are 
subsequently taken up by the self-promoted uptake pathway (Hancock, 1997b). The initial 
association with the bacterial membrane occurs through electrostatic interaction between the AMP 
and the anionic LPS in the outer membrane (Powers and Hancock, 2003). Because cationic AMPs 
have affinities for LPS that are at least three orders of magnitude higher than those for the native 
cations Ca2+ and Mg2+, they competitively replace these ions and, being bulky, disrupt the normal 
barrier property of the outer membrane (Hancock and Chapple, 1999). Hence, the lower activity of 
AMP often seen in high salt containing media or in the presence of divalent cations is a direct 
consequence of enhanced competition for LPS binding sites  (Friedrich et al., 1999; Sanchez-Gomez 
et al., 2008). AMP binding to LPS means that the affected membrane area becomes destabilized and 
develops transient cracks, which permits passage of a variety of small hydrophobic compounds and 
small proteins including the AMPs itself hence the term self-promoted uptake (Hancock, 1997b) 
(Figure 3.2).  
 
 
Figure 3.2. Self-promoted uptake of 
AMPs across the outer membrane of 
Gram-negative bacteria. Antibiotic 
entry is mediated through the water-
filled channels formed by porins. From 
(Hancock, 1997b). 
 
The ability of AMPs to disrupt the barrier function of the outer membrane, also explain their ability 
to increase the activity (i.e. entry) of conventional antibiotics (Cassone and Otvos, Jr., 2010). It has 
been proposed that some AMPs are Gram-positive selective because they are unable to assess or 
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utilize the self-promoted uptake pathway needed for Gram-negative activity (Hancock, 1997b). 
However, some AMPs with lower affinities for LPS binding are still effective permeabilizers and 
hence these may permeabilize by a distinguishable method involving neutralization of a patch of the 
outer membrane, thereby creating the cracks needed for entry (Hancock and Chapple, 1999). In line 
with this, it was intriguingly proposed that bacterial aggregation of Gram-negative bacteria following 
treatment with the non-membrane active insect AMP thanatin, was due to reduced LPS surface 
charge following AMP binding which thus reduced the electrostatic repulsion between bacteria 
allowing aggregation (Fehlbaum et al., 1996).  
 
Binding to LPS is required for Gram-negative activity, but disruption of this is not believed to be the 
direct cause of lethality since the cells can remain viable even after the outer membrane is removed 
(i.e. as in the case of spheroblasts) (McPhee et al., 2005; Scott et al., 1999b). Interestingly, 
transmission electron microscopy revealed visible detachment of the outer membrane from the inner 
cytoplasmic membrane following treatment of Escherichia coli with lactoferrin (Chapple et al., 
1998). Very recently, an outer membrane protein Lpp of the Enterobactericeae family was identified 
as an alternative binding site for AMPs leading to internalization of the Lpp-AMP complex and 
hence suggesting that LPS binding may not be the universal first step in AMP MoA (Chang et al., 
2012).   
 
The importance of the outer membrane in mediating AMP activity is made obvious in studies using 
bacterial strains that are outer-membrane deficient or LPS mutant strains that lack different LPS 
moieties (Junkes et al., 2011). In fact, removal of even single moieties of LPS resulted in a drastic 
reduction in the activity of cyclic peptidomimetics, suggesting that LPS interaction is a prerequisite 
for the self-promoted uptake pathway (Junkes et al., 2011). The outer membrane permeability can be 
assessed using a hydrophobic probe that is excluded by an intact outer membrane, but fluoresces 
strongly when it enters the membrane due to AMP disintegration of the outer membrane (Wu and 
Hancock, 1999). In contrast, the activity of AMPs can be increased by the addition of EDTA (a 
strong permeabilizer of the outer membrane due to cation chelation) (Epand et al., 2010; 
Kondejewski et al., 1996), which was also the case for our peptidomimetics (Figure 3.3.). 
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Figure 3.3. Effect of EDTA pre-treatment on 
the killing activity of one of the α-peptide/β-
peptoid chimeras. Staphylococcus aureus 
(black) and E.coli (grey) treated with EDTA 
(solid), chimera (punctuated) or EDTA+ 
chimera (dotted). Unpublished results. 
 
 
Disruption of the outer membrane will increase the amount of AMP/peptidomimetic that reaches the 
plasma membrane. The cell wall of Gram-positive bacteria will not be disrupted by EDTA treatment, 
and the activity against this group will therefore unaffected by this (Figure 3.3). 
 
The thick cell wall of Gram-positive bacteria is composed of peptidoglycan embedded with polymers 
of alternating phosphate and alditol groups called teichoic acids (Peschel and Collins, 2001), that 
AMPs have to traverse before they can interact with the plasma membrane (Brogden, 2005). No 
model has been proposed for how AMPs traverse this layer, only that after attraction to the Gram-
positive bacterium, the resulting interionic forces simply facilitate AMP accumulation in the cell wall 
(Peschel and Collins, 2001). In contrast to the requirement for LPS binding in utilizing the self-
promoted uptake pathway need for Gram-negative activity, binding to teichoic acid does not 
correlate with the ability of AMPs to kill bacteria, indicating that AMPs use this mechanism to 
contact other targets (Brogden, 2005; Scott et al., 1999a). However, lantibiotics such as nisin use 
lipid II, the fatty acid anchor for the growing peptidoglycan chain, as a docking molecule from which 
it can diffuse into the cell membrane (Brotz et al., 1998; Sahl et al., 2005). The self-promoted uptake 
pathway of Gram-negatives allow quicker access to the cell membrane and hence activity is often 
higher and killing kinetics more rapid than for Gram-positive bacteria which rely on diffusion after 
initial interaction (Giangaspero et al., 2001; Hancock and Rozek, 2002).   
 
3.3. Mechanism of action of membrane-active antimicrobial peptides 
When reaching the plasma membrane the mechanisms of membrane-active and non-membrane 
AMPs diverge (Powers and Hancock, 2003). Though both functional groups will have to interact 
with the plasma membrane to exert their activity only the membrane interaction of membrane-active 
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AMPs leads to loss of bacterial cell viability. From the sequence alone, it can be difficult to predict 
the activity and MoA of a natural AMP (Hancock and Chapple, 1999). The variation in charge and 
hydrophobicity of peptidomimetics makes it possible to predict the interaction with the membrane by 
slightly modifying these parameters (Palermo and Kuroda, 2010). Because of the complexity of 
AMP-membrane interaction, several theoretic models have been proposed, some more controversial 
and others easily accepted, and since these are the foundation of most studies of membrane-active 
AMPs, these will be reviewed first.   
 
3.3.1. Models for membrane interaction 
At the cytoplasmic membrane, the cationic AMPs interact with the negatively charged groups of the 
external leaflet of phospholipids. It is generally accepted that an amphipathic conformation of the 
AMP is required for insertion into the membrane, where the hydrophilic face interacts with the 
phospholipid head groups whereas the hydrophobic face is inserted into the bilayer core (Jenssen et 
al., 2006; Rotem and Mor, 2009). Various models have been proposed for explaining the 
mechanisms behind the resulting damage to the membrane architecture (Figure 3.4). 
 
 
Figure 3.4. Models for AMP-membrane interaction: a) barrel-stave, b) carpet, c) toroidal pore and d) 
aggregate. Modified from (Melo et al., 2009). 
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The first model that was proposed was the barrel-stave model (Figure 3.4a). It has been used to 
interpret the voltage dependent ion-permeable channels in planar lipid bilayer membranes that are 
extremely heterogeneous in size and lifetime (Kordel et al., 1988). In this model the peptides forms 
the staves of the barrel-like pore in which the number of peptides in the pore will determine the size 
(and conductance) of the channel (Wu et al., 1999). This is followed by the progressive recruitment 
of additional monomers to increase pore size and stability (Hancock and Chapple, 1999). Following 
the attraction to the plasma membrane, the AMPs will, at a critical peptide:lipid ratio, reorient 
themselves perpendicular to the lipid bilayer, which they are believed to span (Hale and Hancock, 
2007). The hydrophobic side chains will then face the hydrophobic membrane core, whereas the 
hydrophilic side chains face towards the hydrophilic core that span the width of the membrane. The 
critique of this model points to fact that pores would be too  irregular in size and duration and that 
AMPs too short to be able to cover the width of the membrane are still able to form pores  (Wu et al., 
1999). 
 
The detergent-like properties of some AMPs have been explained using the carpet model (Figure 
3.4b) (Shai, 1995). In this model peptides saturate the surface of the cytoplasmic membrane before 
causing a complete detergent-like disruption of the membrane (Hancock and Chapple, 1999). A 
distinct feature of this model is that no pores are formed but rather that the membrane integrity is 
completely disrupted. It has been disputed due to the fact that though certain peptides completely 
depolarize the membrane at their MIC, they also cause partial collapse of their membrane potential at 
concentrations below the MIC (Wu et al., 1999). This contradicts the carpet model which suggests 
that a certain threshold concentration is needed before the membrane is destroyed (Brogden, 2005). 
Additionally, though membrane dissolution will happen for most AMPs at very high concentration it 
there is limited evidence that this will happen at the minimal effective concentration (Jenssen et al., 
2006). 
 
In the toroidal pore model (Figure 3.4c) insertion of AMPs into the membrane is envisioned to 
induce lipids to bend around peptide aggregates until a continuous channel between the outer and 
inner leaflet is formed lined by both peptide and lipid head groups (Ludtke et al., 1996). This model 
differ from the barrel-stave model in that the peptide remains associated with the lipid head groups 
(Hale and Hancock, 2007). The aggregate model (Figure 3.4d) (Matsuzaki et al., 1996) have some 
reassemblies with toroidal pore model (Jenssen et al., 2006). This model is used for explaining how 
cationic AMPs can kill through both membrane permeabilization and internal target attack (Hale and 
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Hancock, 2007). In this model local aggregation of varied number of peptide molecules within the 
membrane provides a transient passage for irons and internalisation of AMPs (Wu et al., 1999).  
 
It is important to recognize that all of these models may be valid under different conditions and for 
different structural groups of AMPs (Jenssen et al., 2006). Indeed, the existence of all of these 
proposed models have been demonstrated (Table 3.1)   
 
Table 3.1. Proposed models for the membrane activity of selected natural AMPs and peptidomimetics 
Mechanism of membrane action Compound Reference 
Barrel-stave Almethicin (Bechinger, 1999) 
Carpet Melittin diastereomers (Oren and Shai, 1997) 
 α-helical peptides (Giangaspero et al., 2001) 
 Peptidomimetic (Yu et al., 2009) 
Toroidal Peptidomimetic (Azad et al., 2011) 
 Magainin (Ludtke et al., 1996) 
 LL-37 (Lee et al., 2011) 
 Protegrin (Yamaguchi et al., 2002) 
 Melittin (Yang et al., 2001) 
Aggregate Indolcidin (Wu et al., 1999) 
 Mastoparan X (Matsuzaki et al., 1996) 
 
Naturally, all of the above models require some kind of threshold concentration before membrane 
activity can be measured (Melo et al., 2009) for example in leakage or membrane depolarisation 
studies (section 3.3.4). Hence, it is proposed that AMPs have two distinct physical states of binding 
to lipid bilayers (Huang, 2000; Yang et al., 2001); at low peptide:lipid ratios the AMP adsorb in the 
lipid head group region in a functionally inactive state. When a threshold value is reached the AMPs 
forms a pore that is lethal to the cell. The threshold value is determined by both the lipid composition 
of the membrane, which varies between bacterial species, and the secondary structure of the AMP 
(Huang, 2000). Such variations in the interaction between membranes of different lipid compositions 
and different structural groups of AMP may explain the validity of the various models.  
 
3.3.2. Mechanisms of membrane-active natural antimicrobial peptides 
The interaction between natural peptides and the bacterial membrane has been investigated in several 
studies. The least common model is the barrel-stave, which is considered unique for alamethicin (a 
fungal peptide with a large proportion of hydrophobic residues) (Bechinger, 1999). When in contact 
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with lipid membranes it adopts an α-helical configuration, where after the hydrophobic regions align 
with the lipid core region of the bilayer and the hydrophilic regions form the interior of the pore 
(Brogden, 2005). Analysis of multi-channel kinetics using patch-clamp techniques have revealed 
rapid and pronounced conductance fluctuations (Bechinger, 1999) as also proposed in the model.  
 
The majority of membrane-active AMPs that are cationic and water-soluble form toroidal pores (Lee 
et al., 2011). These pores have a pore radius in the range of 15-25 Å (3-5 nm), and are thus 
substantially larger than barrel-stave pore size of 9 Å (1.8 nm) (Yang et al., 2001). Representative 
AMPs of this group include magainin (Ludtke et al., 1996), protegrin (Yamaguchi et al., 2002; Yang 
et al., 2001), melittin (Yang et al., 2001) and LL-37 (Lee et al., 2011), and hence encompass several 
different structural groups (see Chapter 2).  
 
The carpet model has previously been proposed to explain the MoA of α-helical peptides (which 
include LL-37) (Giangaspero et al., 2001; Shai, 1999). The ability of an AMP to transform into a 
helical conformation is one of the most controversial topics in peptidomimetic design (Section 3.3.3). 
It is speculated that helical peptides due to their secondary structure have the optimal separation of 
cationic and hydrophobic residues that would then mediate interaction with lipid head groups and the 
hydrophobic core, respectively (Agawa et al., 1991). Consequently, this would speak in favour of the 
toroidal model as opposed to the carpet model.   
  
The aggregate model is a variation of the toroidal pore model and explains how AMPs may interact 
with the membrane without leading to loss of viability. Thus it is possible that the ability of AMPs to 
act on lipid membranes reflect their mechanism of passage across the membrane and that their actual 
targets are in the cytoplasm (Wu et al., 1999). For instance, pseudin dissipate the membrane potential 
and cause leakage from the cell, but also bind to RNA and inhibit protein synthesis (Park et al., 
2011). This is reflected by a slower killing kinetics compared to other membrane-active peptides, and 
hence membrane activity could by a secondary MoA or only work in conjunction with other cellular 
activities (Park et al., 2011). The mechanism of defensins is similarly not well defined (Brogden, 
2005). Early on they were believed to be membrane active by an unknown mechanism (Lehrer et al., 
1989; Shimoda et al., 1995; Yeaman et al., 1998), but this has been disputed since they are also able 
to interact with intracellular targets (Ganz, 2003) (section 3.4). Hence, membrane interaction seen in 
early studies could only be a consequence of the molecule having to traverse the membrane to reach 
an intracellular target. 
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3.3.3. Structural determinants of peptidomimetic activity 
The recent advances in design strategies and synthesis protocols have facilitated the structural 
optimization of natural peptides and the generation of novel scaffolds of peptidomimetics.  
The synthesis and diversity of peptidomimetics was reviewed in Chapter 2. Here this will be put in 
context by reviewing the importance of structure-activity relationship studies in fine-tuning their 
physiochemical attributes for improved antibacterial properties (Rotem and Mor, 2009).  
 
Studies of the activity of peptidomimetics have demonstrated that membrane activity of a given 
compound depends on its overall physiochemical properties rather than the precise details of its 
structure (Tossi et al., 2000). However, there a two common functional requirements; a net charge 
cationicity that facilitates attraction with the negatively charged surface, and the ability to assume 
amphipathic structures that permit integration into the bacterial cell membrane (Giangaspero et al., 
2001). Additionally, since these compounds primarily are developed for therapeutic use, it is 
important to assure membrane selectivity. The selectivity of peptidomimetics for lysis of bacterial 
cells rather than mammalian cells depends on the appropriate balance between hydrophobicity and 
the distribution of charged side chains in the peptide; if the compounds are too polar hey have little 
affinity for the bacterial membranes, and if they are too hydrophobic they fail to discriminate 
between bacterial and mammalian membranes (Liu et al., 2004) (section 3.6).  
 
Charge of natural AMPs vary widely, from 0 to +16 though most active peptides fall into the 
intermediate range (Tossi et al., 2000). For peptidomimetics charge may be modified by the 
inclusion of basic amino acid such as lysine or arginine, which are protonated at physiological pH 
generating a net cationic charge (Palermo and Kuroda, 2010). Several studies have shown a clear 
correlation between charge and potency (Al-Badri et al., 2008; Dathe et al., 2001; Jiang et al., 2008; 
Taira et al., 2010). However, it is only within a certain range that increased cationicity is associated 
with increased antimicrobial activity; in a study of magainin analogues a net charge above +5 
reduced antibacterial activities (Dathe et al., 2001). This decrease may result in part from excessive 
strong peptide interaction with phospholipid head groups, thereby preventing translocation (Yeaman 
and Yount, 2003). Similarly, other studies did not find an increase in antimicrobial activity if charge 
was increased above moderate levels (Al-Badri et al., 2008; Chongsiriwatana et al., 2008; da Silva et 
al., 2008; Friedrich et al., 1999; Scott et al., 1999b). 
 
The percentage of hydrophobic residues in natural AMPs varies but is generally around 40-60 % 
consistent with the requirement for an amphiphilic structure (Tossi et al., 2000). Hydrophobicity 
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governs the extent to which a peptidomimetic can partition into the lipid bilayer. Since increased 
hydrophobicity is associated with loss of membrane specificity, it is kept relatively constant 
(Yeaman and Yount, 2003), and has primarily been studied as part of the ability of compounds to 
adopt an amphipathic secondary structure (Dathe et al., 1997; Friedrich et al., 1999; Taira et al., 
2010). The levels of charge and hydrophobicity is not necessarily inversely proportional as some 
peptidomimetics also contain high numbers of noncharged polar residues (Tossi et al., 2000). Studies 
of both charge and hydrophobicity highlight the importance of maintaining a balance between the 
hydrophobic and cationic components (Al-Badri et al., 2008; Porter et al., 2002). The range of MIC 
in a series of oligoacyllysines (OAKs) showed that the level of hydrophobicity and charge should be 
in a relatively narrow window to retain full activity (Radzishevsky et al., 2008) (Figure 3.5). 
 
 
Figure 3.5. Relationship between HQ 
(hydrophobicity/charge) properties and 
antibacterial activity against E. coli of 
103 short oligoacyllysines (OAK) 
leading to the visualisation of an optimal 
HQ window (blue). Potent OAKs (MIC≤ 
3µM) are highlighted (red circles). From 
(Rotem and Mor, 2009) modified from 
(Radzishevsky et al., 2008). 
 
It has been suggested that the chemical structure of cationic amino acids, and not simply their 
positive charge, is an important activity determinant. Arginine contains a guanidinium group, which 
has a strong affinity for phospholipids thereby facilitating membrane interaction (Palermo and 
Kuroda, 2010), and hence guanidinylation may enhance antimicrobial activity (Choi et al., 2009). No 
changes in antimicrobial activity were seen by globally substituting several amino acids as long as 
these were of similar polarity and did not change secondary structure (Chen et al., 2005b; Epand et 
al., 2010; Javadpour et al., 1996; Taira et al., 2010). Single amino acid substitutions at central 
positions in the peptide chain may however have an impact on antibacterial activity likely because it 
hinders proper folding into the secondary structure (Friedrich et al., 1999; Kasetty et al., 2011; Lim 
et al., 2005; Perez-Paya et al., 1995). Additionally the attachment of fatty acids to the peptide chain 
has been shown to increase antibacterial activity (Majerle et al., 2003). We saw no increase in 
antimicrobial activity when chimera 34 or 47 was modified with palmitoyl (unpublished results).  
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According to the models of pore formation described above, the peptide has to span the membrane to 
exert its membrane permeabilizing activities. For α-helical peptides it has been predicted that a 
length of 20 amino acid residues is required to span the lipid bilayer (Agawa et al., 1991). Length 
correlates extensively with antimicrobial activity (Agawa et al., 1991; Blondelle and Houghten, 
1992; Javadpour et al., 1996) until activity stagnates or even decreases at a length of around 20 
amino acid residues (Blondelle and Houghten, 1992; Deslouches et al., 2005b). Some suggestions 
have been given to the mechanisms of membrane interaction for shorter peptides (Agawa et al., 
1991). Hence, one intriguing study indicated different membrane interactions for an OAK hexamer 
(charge of + 6) and an octamer (charge of + 8); due to differences in charge only the latter caused 
membrane disruption whereas the other translocated into the cytoplasm (Rotem et al., 2008).  
 
In our peptidomimetics library hydrophobicity is constant at 50 % due to the alternating design of 
natural cationic amino acids (lysine/homoarginine) and the hydrophobic β-peptoids (see Chapter 2). 
We found no influence of type of amino acid (chimera 34 vs. 36), but increased chain length 
(chimera 45-49) had a pronounced effect on a wide spectrum of bacterial species (Table 3.2). 
 
Table 3.2. Minimum Inhibitory Concentration (µM) of six selected chimeras from the present library (Paper I). 
 Chimera 30 Chimera 34 Chimera 36 Chimera 45 Chimera 47 Chimera 49 
S. aureus 8325 5.9 2.8 18.7 141.2 23.8 4.5 
K. pneumoniae ATCC 13883 1.5 2.8 37.5 282.4 23.8 9.0 
S. marcescens ATCC 8100 46.8 45.5 150.0 > 282.4 190.3 71.8 
E. coli ATCC 25922 1.5 2.8 9.4 141.2 3.0 2.2 
E. coli MG1655 1.5 2.8 4.7 141.2 5.9 2.2 
E. coli AAS-EC-009 1.5 2.8 9.4 141.2 11.9 4.5 
E.coli AAS-EC-010 1.5 1.4 9.4 141.2 3.0 2.2 
L. monocytogenes 4446 2.9 1.4 1.1 70.6 3.0 1.1 
L. monocytogenes N53-1 2.9 2.8 1.1 70.6 5.9 1.1 
L. monocytogenes EGD 1.5 2.8 1.1 70.6 3.0 1.1 
V. vulnificus ATCCT 1.5 1.4 2.3 35.3 3.0 2.2 
V. parahaemolyticus ATCCT 1.5 1.4 2.3 70.6 3.0 1.1 
 
A higher degree of secondary structure had been found previously for analogues with chiral β-
peptoid side chains (as in 34 and 36) as compared chimera with achiral β-peptoid residues (as in 30) 
(Olsen et al., 2007), but as seen in table 3.2 this had no influence on antimicrobial activity. 
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The ability of a peptidomimetic to adopt a secondary structure has been extensively debated. 
Traditionally, secondary structure was considered necessary in order to obtain an amphipathic 
residue arrangement of the molecule (Mondal et al., 2010). Especially, the view that a helical 
structure is required for antimicrobial activity has been favoured (Chapple et al., 1998; Chen et al., 
2005b; Porter et al., 2002) and the structure of the helix was determined to be particularly important 
for activity against Gram-positive bacteria (Dathe et al., 1997; Giangaspero et al., 2001). 
Additionally, a significant positional conservation in terms of type of residues types has been found 
for a range of natural AMPs, where hydrophobic residues dominate one face of the helix and polar 
residues the other for optimal membrane interaction (Tossi et al., 2000). The hypothesis that peptides 
need a globally amphiphilic helical conformation has now been abandoned by several groups (Ilker 
et al., 2004; Oren and Shai, 1997; Schmitt et al., 2004) In fact, recent studies have shown that neither 
global amphiphilicity nor regular secondary structure is required for efficient interaction with the 
membrane (Mondal et al., 2010; Radzishevsky et al., 2007), and now also suggested by us (Paper I).  
 
3.3.4. Methods for determining activity against model membranes and viable bacteria 
Virtually all cationic AMPs cause severe membrane disruption if high enough concentrations are 
administered (Hancock and Rozek, 2002; Zhang et al., 2001), which could give false indication of 
the MoA and masking any potential intracellular activity. Consequently if the primary MoA should 
be determined, experiments should not be performed above the MIC (Figure 3.6).  
 
Figure 3.6. Influence of concentration on 
the MoA of a peptidomimetic against E. 
coli. Peptide was added at time zero 
(arrow) and cell viability (bold line), rate of 
RNA synthesis (dashed line) and 
membrane potential (dotted line) measured. 
RNA synthesis was inhibited at 1xMIC and 
the membrane disrupted at 10xMIC. From 
(Hancock and Rozek, 2002). 
 
 
Model membrane has been widely used to determine cell membrane damage induced by peptides 
(Brogden, 2005). For this, single or mixed phospholipid suspensions are prepared as lipid monolayer, 
lipid bilayers or liposomes (Koo et al., 1997; Zhang et al., 2001) or as dye-containing vesicles 
(Mazzuca et al., 2010; Park et al., 2011) and these are then incubated with AMPs. Lipid mixtures try 
to mimic the lipid composition of specific bacteria since this vary pronouncedly; in Gram-negative 
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bacteria phosphatidylglycerol (PG) and phosphatidylethanolalamine (PE) dominate, whereas in 
Gram-positive bacteria PG and cardiolipin (CL) are the most important (Epand and Epand, 2010). 
Formation of pores or general membrane disruption can be experimentally demonstrated by 
measuring the extent of membrane depolarisation or the leakage of intracellular contents to the 
extracellular environment that is a consequence of membrane disruption. Monitoring voltage-
dependent channels in membrane bilayers is useful for assessing the formation and not least the 
stability of the peptide-induced pore (Brogden, 2005). Several studies have measured the 
conductivity of an electrical current generated by the formed pore or used assays with membrane-
potential sensitive dyes as an indicator for membrane-activity (Agawa et al., 1991; Koo et al., 1997; 
Kordel et al., 1988). Membrane depolarisation can however occur due to the activity of both 
membrane-active and non-membrane active AMPs and hence changes in the membrane potential is 
not the lethal event per se (Friedrich et al., 2000; Park et al., 2011; Wu and Hancock, 1999; Yeaman 
et al., 1998). Leakage studies make use of fluorescent dyes (Friedrich et al., 1999; Junkes et al., 
2011; Liu et al., 2004) or measure the amount of leaked intracellular compounds (Johansen et al., 
1997; Zaknoon et al., 2009), although these assays varies widely in sensitivity  (O'Neill et al., 2004). 
Model membranes do not capture the heterogeneity of a real bacterial membrane, and hence it is 
better to use viable cells or protoplasts when possible (Hancock and Rozek, 2002). We measured 
ATP leakage from E. coli treated with chimera 49 at 1.68x107 peptide molecules/bacterium, where 
the MIC value equals 5.4x109 peptide molecules/bacterium (Paper I) (Figure 3.8).  
 
 
Figure 3.7. ATP leakage from S. aureus after the addition of 1000 µg/mL of chimera 49 (left) and the 
corresponding change in the number of viable bacterial cells (right). Left: Mean (SEM) intracellular (IC, solid 
line) and extracellular (EC, punctuated line) ATP concentration for cells treated with chimera 49 (grey) 
compared to MilliQ-treated control (black). Right: Mean (SEM) number of viable cells after addition of 
chimera 49 (grey line) compared to MilliQ-treated control (black line). From Paper I. 
 
Additionally, Scanning Electron Microscopy (SEM) was performed on several species of chimera-
treated bacteria to visualise the damage to the cell envelope (Figure 3.8) (unpublished).  
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Figure 3.8. Scanning Electron Microscopy (SEM) of Staphylococcus aureus (top row), Escherichia coli (middle row) 
and Serratia marcescens (bottom row) treated with sub-inhibitory or supra-inhibitory concentrations of chimera 30. 
MIC was determined for an inoculum at 108 CFU/ml to correct for higher bacterial number needed for SEM imaging 
i.e. MIC levels at 128 µg/mL, 32 µg/mL and 256 µg/mL for the three species, respectively. Unpublished results. 
B B 
 
B 
Activity and mechanism of action of antimicrobial peptides 
33 
 
Damage to the outer cell surface was especially evident for the two Gram-negative bacteria and in 
fact damage to both of them was evident also at sub-MIC concentrations. Expansion of the outer 
membrane leading to the formation of blebs due to peptide activity has been demonstrated earlier for 
E. coli (Hancock and Rozek, 2002). The present chimeras are bactericidal so MIC=MBC, and hence 
it is expected that at MIC levels the bacteria will die (i.e. ATP will leak from the cell and visible 
damage can be seen). However, the results from the ATP leakage assay (for several chimeras) and 
from SEM for chimera 30 suggest that lower levels also exert damage to at least a proportion of the 
bacterial population. None of our results have suggested that the MoA differ between the chimeras in 
the library. Additionally, cell aggregation was evident in SEM images of chimera 30-treated cells but 
was also seen using light microscopy of bacteria treated with the other chimeras, which would be 
expected for a membrane-disrupting peptidomimetic as demonstrated by others (Loit et al., 2010). 
 
Electron microscopy is an excellent method for visualising the actions of AMPs, but it is important 
to use relevant concentration around MIC i.e. we re-determined MIC to correct for the higher 
inoculums needed for SEM (Figure 3.8). SEM or TEM (transmission electron microscopy) has been 
used in several studies for determining membrane activity (Azad et al., 2011; Hartmann et al., 2010; 
Sallum and Chen, 2008). For instance melittin diastereomers caused complete lysis of E. coli at MIC, 
whereas patches were observed below MIC (Oren and Shai, 1997). Additionally, confocal laser-
scanning microscopy has been used to visualize the localization of peptide (Park et al., 2011; 
Sochacki et al., 2011) and solid-state NMR spectroscopy used to measure the orientation and 
penetration of AMPs into lipid bilayers or bacterial cells (Bechinger, 1999; Pius et al., 2012).  
 
3.4. Non-membrane and intracellular targets of antimicrobial peptides 
The majority of mechanistic studies of AMP activity have focused on the membrane disruption 
abilities of these compounds, but it is clear that some AMPs also possess non-membrane activities, 
which may either be their primary activity or work in conjunction with their activities against the 
membrane (Otvos, Jr., 2005). Hence, rather than disrupting the membranes, these peptides are able to 
traverse the membrane and subsequently bind to targets in the cytoplasma disrupting vital functions 
(Palermo and Kuroda, 2010).Translocation has been proposed to occur by a process related to the 
aggregate model (section 3.3.1) by transient disruption of the membrane without leading to 
permeabilization (Powers and Hancock, 2003).  
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Figure 3.9. Mechanisms of action for intracellular antimicrobial peptide activity displayed here with E. coli 
as the target organism. From (Brogden, 2005). 
 
The internalization of AMPs may be determined experimentally. It can be visualized by confocal 
laser microscopy as elegantly demonstrated for distinguishing the localisation of polymyxin B and 
the non-lytic proline rich Bac71-35 (Benincasa et al., 2009). In the same study a flow-cytometry 
method based on fluorescence quenching was described (Benincasa et al., 2009). Additionally, 
recently transposon libraries was used to unveil the intracellular target and route of cellular entry of 
antibiotics which possibly could be modified for elucidating Amp targets as well (Wang et al., 
2011a).   
 
Once in the cytoplasm, AMPs can interact with DNA, RNA and/or cellular proteins or inhibit the 
synthesis of these compounds. Consequently, loss of viability is often much slower than for 
membrane-active AMPs and may take several hours (Kragol et al., 2001). However, the toad AMP 
buforin II penetrates E. coli and binds to nucleic acids in the cytoplasma while still causing rapid cell 
death (Park et al., 1998). Interestingly, this AMP has a homology with DNA-binding histones, which 
are also being developed as therapeutic AMPs (Pavia et al., 2011), and which may thereby also 
explain its affinity for DNA. Another α-helical AMP, pseudin-2, isolated from the South American 
frog Pseudis paradoxa, inhibits protein synthesis by binding to RNA (Park et al., 2011). 
Additionally, a short OAK peptidomimetic displayed the ability to translocate across the membrane 
and inhibit DNA functions (Rotem et al., 2008). Though it was originally concluded that the MoA of 
bovine neutrophil AMP indolcidin was through membrane permeabilization (Hale and Hancock, 
2007), this was since disputed (Wu et al., 1999) and an alternative MoA proposed, when it was 
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discovered that indolicidin induce filamentation of E.coli which is thought to result from DNA 
synthesis inhibition (Subbalakshmi and Sitaram, 1998). An AMP that targets DNA repair has also 
been characterised (Su et al., 2010). Another class of intracellular targets are the ones that inhibit 
enzymatic activity either by sequestrating ATP (Hilpert et al., 2010) or by inhibiting the ATPase 
action such as pyrrhocoricin, which inhibits the activity of the heat shock protein DnaK thereby 
preventing chaperone-assisted folding (Kragol et al., 2001). 
 
In the case of  lantibiotics, several antibacterial activities are combined for increased potencies 
against Gram-positive bacteria; in addition to the pore-forming abilities of these compounds they 
also interact with pyrophosphate-binding sites on the membrane-bound cell wall precursor lipid II 
leading to inhibition of peptidoglycan biosynthesis (Breukink and de, 2006) (Figure 3.10).  
   
 
Figure 3.10. Lipid II-mediated activity of 
lantibiotics. Lipid II carries the completed 
subunit of the cell wall, which needs to be 
polymerised to the murein network. Binding 
of nisin to lipid II block the polymerisation 
reaction. From (Sahl et al., 2005). 
Such a non-membrane external target leading to the inhibition of cell wall biosynthesis, is similar to 
that of the glycopeptide antibiotic vancomycin (Sahl et al., 2005) and has recently been demonstrated 
for other AMPs. The MoA of the fungal defensin, plectasin, was recently reported to also be related 
to lipid II binding, although in a different step in the biosynthesis pathway than lantibiotics or 
vancomycin (Schneider et al., 2010). Similarly, studies on a family of protegrin peptidomimetics 
showed that the MoA against Pseudomonas involved inhibition of LptD, an outer-membrane protein 
that functions in the assembly of LPS, and hence a bacteriostatic activity different from the lytic 
activity of most peptidomimetics(Srinivas et al., 2010). Recently, a human defensin was shown to 
inhibit cell wall biosynthesis in Staphylococcus aureus (Sass et al., 2010), though the MoA of this 
peptide has always been thought to be a result of membrane permeabilization. In line with this, 
seminalplasmin, an AMP from bovine seminal plasma, lyses E. coli by stimulating autolytic 
enzymes(Chitnis and Prasad, 1990). Cell wall lytic enzymes of S. simulans were also activated by the 
lantibiotic Pep 5 leading to weakened cell wall and cell lysis (Bierbaum and Sahl, 1987). 
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Lack of membrane activity has indicated that other natural AMPs and peptidomimetics may have an 
intracellular target (Fehlbaum et al., 1996; Friedrich et al., 2000; Junkes et al., 2011; Wu et al., 
1999). The models for membrane activity predicts that AMP MoA is not receptor based which is 
why D-peptides are generally as activity as L-analogues (Maloy and Kari, 1995). Some studies where 
membrane activity was not found or was only minor additionally indicated the existence of a 
stereospecific target such as a receptor. Notably, it was demonstrated that both D- and L-enantiomers 
of thanatin are active against Gram-positive bacteria, only L-thanatin is activity against Gram-
positive bacteria (Fehlbaum et al., 1996). Similarly, a non-pore forming mechanism involving 
stereospecificity was also proposed for apidaecin, a proline-rich insect AMP, since the D-enantiomer 
was completely devoid of antibacterial activity (Casteels and Tempst, 1994). 
 
3.5. Effects of sub-lethal concentrations of antimicrobial peptides 
The realization that several AMPs have intracellular targets and that some cationic compounds may 
even contain a delivery module that allows entry of foreign cargo into the bacterial cell (Foged et al., 
2008) has lead to the realization that AMPs may also have more subtle intracellular effects (Otvos, 
Jr., 2005). At concentration well below the MIC value the membrane may be depolarised (Friedrich 
et al., 2000; Wu et al., 1999) and peptide-mediated flip-flop of phospholipid may also occur at 
concentrations much lower than those that for instance cause calcein released across the membrane 
(Hancock and Rozek, 2002; Zhang et al., 2001). Also, electron microscopy of bacterial cells treated 
with mellitin diastereomers indicated membrane structural changes well below the MIC (Oren and 
Shai, 1997). These results indicate that low amounts of AMP may translocate into the bacterial cell 
when these are exposed to sub-lethal concentrations without causing damage to the cytoplasmic 
membrane (Patrzykat et al., 2002).  
 
Several bacteria respond to the presence of AMPs by activating two-component systems, which 
induces structural changes that confer increased tolerance to subsequent exposure of these 
compounds (section 4.2). Obviously this is induced at concentrations that do not kill the bacterial 
cell. Stress responses are often detected using reporter fusions (e.g. lacZ) and may help to 
characterize the mode of antibacterial action of new compounds (Bianchi and Baneyx, 1999; Davies 
et al., 2006). Stress-responses can also be examined using transcription analyses, which has shown 
that considerable change in the up- or down-regulation of genes may occur at low concentrations 
(Chiu et al., 2010; Hong et al., 2003; Kruse et al., 2009). The critical parameter in providing 
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meaningful expression profiles is the concentration of the inhibitor, since low concentrations are 
needed to provide a specific response (O'Neill and Chopra, 2004).  
 
We saw considerable differences in the reduction of growth, when different bacteria where exposed 
to sub-lethal concentrations of chimera revealing that stress-responses (and thereby possible the 
MoA) may vary between different bacteria (Paper I). Transcription profiles from exposed bacteria 
may provide a better understanding of the MoA of the chimeras. A study of pleurocidin-derived 
AMPs showed that though these compounds damage the membrane at concentration at or above the 
MIC, at concentration below the MIC only macromolecular synthesis (DNA, RNA, proteins) was 
inhibited (Patrzykat et al., 2002). 
 
3.6. Membrane selectivity and determination of toxicity 
The application of AMPs as therapeutic antibacterial agents is often limited by unfavourable toxicity 
profiles towards human cells and can restrict their use to topical applications (Hancock and Chapple, 
1999). Indeed, the MIC value of a potential new compound reflects its therapeutic potential, since 
moderate MIC values will necessitate the use of higher doses which could lead to unwanted activity 
towards host cells (Zasloff, 2002). Several antibiotics are toxic in high doses but are still usable due 
to their very low MIC values. Host toxicity is predominantly evaluated in terms of hemolytic 
activity, although the susceptibility of erythrocytes is not necessarily extendable to other host cells 
(Tossi et al., 2000). Toxicity can occur as a consequence of the structural determinants that are 
modified for higher antibacterial activity. Excessively hydrophobic peptides are indiscriminately 
toxic to both human and bacteria cells because their hydrophobic nature mediates insertion into 
human cell membrane without the aid for electrostatic interaction needed for bacterial activity 
(Palermo and Kuroda, 2010), (Figure 3.10). 
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Figure 3.11. Membrane targets of 
AMPs and the basis of membrane 
selectivity. From (Zasloff, 2002). 
 
 
Bacterial cytoplasmic membranes contain a large proportion of negatively charged (anionic) 
phospholipids such as phosphatidylglycerol and cardiolipin as wells as neutral (zwitterionic) 
phospholipids e.g. phosphatidylcholine (McPhee et al., 2005). This latter phospholipid is also found 
in eukaryotic membranes, which is composed principally of lipids with no net charge (Zasloff, 
2002). Hence, due to their cationic charge, AMPs have selectivity for bacterial membranes. The 
negatively charged bacterial cell surface and a high transmembrane potential provide increased 
attraction towards bacteria (Yeaman and Yount, 2003).  
 
The comparison between toxicity profiles has been hampered by the fact that a standardised protocol 
for determining hemolysis has been lacking (Palermo and Kuroda, 2010). Selectivity is often 
reported as the therapeutic index defined as the ratio of bacterial cell killing to eukaryotic cell killing 
i.e. MHC/MIC, where the former equals to maximum concentration that produces no hemolysis 
(Chen et al., 2005b; Jiang et al., 2008). Additionally, the concentration that causes 50 % hemolysis 
(EC50) has been widely used (Dathe et al., 1997; Ilker et al., 2004). Significant hemolysis occurring 
only at concentration much higher than the antibacterial MIC value indicates selectivity for bacterial 
cells over mammalian cells (Porter et al., 2002). 
 
Studies of peptidomimetic have shown that strong hemolysis generally correlated with high 
hydrophobicity (Dathe et al., 2001; Ilker et al., 2004), high amphipathicity (Al-Badri et al., 2008; 
Chen et al., 2005b) and high helicity (Dathe et al., 1997; Giangaspero et al., 2001; Javadpour et al., 
1996; Oren and Shai, 1997). For our series of chimeras (where hydrophobicity is kept constant) 
length is the most important determinant for increased cytotoxicity (H. Franzyk, personal 
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communication). It is not always that increased hemolysis correlates with increased antibacterial 
activity (Giangaspero et al., 2001; Kondejewski et al., 1996; Schmitt et al., 2004). The effect of 
secondary structure on hemolysis indicates that structuring is more important for the interaction with 
eukaryotic membranes, which may suggest that different molecular mechanisms are underlying the 
antimicrobial and haemolytic activities of these compounds (Carotenuto et al., 2008). 
 
3.7. Conclusions from chapter 3 
Antimicrobial peptides (AMPs) have a wide spectrum of activity. The cationic nature of 
antimicrobial peptides facilitates their attraction to the negatively charged bacterial surface. Though 
they have been described as “dirty drugs” simultaneously disturbing many cellular functions, most 
antimicrobial peptides target the bacterial cell membrane, although distinct intracellular actions also 
have been reported. Several models for membrane interaction have been proposed. The most 
important structural determinants of peptidomimetic activity include charge, length, hydrophobicity, 
amphipathicity and secondary structure, since these variables may optimize the interaction with the 
plasma membrane. Small modifications in structural parameters can improve antibacterial activity, 
though this may also lead to increased hemolytic activity. Membrane activity can be determined 
using different methods including assays for membrane depolarisation and permeabilization, 
microscopy and solid state NMR spectroscopy. We used an ATP leakage assay and scanning 
electron miscopy to demonstrate that the present chimeras are likely to be membrane-active. 
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4. Bacterial resistance to antimicrobial peptides 
 
The discovery of antibiotics for use against bacterial pathogenic bacteria gave hope for a future 
where all infectious diseases could be controlled (Fernandez et al., 2010). With the emergence and 
rapid spread of bacterial resistance to antibiotics it soon became clear that this would not be the case. 
A variety of compounds are being tested as future alternatives to the conventional antibiotics, but 
now more effort is put into predicting and preventing potential resistance development (Baquero, 
2001). Part of the promise of antimicrobial peptides (AMPs) is that since they target the Achilles’ 
heel of bacterial membrane structure (Zasloff, 2002) and have co-evolved with bacteria without 
development of widespread resistance (Peschel and Sahl, 2006), resistance to these compounds is 
considered unlikely. However, it is vital that this holds true, since resistance to AMPs could 
ultimately compromise the activity of our own immune system (Bell and Gouyon, 2003) (Chapter 5). 
In this chapter I will review the most common mechanisms that confer bacterial resistance to AMPs 
and relate this to resistance development against the α-peptide/β-peptoid peptidomimetics. 
Additionally, the concept of cross-resistance within groups of AMPs will be reviewed. 
   
As for antibiotics, three major types of resistance to AMPs are known to exist; intrinsic, acquired and 
adaptive (Fernandez et al., 2011) (Table 4.1.).  
 
Table 4.1. Outline of the characteristics of three major types of resistance to antimicrobials. Modified from 
(Fernandez et al., 2011). 
Type of resistance Intrinsic Acquired Adaptive 
Acquisition Not acquired, part of the 
genetic make-up of the strain 
or species 
Mutation Changes in the gene 
expression triggered by 
environmental factors or 
presence of antimicrobials 
  Horizontal transfer  
Characteristics Inheritable 
Stable 
Irreversible 
Inheritable 
Stable 
Irreversible 
Not inheritable 
Transient 
Generally reverts upon 
removal of inducing signal 
 Independent of environment Independent of environment Dependent of environment 
 
Whereas intrinsic resistance is an inherent genetic feature of the bacterial strain, exposure to AMPs 
can result in bacteria acquiring resistance either through mutations or by exploiting the phenomenon 
of adaptive resistance (Fernandez et al., 2011). Hence, the therapeutic use of AMPs can potentially 
result in the development of acquired and adaptive resistance, and since therapeutic use is also the 
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goal for the peptidomimetics, these two types of resistance will therefore be the primary focus of this 
chapter. The following discussion will be focused on resistance towards AMPs; as discussed in 
section 4.3.2 very few studies have dealt with resistance towards peptidomimetics. However, due to 
their similarity in the mechanism of action, it is likely that acquired resistance mechanisms against 
peptidomimetics will be similar to the ones described for AMPs.  
 
4.1. Mechanisms of intrinsic and acquired resistance 
Both Gram-negative and –positive bacteria use multiple strategies to prevent killing by AMPs 
(Figure 4.1). These include changing the charge and permeability of the different layers of the cell 
envelope, removing AMPs by efflux transporters and digesting by bacterial proteases.  
 
Figure 4.1. Mechanism 
of bacterial resistance 
to antimicrobial 
peptides. From (Gallo 
and Nizet, 2003). 
 
 
 
The mechanisms involved in the different types of resistance are generally similar whether these 
constitute an intrinsic bacterial feature or develop through environmental stimuli or mutations, and 
the mechanisms will therefore be reviewed simultaneously. 
 
4.1.1. Modification of outer cell layers 
The anionic charge of the outer cell layer of bacteria mediates the initial attraction between the 
cationic AMP and the bacterial cell (Zasloff, 2002) (Chapter 3). Hence, modulating cell surface 
charges is a common strategy for bacteria to prevent AMP activity. 
 
Gram-positive bacteria such as staphylococci are surrounded by a thick cell wall composed of 
peptidoglycan and polymers of alternating phosphate and alditol groups termed teichoic acids. 
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However, teichoic acids are negatively charged which facilitate electrostatic attraction of cationic 
AMPs. Esterification of teichoic with the positively charged D-alanine decreases the negative net 
charge of teichoic acids promoting AMP resistance (Otto, 2009). The mechanism is catalysed by 
enzymes encoded within the dlt operon and contributes to bacterial resistance in many Gram-positive 
bacteria including Staphylococcus aureus, Clostridium difficile, Streptococcus pneumoniae and 
Lactococcus lactis (Kovacs et al., 2006; Kramer et al., 2008; McBride and Sonenshein, 2011; 
Peschel et al., 1999). In addition, thickening of the peptidoglycan layer has also been shown to occur 
in L. lactis upon acquisition of resistance (Kramer et al., 2008). 
 
The outer membrane of Gram-negative bacteria constitutes a semi-permeable barrier that in many 
species mediates intrinsic resistance to AMPs as well as antibiotics (Goldstein et al., 1983; Hancock, 
1997c). The enterobacterial outer membrane consists of an inner monolayer of phospholipids and an 
outer surface monolayer of lipopolysaccharide (LPS) (see Figure 4.3). LPS molecules have a high 
negative charge, providing an anionic external surface similar to that seen for teichoic acid in Gram-
positive bacteria. This facilitates attraction of cationic AMPs, however Gram-negative bacteria have 
developed multiple ways of modulating LPS charge by changing its chemical composition. These 
changes are often associated with the activity of two-component systems, the mechanisms of which 
will be reviewed in section 4.2. The most common method of reducing LPS charge is by the addition 
of 4-amino-deoxy-arabinose to lipid A, a component of LPS (Trent et al., 2001) (Figure 4.2).  
 
Figure 4.2. Chemical structure of 
LPS from AMP-sensitive (Salmonella 
minnesota) and resistant (Proteus 
mirabilis) strains. The resistant strain 
has ~50 % substitution with amino-
arabinose in the LPS layer (dark area) 
which reduces the negtaive net charge 
compared to the suscpetibile strain. 
This is similar to that seen for 
enterobactericaeae. 
From (Howe et al., 2007).  
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This partly neutralizes the negative charge of lipid A, thereby reducing the electrostatic charges with 
AMPs. Lipid A modification with amino-arabinose has been investigated in enterobactericeae and 
found in polymyxin B-resistant strains of Escherichia coli, Salmonella typhimurium and Klebsiella 
pneumoniae (Helander et al., 1996; Nummila et al., 1995; Zhou et al., 2001). This may be a result of 
constitutive expression of the PmrAB regulon (Froelich et al., 2006) (Section 4.2).    
 
Decreased susceptibility to AMPs may also occur due to decreased permeability of the outer 
membrane as seen in a polymyxin B-resistant E. coli (Rahaman et al., 1998), where the extent of 
permeability was determined by using a fluorescent dye. The mutant displayed changes in the 
composition of LPS and the amounts of outer membrane proteins including porins making this the 
likely mechanism of resistance (Rahaman et al., 1998). The outer membrane has been described as a 
molecular sieve and the porins as the holes of the sieve (Hancock, 1997c). Hence, tight regulation of 
porins may provide resistance to AMPs (Mathur and Waldor, 2004). Scanning electron microscopy 
(SEM) of the cell surface of AMP-resistant strains has revealed visible ultra-structural changes to the 
outer membrane following acquisition of resistance (Sallum and Chen, 2008). It is likely that this is 
mediated by structural changes to both LPS and outer membrane proteins. 
 
Some inherently AMP-resistant species such as Serratia and Morganella express an outer membrane 
that lacks the appropriate density of acidic lipids to provide AMP-binding sites (Zasloff, 2002). S. 
marcescens is well-known for its resistance to AMPs, and the outer membrane is likely to be the 
cause of this (Goldstein et al., 1983; Viljanen and Vaara, 1984). Perhaps as a consequence of this, it 
was also the only of the tested bacterial species which was resistant to the α-peptide/β-peptide 
peptidomimetics (Paper I).  
 
Though peptidoglycan is primarily a feature of the Gram-positive cell wall, Gram-negative bacteria  
posses a thin layer of peptidoglycan in the periplasmic space between the inner and outer 
membranes, which ensures structural integrity to the cell by preventing osmolysis (Laubacher and 
Ades, 2008) (Figure 4.3). 
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Figure 4.3. Structure and 
composition of the cell 
envelope of Gram-
negative bacteria. From 
(Raetz, 1993). 
 
 
When the cell grows and divides, murein hydrolases cut the peptidoglycan, while penicillin-binding-
proteins (PBPs) ligate new strands to the existing peptidoglycan layer; a process which evidently 
needs to be tightly regulated (Typas et al., 2011; Uehara and Bernhardt, 2011). Peptidoglycan stress 
due to antibiotic-mediated inhibition of PBPs activates the Rcs phosphorelay in E. coli leading to 
enhanced survival in the presence of antibiotics (Laubacher and Ades, 2008). It is not clear what 
genes in the Rcs regulon mediate survival, but the authors speculate that the Rcs pathway may 
strengthen the outer membrane permeability barrier (Laubacher and Ades, 2008). In E. coli a variety 
of peptidoglycan hydrolases are responsible for remodelling of the peptidoglycan layer (van 
Heijenoort, 2011). As part of characterizing the resistant isolates developed through continuous 
selection of E. coli to compound 34 (Paper II, Section 4.3), we decided to whole-genome sequence 
some of these isolates and compare them to the ancestral wild type (E. coli ATCC 25922). An 
amino-acid changing SNP in the gene encoding the membrane-bound lytic murein transglycosylase 
(MltD) was one out of four SNPs found only in high-resistant isolates (Paper II). Overproduction of 
MltD in E. coli has been shown to lead to spheroplast formation and cell lysis (van Heijenoort, 
2011). Conversely, inactivation of the mltD gene in Vibrio anguillarum by homologous 
recombination facilitated resistance to antibiotics, which the authors speculate could be due to an 
inability of MltD to weaken the outer membrane structure (Xu et al., 2011). We will elucidate the 
role of this SNP in resistance acquisition by introducing this into the wild type strain. 
  
4.1.2. Decreased charge or permeability of the bacterial plasma membrane 
Many AMPs exert their antibacterial effect through pore formation or disintegration of the bacterial 
plasma membrane leading to leakage of cell contents and ultimately cell death (Brogden, 2005). 
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Therefore, the bacterial cell membrane can therefore be considered the primary target of AMPs. This 
target is very different from the distinct targets of most antibiotics, where resistance in some cases 
can be achieved through single point mutations of target enzymes (Hancock, 1997a). The overall 
design of the bacterial membrane structure is not easily redesigned (i.e. mutated) and would, in 
theory, require a myriad of mutations to retain integrity and function, which has been proposed to 
make AMP resistance unlikely (Zasloff, 2002). In spite of this hypothesis, multiple studies have 
shown that structural changes of the plasma membrane can mediate AMP resistance without leading 
to fitness cost. The cationic charge of AMPs allows them to interact and be inserted into the anionic 
plasma membrane (Zhang et al., 2001) (Chapter 3). Hence, bacteria may prevent AMP activity by 
reducing the negative charge of the plasma membrane, which reduces bacterial affinity for AMPs 
and renders the bacteria more tolerant to these (Ernst and Peschel, 2011). The reduction is negative 
net charge is created by modifying the anionic membrane phospholipids with cationic amino acids; 
in S. aureus the modification of phosphatidylglycerol with lysine confers resistance to human AMPs 
(Peschel et al., 2001). Interestingly, modification of phosphatidylglycerol with alanine (a neutral 
amino acid) also conferred resistance to the tested AMP protamine (Klein et al., 2009) (Figure 4.4).   
 
 
Figure 4.4. Aminoacylation with lysine or alanine in the membranes of S. aureus (left) or Pseudomonas 
aeruginosa (right). Though only lysine is charged, modification with both types of amino acids leads to 
AMP resistance. Positively charged molecules are indicated in blue and neutral ones in grey. From (Roy et 
al., 2009). 
 
Lysine-modified phosphatidylglycerol are naturally present in many Gram-positive bacteria (Ernst 
and Peschel, 2011), and consequently the responsible MprF enzyme was not discovered until its 
inactivation increased the AMP susceptibility of a S. aureus mutant (Peschel et al., 2001). 
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Translocation or “flipping” of lysyl-phosphatidylglycerol to the outer membrane leaflet (leading to 
asymmetry in the membrane phospholipid composition) will hence also increase the net positive 
surface charge leading to increased resistance (Jones et al., 2008). Similarly, reduced levels of 
phosphatidylglycerol as a result of mutations in its synthase can also lead to reduced net negative 
charge creating resistance to daptomycin (a membrane-active antibiotic) (Hachmann et al., 2011). It 
has however also been proposed that the observed resistant phenotype of bacteria with increased 
lysyl-phosphotidylglycerol content could be a consequence of increased membrane stability rather 
than repulsion of AMPs (Kilelee et al., 2010). Increased membrane rigidity has been seen for 
resistant mutants which is likely to reduce membrane penetration by AMPs (Mehla and Sood, 2011; 
Mishra et al., 2011a). It is interesting that the other extreme (very fluid membranes) has also been 
associated with increased resistance (Bayer et al., 2000; Jones et al., 2008) indicating the existence of 
a membrane order optimum for AMP activity. 
 
4.1.3. Efflux transporters 
If the AMP is successful in traversing the outer layers of the cell envelope, many bacteria make use 
of efflux systems that expel these again before they can reach the plasma membrane or an 
intracellular target (Hancock, 1997c). Efflux systems fall into four categories: ATP-binding proteins, 
major facilitator proteins, resistance-nodulation-division proteins and small multidrug resistance 
proteins with many bacteria expressing more than one protein (Bell and Gouyon, 2003). Efflux 
pumps are a very common strategy in bacterial resistance to antibiotics (Li and Nikaido, 2004). 
However, though there are examples of efflux-mediated AMP resistance, the requirement for direct 
recognition of certain AMP sequences or structural motifs may have compromised the ability of 
efflux transporters to serve as a general mechanism of resistance against AMPs (Peschel and Sahl, 
2006). Accordingly, producer self-protection by ATP-dependent EpiFEG in S. epidermidis is specific 
to the epidermin produced (Otto et al., 1998). This is in opposition to efflux proteins that expels a 
broad range of compounds such as organic cations or several classes of antibiotics; a major facilitator 
protein is encoded by the qacA locus on the psK1 plasmid which confers staphylococci resistance to 
several classes of antibiotics and to platelet microbicidal protein 1 (Kupferwasser et al., 1999). 
Similarly, the MltrCDE multi-drug efflux pump of Neisseria gonorrhoeae provides resistance 
against a diverse range of AMPs, though not to human defensins (Shafer et al., 1998). Temperature-
dependent efflux systems (Bengoechea and Skurnik, 2000) and proteins with a dual role as K+ 
transporters (Parra-Lopez et al., 1994) has also been shown to be implicated in AMP resistance. 
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4.1.4. Proteolysis and inactivation of AMPs 
It is apparent that bacteria may obstruct AMP activity by proteolysis. However, the success of this is 
widely determined by the structure of the AMP; a simple linear structure or α-helical structure such 
as that of the human cathelicidin LL-37 is relatively susceptible to proteolysis by the outer 
membrane protease PgtE of Salmonella enterica (Guina et al., 2000). Therefore making AMP 
structures more rigid through the introduction of disulfide bridges renders AMP considerably more 
resistant to proteolysis (Peschel and Sahl, 2006) and the occurrence of disulfide-bridged defensins in 
a variety of organism underscore the virtue of this structure (Ganz, 2003). In E. coli the OmpT 
protease is responsible for the recovery of growing cells after protamine treatment (Stumpe et al., 
1998).  
 
Since proteases only have limited effect on more complex AMP structures, some bacteria have 
evolved mechanisms for extracellular trapping and neutralization of AMPs, which can however be 
quite specific for certain AMPs. Staphylococcus aureus produce staphylokinase, which binds α-
defensins and completely eliminate the bactericidal effect of these compounds (Jin et al., 2004). 
Another example is given by the streptococcal inhibitors of complement (SIC) in Streptococcocs 
pyogenes (Fernie-King et al., 2004), however, the specificity of this mechanism is in the extremes 
since SIC binds strongly to human β-defensin 2 and 3 but not at all to human β-defensin 1 (Fernie-
King et al., 2004).  
 
4.2. Adaptive resistance via Gram-negative two-component systems 
Though resistance mechanisms confer an immense advantage for bacteria in the presence of AMPs, 
the constitutive expression of genes that mediate structural changes or confer inactivation of AMPs 
may entail a fitness cost when the compound is are not present (Andersson, 2006). Many bacteria 
have therefore developed systems that restrict the resistance-conferring response to conditions where 
AMPs are actually present in the environment. Two-component systems consist of a sensory kinase 
and a response regulator, which allow the bacteria to sense and respond to environmental changes or 
stimuli (Stock et al., 2000). Such systems are an intrinsic feature of these bacteria, however, they are 
only activated when induced thereby mediating adaptive (or inducible) resistance. The systems are 
present in both Gram-negative and –positive bacteria (Fernandez et al., 2011) of which only the two-
component systems present in Gram-negative bacteria will be reviewed in this section. 
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Adaptive resistance is described as an auto-regulated phenomenon characterised by induction of 
resistance in the presence of the AMP and reversal to the sensitive phenotype in its absence (Skiada 
et al., 2011). Consequently, exposure to a compound will increase tolerance to subsequent exposures 
(Daikos et al., 1990) (Figure 4.5). 
 
 
Figure 4.5. How previous exposure to an antibacterial (here aminoglycoside) leads to adaptive resistance in P. 
aeruginosa. Upper graphs show the number of variable bacteria at different times without prior drug explosive 
(control, left panel) with 1 hour prior drug exposure to 8xMIC and with continuous drug exposure to 1xMIC 
after the initial drug exposure of 8xMIC. Lower graphs show the bactericidal rate measured after addition of 
4xMIC at successive hourly intervals. Adaptive resistance is evident in the middle and right panel; adaptive 
resistance is enhanced and prolonged with grown in continuous presence of the drug (right panel). From 
(Skiada et al., 2011). 
 
Extensive research carried out in Pseudomonas and Salmonella  has within the last decade provided 
a much clearer picture of the mechanism behind adaptive resistance and the regulatory pathways 
involved (Fernandez et al., 2011).  
 
In P. aeruginosa three two-component systems involved in the process of adaptive resistance have 
been described to date. These systems all result in the incorporation of 4-aminoarabinose in lipid A 
leading to a decreased negative charge of the LPS (section 4.1.1 and Figure 4.2). The model AMPs 
used  has primarily been of the polymyxin group (polymyxin B and colistin) though adaptive 
resistance to other AMPs has also been described (Fernandez et al., 2011). All three two-component 
systems result in the up-regulation of genes in the arn operon formerly known as the polymyxin 
resistance operon or pmr (Falagas et al., 2010) (Figure 4.6).  
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Figure 4.6. Model of P. aeruginosa PhoPQ and PmrAB regulatory networks in resistance to AMPs. The 
“unidentified system” to the lower right has now been identified and named the ParRS system (see text for 
details). From (Gooderham et al., 2008). 
 
The level of divalent cations in the environment has a large role in the activation of two-component 
systems; in P. aeruginosa both PhoPQ and PmrAB are activated independently by low 
concentrations of Mg2+, likely to reflect starvation conditions (Gooderham and Hancock, 2009). The 
PhoPQ was the first two-component system described in P. aeruginosa, identified due to its high 
similarity to the PhoPQ system of Salmonella typhimurium (Macfarlane et al., 1999). This was 
followed by the identification of the PmrAB system (McPhee et al., 2003). Under low concentrations 
of Mg2+ these two systems induce the modification of lipid A by up-regulating the arn operon, and it 
has been shown that mutants in these systems may lead to constitutive expression of the system and 
stable resistance to polymyxins (Macfarlane et al., 1999; McPhee et al., 2003). However, AMPs 
induce the arn operon independently of the PhoPQ and PmrAB systems and are able to do this under 
higher (physiologically relevant) concentrations of divalent cations (Gooderham et al., 2008). The 
puzzle was finally solved in 2010 with the identification of the ParRS two-component system, which 
is activated by AMPs regardless of the concentration of Mg2+ (Fernandez et al., 2010) making it 
relevant for mediating adaptive resistance in vivo. Mutations in the ParRS system only affect sensing 
of polymyxins and indolicidin indicating the presence of specific recognition pathways for different 
structural groups of AMPs (Fernandez et al., 2010). Interestingly, the ParRS system has recently 
been shown to confer resistance to several different classes of antibacterials (AMPs as well as 
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conventional antibiotics) by inducing an arsenal of different resistance mechanisms i.e. LPS 
modifications, increased drug efflux and reduced permeability of porins (Muller et al., 2011). 
 
The regulatory network of two-component systems and divalent cation sensing in Salmonella is 
different from that of P. aeruginosa though they possess similar systems encoded by homologues 
genes. Notably, in Salmonella AMPs are able to activate the PhoPQ system (Bader et al., 2005) 
(Figure 4.7). 
 
 
Figure 4.7. Model of 
Salmonella spp. PhoPQ and 
PmrAB regulatory networks 
in resistance to AMPs. From 
(Gunn, 2008). 
 
 
AMPs are detected via their interaction with the sensor domain of PhoQ (Bader et al., 2005). 
Accordingly, it has elegantly been proposed to use the PhoQ-activating potential, a predicament of 
the development of resistance, in the optimization of novel AMP-like structures (Kindrachuk et al., 
2007). PhoPQ regulates genes involved in cell envelope remodelling and proteolytic cleavage of 
AMPs (Fernandez et al., 2011; Guina et al., 2000). In addition, the activated PhoP transcriptional 
regulator induces the transcription of the pmrD gene, the product of which leads to stabilization of 
the phosphorylated form of PmrA (Fernandez et al., 2011). PmrA is then able to induce the 
expression of genes in the pmr operon (homologue to the Pseudomonas arn operon) involved in the 
modification of LPS (Gunn, 2008). Hence, both the PhoPQ and PmrAB systems are involved in the 
modification of LPS (Ernst et al., 2001; Zhou et al., 2001) (Figure 4.8). 
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Figure 4.8. Chemical 
structure of S. typhimurium 
LPS with PhoPQ- and 
PmrAB-mediated structural 
modifications. From (Ernst 
et al., 2001). 
 
 
 
In Salmonella the PhoPQ and PmrAB systems also respond to the different environments 
encountered during the lifestyle of this species. PhoPQ responds to decreased Mg2+ concentrations 
and both systems are activated in environments with low pH i.e. two parameters that are both known 
to present within the macrophage phagosome (Ernst et al., 2001; Gunn, 2008). Another interesting 
two-component system in S. typhimurium named the CprxRA was shown to mediate protamine 
resistance by up-regulating the expression of peptidoglycan amidases (section 4.1.1) (Weatherspoon-
Griffin et al., 2011). The authors believe it is plausible that this system confer resistance to AMPs by 
combating the damage of the cell envelope caused by these or alternatively by modifying the outer 
membrane to prevent AMP binding.  
 
This proposed mechanism is very similar to how we propose a mutation in the mltD gene could 
confer resistance to one of our chimeras (Paper II). Two-component system have not been 
extensively studied in E. coli as it has for Pseudomonas and Salmonella; peptidoglycan stress 
responses also mediate resistance to antimicrobials in E. coli but this is mediated by a phosphorelay 
system (Laubacher and Ades, 2008). Resistance mediated by either perturbations or structural 
changes of the peptidoglycan layer is interesting as it is not normally considered the primary target 
for novel resistance mechanisms in Gram-negative bacteria, since this layer is very thin compared to 
what is seen in Gram-positive bacteria. In E. coli PmrA also activate genes involved in the 
modification of lipid A with 4-aminoarabinose and subsequent resistance to AMPs (Froelich et al., 
2006; Gunn, 2008; Guo et al., 1998). The activation of PmrA is, however, different from that of 
Salmonella, since PmrD is present but fails to inactivate PmrA (Gibbons et al., 2005). Regardless of 
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this, we consider it unlikely that two-component system or other sensing systems are involved in the 
resistance to the chimeras, and neither to the resistance to polymyxin B evolved in the same study. 
This conclusion is made from the fact that resistance to both of these compounds was heritable (i.e. 
resistance was not eliminated in the absence of the drug) (Paper II). The expression of the pmr 
operon in yet another enterobactericeae, Klebsiella pneumoniae, is regulated by PhoP, PmrD and 
PmrA in a similar way to Salmonella (Cheng et al., 2010). 
 
4.3. Acquisition of resistance through cumulative changes 
The potential for development of resistance to new antimicrobial agents is often described in terms 
of resistance frequencies (O'Neill and Chopra, 2004). Such frequencies are determined by plating 
bacterial cultures on selective plates with compound concentrations above MIC and counting the 
number of resistant mutants arising after a defined time period. Low resistance potentials are often 
associated with antibacterials with more than one cellular target (O'Neill and Chopra, 2004), as 
described for AMPs. Though resistance frequencies have been mostly examined for antibiotics, 
spontaneous resistance towards AMPs have been reported (Macwana and Muriana, 2012). 
Transposon mutant libraries constitute another approach for developing AMP resistant mutants. 
Since the transposon element randomly inserts into the genome, this may disrupt genes involved in 
bacterial susceptibility, which allows for subsequent identification of colonies with increased 
resistance when plated on selective plates (Thomsen et al., 2010). AMPs have often been described 
as “dirty drugs” that disturb many biological functions with low potency rather than blocking a 
specific high affinity target (Peschel and Sahl, 2006). Hence, mutations in multiple specific pathways 
or structures are often needed to obtain high levels of AMP resistance, which is only rarely achieved 
with the above methods. Instead resistance may be evolved by the sequential accumulation of 
mutations of small individual effect.  
 
4.3.1. The application of continuous selection for resistance development 
Bacterial populations will inevitably evolve both in vivo (Lieberman et al., 2011) and in vitro 
(Barrick et al., 2009). As they do so resistant bacteria arise at low frequency by mutation (Bell and 
Gouyon, 2003; Conrad et al., 2011). Continuous exposure to an antibacterial will select for those 
mutations that confers increased fitness or tolerance in the presence of the selective agent since 
resistant bacteria will have an advantage and still be able to grow. For example E. coli has a large 
mutational target size for increased tolerance to antibacterial drugs (Girgis et al., 2009). Continuous 
selection is the process by which bacteria adapt to the presence of antimicrobial drugs (Bell and 
Bacterial resistance to antimicrobial peptides 
53 
 
Gouyon, 2003). Interaction between antibacterial agents and microbial populations can occur even at 
very low concentration (Girgis et al., 2009) hence concentrations several times lower than the MIC 
are often the starting point for adaptation. The progressive enrichment in low-level resistant 
populations can then favour secondary selection for more specific and effective mechanisms of 
resistance i.e. directional selection (Baquero, 2001).  
 
4.3.2. Evolution of AMP resistance in the laboratory 
Several studies have attempted to develop resistance to AMPs by continuous selecting for growth in 
the presence of the compound, a process which has been termed adaptive laboratory evolution 
(Conrad et al., 2011). The success rate (i.e. the successful development of resistance) of these studies 
varies extensively and seems to depend on the number of passages, initial concentrations, number of 
individual lineages and whether or not the concentration is kept constant or gradually increased 
(Farrell et al., 2010; Kramer et al., 2006; Perron et al., 2006; Steinberg et al., 1997; Zaknoon et al., 
2009). In general, resistance development is tracked over time (Figure 4.9). 
 
 
Figure 4.9. Resistant 
development profiles of 
XF-73, a dicationic 
porphyrin (black triangles) 
compared with selected 
conventional antibioitcs 
against S. aureus. From 
(Farrell et al., 2010). 
 
As done in the study with XF-73, a membrane-active antimicrobial (Farrell et al., 2010) (Figure 4.9)  
resistance development of novel antimicrobials is often compared to that of conventional antibiotics 
(Steinberg et al., 1997; Zaknoon et al., 2009). However, this is complicated by the fundamental 
differences between antibiotics and AMPs; the mutation rates for are generally higher for antibiotic 
resistance, and most AMP resistance mechanism often only result in reduced susceptibility to AMPs 
i.e. low levels of resistance (Peschel and Sahl, 2006). Development of resistance to a specific AMP 
should therefore ideally only be compared to that of other AMPs. 
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In paper II we describe the development of resistance to a synthetic AMP peptidomimetic 
(compound 34) and the natural AMP polymyxin B. Heritable resistance to compound 34 was 
demonstrated in several lineages (Table 4.2).  
 
Table 4.2. Changes in the Minimum Inhibitory Concentration (µg/mL) of compound 34 after continuous 
selection and the stability of this after five passages in unsupplemented media. From Paper II. 
Lineage number After selection Stability 
1 n.a. 128-256 
2 256 256 
3 n.a. 128 
4 256 128 
5 64-128 128 
6 n.a. 64-128 
7 128 128 
8 n.a. 32-64 
9 n.a. 128 
10 256 32 
MIC of E. coli ATCC 25922: 8 µg/mL; n.a.: Could not be revived in supplemented media 
 
The pronounced variation in the level of resistance and the stability of this (i.e. lineage 10) indicate 
the presence of multiple resistance mechanisms and/or bacterial population structures in the different 
lineages. This was the first time stable, heritable resistance was demonstrated to a synthetic AMP, 
though another successful study has been performed with the AMP analogue pexiganan (Perron et 
al., 2006). The best parameter for successful development of resistance consequently seems to be 
graduate increases in concentration (Paper II).   
 
Continuous selection experiments have also been shown to be useful for developing resistance to 
antibiotics (Camargo et al., 2008; Girgis et al., 2009; Lee et al., 2010; Palmer et al., 2011). Since 
antibiotic resistance is fairly feasible to develop in the lab, the focus is often on the spread of 
resistance-conferring mutations and bacterial heterogeneity in the evolved populations (Lee et al., 
2010). The development of next generation sequencing technologies has provided the means to study 
the molecular basis of evolution of a genome scale (Conrad et al., 2011). Indeed, whole-genome 
sequencing of highly resistant isolates makes it possible to elucidate the mechanisms behind 
resistance (Hachmann et al., 2011; Lee et al., 2010; Palmer et al., 2011). Point mutations found in 
evolved isolates can then be introduced into the wild type to determine that these are indeed 
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responsible for resistance (Hachmann et al., 2011). The use of hyper-mutator strains has greatly 
facilitated the process by which bacteria are continuous selected for growth in the presence of 
antibacterials (Miller et al., 2002; O'Neill and Chopra, 2001). Hyper-mutator strains can be used to 
predict the emergence of very rare mutants (Baquero, 2001); additionally mutator phenotypes may 
also evolve in bacterial populations (Barrick et al., 2009), which greatly accelerates the rate of 
evolution.  
 
Resistance to AMPs is seldom seen in nature (Zasloff, 2002), where bacteria and natural AMPs seem 
to have co-evolved (Peschel and Sahl, 2006). In nature bacteria are exposed to a range of AMPs with 
different mechanisms of action, whereas in the laboratory lineages can be exposed to a particular 
stress that limits growth creating an intense selection likely to cause specific adaptation (Perron et 
al., 2006). Hence, it is possible that the development of AMP for therapeutic use will not be retarded 
by the observation that AMP resistance can be developed in vitro.  
 
4.3.3. Resistance formed by population-based resistance mechanisms 
Isogenic clones will evolve differently if given enough time (Blount et al., 2008), and this will 
happen with or without the selection pressure of an antimicrobial agent. However, though some 
heterogeneity is expected, it is puzzling how less resistant isolates are able to survive (and evolve?) 
in the presence of high concentrations of antibacterials (Figure 4.10).  
 
 
Figure 4.10. MIC (µg/mL) for compound 34 against individual isolates from lineage 2 (A) and lineage 5 (B). 
The MIC of all isolates is below the population MIC. Solid line: population MIC, punctuated line: wild type 
MIC. From Paper II. 
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We (Paper II) and others (Lee et al., 2010) have demonstrated that the majority of individual isolates 
are less resistant than the population as a whole (Figure 4.10). One obvious explanation is that the 
population is not stable enough to maintain high levels of resistance, but other population-based 
resistance mechanisms could also be responsible for this discrepancy. Microenvironments has been 
shown to accelerate the emergence of bacterial antibiotic resistance (Zhang et al., 2011), and 
although a structured environment is not formed during liquid growth it is possible that there slight 
differences in the local concentrations of the compound. This will lead to the development of 
subpopulations e.g. bacterial aggregation has been seen in the presence of antimicrobials.  
 
In a study of antibiotic resistance following continuous culturing of E. coli it was proposed that a few 
highly resistant isolates improve the survival of the less resistant members of  the population (Lee et 
al., 2010). They do this through the production of indole, a signal molecule that induces protective 
mechanisms in the less resistant cells. Since the production of indole entails a fitness cost, this 
mechanism is equivalent to a form of bacterial kin selection that enhances the survival capacity of 
the overall population (Lee et al., 2010). The presence of a few highly resistant isolates in a bacterial 
population has also been demonstrated with colistin as the selective agent (Adams et al., 2009).   
 
The term “epigenetics” describes the heritable variations in gene expression pattern that exists within 
an isogenic population. It has been demonstrated that epigenetic inheritance can mediate resistance to 
antibiotics (Adam et al., 2008) (Figure 4.11).  
 
 
Figure 4.11. Model for the 
evolution of antibacterial 
resistance based on epigenetic 
inheritance. Within isogenic 
populations there is random 
variation in the expression levels 
of genes. Antibacterial exposure 
(horizontal arrows) selects cells 
with gene expression that favours 
survival. Modified from (Adam 
et al., 2008). 
 
Characteristics of antibiotic resistance based on epigenetic-based inheritance include extremely high 
reversion rates to antibiotic sensitivity (over 50 %) and altered gene expression patterns in resistant 
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cells (Adam et al., 2008). For instance over-expression of the gene encoding glutamate 
decarboxylase resulted in increased ampicillin resistance. Spontaneous epigenetic modifications has 
also been studied in the expression of cell surface antigens and antibiotic persister cells (Avery, 
2006).  
 
Finally, epistasis interactions i.e. how the phenotypic effects of a mutation depends on the other 
mutations in the genome (Chou et al., 2011) may drive the acquisition of resistance and contribute to 
the overall level of resistance within the population (MacLean et al., 2010; Trindade et al., 2009).  
 
4.4. Cross-resistance between AMPs and peptidomimetics 
Development of resistance is most often a result of selection pressure with a single selective agent, 
which explain the effectiveness of combination therapies in preventing antibiotic resistance 
(Fischbach, 2011). However, the evolved resistance mechanism may also confer resistance to other 
compounds besides the primary agent i.e. cross-resistance. Resistance to AMPs varies greatly in 
specificity: in some cases it is highly specific and only protects bacteria against a narrow range of 
peptides, whereas other cases involve mechanisms that confer broad resistance against many 
structural types of AMPs  (Bell and Gouyon, 2003). Indeed, several resistance mechanisms are based 
on the recognition of specific sequences or motifs, making cross-resistance less likely (Fernie-King 
et al., 2004; Kupferwasser et al., 1999; Peschel and Sahl, 2006).  
 
In studies where no cross-resistance is seen, the inability of a specific resistance mechanism to 
protect against AMP activity is likely to be a result of slight differences in the AMP mechanism of 
action (Macwana and Muriana, 2012). Nevertheless, the difficulties in predicting AMP cross-
resistance is clearly evident, since other studies have demonstrated that the resistance developed 
against structurally unrelated AMPs share a common mechanism (Mathur and Waldor, 2004; Mehla 
and Sood, 2011). Two-component systems has also show to be induced by unrelated AMPs, thereby 
forming the potential for cross-resistance between many structural groups (Farris et al., 2010; 
Jochumsen et al., 2011; McPhee et al., 2003).  
 
We demonstrated pronounced levels of cross-resistance within the peptidomimetics library, when E. 
coli had been cultured with a single chimera (Paper II) (Figure 4.12).    
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Figure 4.12. E. coli 
cross-resistance 
between compound 34 
and 36. Asterisk marks 
wild type MIC for 
both compounds. From 
Paper II.  
 
 
 
Cross-resistance was evident between compound 30, 34 and 36 which displays different amino acid 
side groups (lysine/homoarginine), length (12/16 amino acids) and chirality (chiral/non-chiral) (see 
Chapter 2 for the structural design of the different compounds). These results indicate that resistance 
developed against the overall design of the peptidomimetics rather than the specific structural 
moieties. Of note, the level of chirality is believed to have a large impact on the secondary structure 
of the compound, which could affect the interaction with the bacterial membrane (Deslouches et al., 
2005b; Zhang et al., 2001). We did not find cross-resistance to other membrane-active peptides, 
making it even more interesting that AMP resistance mechanisms based on structural changes of the 
cell envelope, and of the outer membrane in particular, have been shown to also confer resistance to 
conventional antibiotics which nonetheless interact with the membrane in a substantially different 
way than AMPs  (Fernandez et al., 2010; Muller et al., 2011; Rahaman et al., 1998).  
 
4.5. Conclusions from chapter 4 
Bacteria use several different resistance mechanisms for protecting themselves against the activity of 
AMPs. The most common of these include modification of the cell envelope or membrane (leading 
to decreased charge or permeability), efflux pumps and proteases. Additionally, resistance may be 
induced by AMP sensing of two-component systems. Continuous selection provides a way of 
acquiring resistance through cumulative changes, which was successfully employed for the 
peptidomimetics. Modification of the peptidoglycan layer in the cell envelope of E. coli is the likely 
cause of resistance to the α-peptide/β-peptoid chimeras.
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5.  Antibacterial activity under physiologically relevant conditions 
 
A critical step in the further advancement of novel antimicrobial compounds is the transition from 
test tube activity to characterisation in biological environments. Due to the inherent properties of the 
peptidomimetic (or antimicrobial peptide, AMP), the compound may interact with blood or tissue 
components leading to changes in activity. Changes in activity due to the presence of various 
immune factors constitute a major obstacle in predicting peptide activity in vivo and this topic is 
therefore the primary focus of this chapter. Understanding the effect physiological environments may 
have on the antibacterial activity of these compounds will enables us to provide a preliminary 
evaluation of their therapeutic potential. 
 
5.1.  Factors influencing AMP activity in a physiological environment 
Three years ago a study was published in Nature on the activity of Platensimycin, an inhibitor of the 
type II fatty acid synthesis pathway, in a model that simulate environments relevant to infection i.e. 
human serum (Brinster et al., 2009). Platensimycin is one of many natural antibiotics characterised 
within the last years, which has showed great potential against Gram-positive bacteria in standard 
laboratory media. However, serum (and thereby also blood) contains large amounts of fatty acids, 
and once activity was determined under these biologically relevant conditions, inhibition of fatty acid 
biosynthesis was completely abolished since the bacteria naturally will use the fatty acids that are 
available to them (Brinster et al., 2009). This is an excellent example of the need to determine and 
understand activity of new antimicrobial compounds under relevant physiological conditions. 
 
Physiological relevant conditions can lead to a decrease in or a complete loss of activity of otherwise 
promising compounds making these unusable for systemic use (O'Neill and Chopra, 2004; Powell et 
al., 1993; Sabath, 1978). The structure of AMPs makes them particularly sensitive to biological 
environments and to date many clinical trials (i.e. Phase III) have therefore been restricted to topical 
applications (Andres, 2011; Yeung et al., 2011). A well known example of a therapeutic AMP 
currently on the market is colistin (or polymyxin E), a bacteriocin structurally similar to polymyxin 
B and isolated from Bacillus polymyxa. Colistin is widely used for aerosol treatment of 
Pseudomonas aeruginosa in cystic fibrosis patients (Michalopoulos and Papadakis, 2010), although 
high levels of resistance and toxicity issues has strongly affected its use (Falagas et al., 2010; 
Fernandez et al., 2010). The increased salinity of the bronchopulmonary fluids in cystic fibrosis 
patients constitute a large obstacle in the development of new AMPs against lung infections in these 
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patients since the activity of AMPs is extremely sensitive to salt concentrations, thereby creating a 
market for the development of salt-resistant AMPs (Deslouches et al., 2005a; Friedrich et al., 1999; 
Goldman et al., 1997). It is not clear if the mechanism behind salt sensitivity is obstruction of 
binding sites on the bacterial membrane or reduced stability of the compound (Deslouches et al., 
2005a). 
 
Degradation of AMPs by body proteases can lead to premature blood clearance creating 
unfavourable pharmacokinetics (Yeung et al., 2011). Testing serum stability has therefore become an 
essential part of AMP development (Jenssen and Aspmo, 2008) and strategies to stabilize peptides 
against serum proteases is an important part of the structural design (Knappe et al., 2010). The α-
peptides/β-peptoids, which are the focus of this thesis, have previously been found to be resistant to 
proteases (Olsen et al., 2007; Olsen et al., 2010), which can be attributed to structural features of the 
peptoid moiety (Chongsiriwatana et al., 2008; Godballe et al., 2011) (Chapter 2). In addition to 
protease degradation, protein binding may also decrease serum levels of the unbound antibacterial 
thereby indirectly reducing antibacterial activity (O'Neill and Chopra, 2004). Binding to albumin or 
lipoproteins can therefore also explain lower activity in serum or whole blood compared to what is 
seen in standard media (Deslouches et al., 2005a; McKay et al., 2009; Sorensen et al., 1999). 
 
One of the major worries regarding the therapeutic use of AMPs or peptidomimetics is that their 
mechanism of action is very similar to the action of natural AMPs, from which they have been 
designed, as well as other compounds of the innate immune system. Interaction with components of 
our own immune system makes it difficult to predict peptide activity in vivo and could potentially 
have unknown consequences on our ability to fight infections (Bell and Gouyon, 2003).  
 
5.2.  Antibacterial compounds of the innate human immune system 
Before discussing the effects the simultaneous activity of immune factors and antimicrobial peptides, 
I will first give a brief introduction to the immune factors which may affect peptide activity. I will 
only mention other parts of the immune system (e.g. immune cells) in their role as producers or 
mediators of activity. 
 
5.2.1. The ubiquitous innate defence molecules 
The neutrophils are central cellular effectors of the innate system with many of the blood active 
antimicrobial proteins and peptides in their granule-associated arsenal (Levy, 2000). These cells 
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contain two types of cytoplasmic granules; the primary (azurophil) and secondary (specific) after the 
order in which they are synthesized (Levy, 2000). The content of the primary granule is largely 
released into the phagolysosome thereby exposing ingested bacteria to its contents (Figure 5.1).  
 
 
Figure 5.1. Neutrophil degranulation of 
antimicrobial proteins and peptides. Secondary 
granules are more prone to degranulate their 
contents into the extracellular fluid, whereas 
primary granules are predominately degranulated 
into the phagolysosome. From (Levy, 2000). 
 
 
 
The phagolysosome is the mature phagosome, which is also an essential feature of the activity of 
macrophages and dendritic cells, and is designed for degradation of engulfed microorganism 
(Flannagan et al., 2009). The phagosome has a central role in the generation of oxygen-dependent 
immune factors, which will be described later. The contents of the primary granule include 
defensins, AMP-like compounds and lysozyme. Since these compounds are primarily released 
intracellularly their concentration in the blood is low; additionally the defensins are strongly 
inhibited by cations and blood proteins and their activity would therefore be inhibited in the 
extracellular environment  (Levy, 2000). In contrast to the primary granule of neutrophils, the 
contents of the secondary granule is primarily released into the extracellular space (Figure 5.1), and 
larger concentrations of these compounds which include cathelicidins, lactoferrin and lysozyme will 
therefore be present in the blood (Levy, 2000; Sorensen et al., 1999). 
 
The peptidomimetics designed by KU Pharma mimic the structure and mechanism of action of 
natural AMPs. The diversity of natural AMPs was reviewed in Chapter 2, but some additional 
explanations seem justified for human AMPs. As for other mammals a cocktail of AMPs belonging 
to different structural classes are expressed in humans (Zasloff, 2002), which are likely to have 
overlapping activities (Hancock and Sahl, 2006; Rieg et al., 2011) or ability to form synergy with 
each other (Chen et al., 2005a; Yan and Hancock, 2001). Multiple studies have shown that AMPs 
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protect against invasive bacterial infections particularly at epithelial surfaces, which is a common 
place of expression of these compounds (Goldman et al., 1997; Islam et al., 2001; Nizet et al., 2001).  
  
In humans two families of AMPs exist, the cathelicidins and the defensins (Brown and Hancock, 
2006; Maroti et al., 2011). The sole representative of the cathelicidins in humans is LL-37 (Bowdish 
et al., 2005), which is produced by proteolytic cleavage of the hCAP-18 precursor protein (Nijnik 
and Hancock, 2009). As indicated by the name it is a 37 amino acid long AMP, and has an α-helical 
secondary structure (Figure 5.2., for more information on the different structural families of AMP 
see Chapter 2). LL-37 is produced by both neutrophils and epithelial cells (Nijnik and Hancock, 
2009), and is an important part of the innate immune defence at epithelial surfaces for protection 
against skin infections (Nizet et al., 2001). Due to its release from neutrophils into the extracellular 
fluid large concentrations in the µg/mL range have been found in plasma (Zahner et al., 2010) 
though often bound to lipoproteins (Sorensen et al., 1999). Like many other AMPs, LL-37 target the 
bacterial plasma membrane leading to permeabilization of this followed by rapid cell death though 
the exact mechanisms behind membrane interaction are still unclear (Lee et al., 2011).  
 
 
 
Figure 5.2. Structure of the two families of human AMPs; the defensins and the cathelicidin (LL-37). The 
defensins can be further sub-divided based on the linking pattern between cysteine. Modified from (Hancock 
and Sahl, 2006). 
 
Defensins constitute the other group of AMPs in humans (Hazlett and Wu, 2011). They have a β-
sheet structure linked by three disulfide bonds formed by six cysteine residues and can be classified 
into two main classes, α- and β-defensins based on the linking pattern between these cysteines 
(Ganz, 2003) (Figure 5.2). The α-defensins are concentrated in the neutrophils granules but also in 
the Paneth cells of the small intestine, while β-defensins are primarily secreted by mucosal surface 
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epithelia (Hazlett and Wu, 2011). In humans six α-defensins (human neutrophil peptide, hNP 1-4 and 
human defensin, hD 1-2) and four β-defensins (human beta defensins, hBD 1-4) have been found to 
date (Hazlett and Wu, 2011). The mechanism of action of defensins is, similarly to that of LL-37, 
permeabilization of the bacterial plasma membrane leading to cell lysis (Lehrer et al., 1989). Some 
strains of Staphylococcus aureus are resistant to defensins  (Peschel et al., 2001) though resistance is 
not reflected in the clinical manifestations of infection with this bacterium (Rieg et al., 2011). 
 
Other antimicrobial compounds of the innate immune defence with an AMP-like mechanism of 
action include the bactericidal/permeability-increasing protein (BPI), lactoferrin and the serprocidins 
(Levy, 2000). The BPI protein has a prominent role in the activity against Gram-negative bacteria in 
that it displays high activity in blood, serum and plasma, exerts multiple activities against bacteria 
(i.e. lysis, opsonisation, neutralization of LPS) and can act in synergy with defensins, LL-37 and the 
complement system (Elsbach and Weiss, 1998; Schultz and Weiss, 2007).  
 
The enzymatic activity of lysozyme involves hydrolysis of the peptidoglycan layer of the bacterial 
cell envelope, and since this is primarily found in Gram-positives its activity is predominantly 
limited to these bacteria. It is produced by both primary and secondary granules and is present in 
µg/mL concentrations in the blood (Taylor, 1983) but is also abundant in body secretions. Lysozyme 
activity is mainly mediated through synergy with other antimicrobial compounds of the innate 
immune defence and synergy has been found to both AMPs (Bals et al., 1998; Yan and Hancock, 
2001) and the antibody-complement system (Taylor, 1983). This suggests that lysozyme gains access 
to the peptidoglycan substrate only after the integrity of the outer membrane has been compromised 
by another compound. For this reason, lysozyme alone is not considered effective against Gram-
negative bacteria. Modification of the peptidoglycan backbone of Gram-positive bacteria decreases 
the bacterial sensitivity to lysozyme thereby preventing cell lysis (Davis and Weiser, 2011).  
 
Activated neutrophils and macrophages increase oxygen consumption in what has been termed the 
respiratory burst (Levy, 2000) leading to the production of reactive oxygen (ROS) and nitrogen 
species (RNS), which form the oxygen-dependent part of the innate immune defence (Fang, 2004). 
The NADPH-dependent phagocyte oxidase found in neutrophils release superoxidase into the 
phagosomal lumen upon phagocytosis which is then converted into hydrogen peroxide (Flannagan et 
al., 2009; Radtke and O'Riordan, 2006). Experimental wound models in zebrafish has demonstrated 
that concentrations of hydrogen peroxide can reach 50 µM near a wound margin (Niethammer et al., 
2009). Nitric oxide is particularly associated with macrophages where it is produced by the inducible 
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nitric oxide synthase (iNOS) before it is converted to reactive nitrogen species (Radtke and 
O'Riordan, 2006). Both ROS and RNS interact with numerous bacterial targets leading to protein 
inactivation, lipid conversion and irreversible DNA damage (Flannagan et al., 2009). 
 
5.2.2. Formation and role of the complement-antibody complex 
The bactericidal and bacteriolytic properties of serum or plasma against susceptible Gram-negative 
bacteria stems primarily from the complement cascade (Taylor, 1983). The complement system is 
present in the blood as inactive pre-cursor proteins but will when triggered be activated through one 
of  three distinct cascades, the classical, alternative or lectin pathway of complement activation 
(Trouw and Daha, 2011). Activation of either of these pathways by Gram-negative bacteria leads to 
the formation and insertion into the bacterial envelope of a multi-component complex, the membrane 
attack complex (MAC), leading to pore formation and bacteriolysis (Kondos et al., 2010) (Figure 
5.3).  
 
 
Figure 5.3. Complement cascade, In 
vertebrates there are three cascade 
pathways: classical, lectin and alternative. 
This can lead to the formation of the 
membrane attack complex (MAC) causing 
pore formation in the membrane. From 
(Danilova, 2006). 
 
Several studies (Frank et al., 1987; Tanaka et al., 2010; Taylor, 1983) have shown that pore 
formation due to complement activity is dependent on the presence of antibodies since antibody-
depleted serum is unable to form pores on the bacterial surface (Figure 5.4). 
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Figure 5.4. Bacteriolysis of serum-treated Pseudomonas aeruginosa caused by visible pore formation. 
Pictures from left to right show pre-treated cells (far left) and cells in different stages of bacteriolysis. Lysis 
was associated with disposition of complement component C9 but only in the presence of antibodies.  
Modified from (Tanaka et al., 2010). 
 
It has been suggested that antibodies directs the complement attack by enhancing the specificity of 
the reaction (Frank et al., 1987; Joiner et al., 1987) but it also has an involvement in the formation of 
the pore complex itself (Tanaka et al., 2010). 
 
Heat-treatment of plasma (Hazen, 1943; Zinsser and Johnson, 1911) proved early on to be a simple 
way to inactivate the complement system, and this method can be used to get a preliminary 
indication of the role of the complement in studies where the bactericidal effect of plasma or synergy 
with antimicrobial compounds needs elucidation (as explained in the next section). Another more 
direct method for complement inactivation is the use of antibodies to inhibit specific components of 
this system (Darveau et al., 1991; Dutcher et al., 1978). 
 
The evasion of complement activity by bacteria can result in persistence of infection (Granoff, 2009; 
Zipfel, 2009). In such serum-resistant strains the MAC is formed but not properly inserted into the 
membrane (Frank et al., 1987). 
 
5.3.  Activity of antibacterials in the presence of innate immune factors 
Since the activity of the innate immune system is formed by a complex network of antimicrobial 
compounds, the introduction of foreign antimicrobial drugs into this system can have consequences. 
Antibiotics for treatment of bacterial infections were a landmark in modern medicine and are now 
the common route when the immune system fails. The structure and mechanism of AMPs are 
different and could potentially have more dire consequences on the function of the immune system. 
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Hence, it is important to investigate the activity of these compounds in the presence of an active 
immune system.  
 
5.3.1. Activity in the presence of single immune factors 
It has been stated that the therapeutic use of AMPs could “arm the enemy” (Bell and Gouyon, 2003) 
i.e. allow the bacteria to develop AMP resistance, which could affect bacterial susceptibility to 
human AMPs. In fact a few studies have indicate that this concern is justified (Habets and 
Brockhurst, 2012; Jones et al., 2008; Mishra et al., 2011b), but similar studies with antibiotics have  
suggested that they too could be a cause of concern (Kristian et al., 2007; Zahner et al., 2010). Cross-
resistance of daptomycin-resistant Staphylococcus aureus to human AMPs (i.e. hNP-1 and thrombin-
induced platelet bactericidal protein (tPMP)) has been found in two separate studies (Jones et al., 
2008; Mishra et al., 2011b). Daptomycin is a lipopeptide antibiotic, but have a similar membrane-
disrupting mechanism of action as many AMPs. Bacteriostatic antibiotics may similarly impair the 
activity of LL-37 against Escherichia coli and S. aureus in vitro as well as the complement-mediated 
killing of E. coli (Kristian et al., 2007).  
 
The combination of antimicrobial drugs and immune factors can also result in synergy. 
Consequently, sub-inhibitory concentrations of antibiotics increase the bacterial susceptibility to 
hNP-1 and tPMP (Xiong et al., 1999), the stability of membrane attack complex of the complement 
cascade (Schweinle and Nishiyasu, 1992) and neutrophil phagocytosis (Mandell and Afnan, 1991). 
In vitro synergy has also been demonstrated between lysozyme and different groups of AMPs (Bals 
et al., 1998; Yan and Hancock, 2001). However, we were not able to demonstrate synergy between a 
chimera and various immune factors (a short analogue of LL-37, lysozyme or hydrogen peroxide) in 
their activity against E. coli nor did we find a change in the susceptibility to these compounds after 
acquisition of chimera resistance (Paper III). 
 
The mechanisms behind the interaction of immune factors and antimicrobials are often unknown, 
and it seems like that the exact mechanisms vary between different combinations. One study showed 
that the antagonistic effect of bacteriostatic antibiotics on LL-37 activity was due to preferential 
targeting at the plane of cell division of the latter, a condition of heightened susceptibility that the 
bacteriostatic antibiotics prevented (Kristian et al., 2007). Generally, for drugs having intracellular 
targets, the activity of immune factors (AMPs, lysozyme or complement) is likely to disrupt the cell 
envelope thereby potentially increasing the intracellular concentrations of the compound (Dutcher et 
al., 1978). Increasing the permeability of the bacterial cell membrane is also an effective method in 
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combinatory antimicrobial drug treatment or for sensitization of resistant strains (Pomares et al., 
2010). Many immune factors are active against different components of the cell envelope, of which 
the cell membrane is an often described target for natural AMPs and the principle target of synthetic 
AMPs (Vooturi and Firestine, 2010). However, since large variations occur in the exact interaction 
of drugs or immune factors with components of cell envelope, seen by the lack of cross-resistance 
often found between membrane-active AMPs, it is possible that the activity of one compound primes 
the bacterial cell for activity of the other (Dutcher et al., 1978; Schweinle and Nishiyasu, 1992; 
Vaara and Vaara, 1983).  
 
In line with this, we saw that disruption of the outer membrane by the chelating agent EDTA 
subsequently increases the susceptibility of E. coli to the chimeras (Figure 3.3) indicating that 
combining the chimeras with another compound that has the cell envelope as a target can at least in 
some cases result in synergy. 
 
5.3.2. Activity in a simulated immune system environment  
Human or mammalian whole blood and cell-free derivatives thereof are widely used simulated in 
vivo systems for predicting the potential systemic activity of antimicrobial compounds (Taylor, 
1983). Whole blood demands easy access to donors, and the majority of studies have therefore been 
done with blood serum; blood which has been allowed to clot after which blood cells are removed.  
However, adding anticoagulant to freshly drawn blood before removal of blood cells will result in 
blood plasma, which essentially is the cell-free fraction of whole blood while still containing the 
same soluble components and is hence likely to be a more correct model system than serum. 
 
Determining the effect single immune factors may have on the activity of antimicrobial drugs (as 
described above) is relatively straightforward and ideas to the mechanism behind interactions can 
even be proposed if the bacterial target of both individual compounds is known. Determining cause 
of effects in a less easily defined immune system environment such as blood plasma or blood serum 
is more difficult because it is often not known what plasma or serum components actually mediates 
an effect. In cases where the blood plasma in itself seem to exert an effect on the bacteria it becomes 
even more difficult to distinguish plasma-mediated potentiation of drug activity from the bactericidal 
activity of blood plasma (Paper III).  
 
As part of the pre-clinical development of new antimicrobials, the activity of these compounds is 
often determined in whole blood, plasma or serum to determine the potential in vivo activity in a 
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simple (and safe) model. Hence, activity has been determined in these fluids for both antibiotics 
(Dutcher et al., 1978; Pruul and McDonald, 1992) and AMPs (Deslouches et al., 2005a; Viljanen et 
al., 1986; Yeaman et al., 2002; Zhanel et al., 1998). Since it is our aim to use the present 
peptidomimetics for therapeutic use, we similarly wanted to determine their activity in a simulated in 
vivo system such as human blood plasma and chose a single α-peptide/β-peptoid chimera (compound 
30) from the library for this. We found a pronounced increase in activity in the presence of blood 
plasma (Table 5.1, Paper III). 
 
Table 5.1. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of 
compound 30 against Escherichia coli grown in MHB with/without human blood plasma, From Paper III.  
Growth conditions MIC (µg/mL) MBC (µg/mL) 
MHB media 4 4 
MHB + 50 % plasma 0.125-1 1 
MHB + 50 % inactivated plasma 8 8 
 
The potentiation by plasma was abolished following heat-treatment similar to observations in 
previous studies of AMP activity (Fierer and Finley, 1979; Vaara et al., 1984; Yeaman et al., 2002; 
Zhanel et al., 1998). It is well known that heat-treatment of plasma inactivates the complement 
system (Hazen, 1943). It has therefore become a widely used method to establish the role of 
complement in plasma potentiation of antimicrobial drugs  (Kristian et al., 2007; Odio et al., 1984; 
Pruul and McDonald, 1992). The relevance of heat-inactivation in these studies is emphasized by the 
proposal that the bacteriolytic activity of plasma and serum against Gram-negatives stems primarily 
from complement-mediated killing (Taylor, 1983). 
 
Other studies have used complement-directed antibodies (Dutcher et al., 1978) or complement  
deficient sera (Darveau et al., 1991; Darveau and Cunningham, 1990; Fierer and Finley, 1979; Vaara 
et al., 1984) to investigate the role of complement in plasma potentiation. Consequently, in the 
majority of studies with heat-treatment or complement-deficient serum it is suggested (or even 
concluded) that complement is responsible for observed plasma potentiation of antimicrobial drugs 
((Darveau et al., 1991; Davidson et al., 1991; Dutcher et al., 1978; Fierer and Finley, 1979; Tateda et 
al., 1993); only in a single study did heat-inactivation of serum not inhibit the enhancement of 
antibiotic activity (Pruul and McDonald, 1992), but no suggestions was made to what serum 
components then mediates the observed effect. 
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The knowledge that blood components may potentiate the activity of antimicrobial drugs is 
important in the fight against AMP- and antibiotic-resistant bacteria, since it can be speculated if de 
facto resistance actually will be diminished once bacteria enter the body. We demonstrated that 
plasma susceptibility of three chimera-resistant isolates increased following resistance acquisition 
and that chimera MIC against these isolates returned to wild type level in the presence of plasma 
(Paper II).  A few other studies have investigated plasma susceptibility of antibiotic-resistant strains  
(Alexander et al., 1980; Dutcher et al., 1978; Kristian et al., 2007; Odio et al., 1984), but several of 
these studies were done with unstable (i.e. inducible resistant ) strains or found no changes in the 
effect of serum addition compared to what is seen for antibiotic-susceptible strains. One study (Odio 
et al., 1984) did, however, show that the MIC of a mezlocillin-resistant E. coli approached the MIC 
of mezlocillin-susceptible E. coli in the presence of serum.  Though the results from our study are 
still preliminary, they speak strongly against the notion that the use of AMP therapeutics would “arm 
the enemy” as have been previously suggested (Bell and Gouyon, 2003).  
 
5.4.  Conclusions from chapter 5 
Evaluation of the therapeutic potential of AMPs and peptidomimetics includes determining the 
activity of these compounds under physiologically relevant conditions. However, once in body fluids 
AMPs are prone to bind to proteins, be degraded by proteases or interact with the immune system 
making it difficult to predict the potential in vivo activity.  The activity of the immune system is 
mediated by a complex network of antimicrobial compounds that can diminish or increase the 
activity of therapeutic AMPs. Blood plasma or blood serum can be used as simulated in vivo 
systems. Several studies have shown that potentiation of AMP activity in this environment is due to 
interaction with the complement system, and our results indicated that the same was the cause for the 
observed plasma potentiation of α-peptide/β-peptide activity. Using chimera-resistant isolates we 
additionally showed that acquisition of resistance lead to increased plasma susceptibility. Our results 
significantly increase the therapeutic potential of these compounds. 
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6. Concluding remarks and future perspectives 
 
Antimicrobial peptides (AMPs) are considered promising future drugs for treatment of bacterial 
infections. Several AMPs are now in clinical development, and an additional few have already been 
marketed. However, due to unfavourable toxicity towards human cells the application of these 
compounds is often restricted to topical use. The balance between retaining high antibacterial activity 
and limiting toxic effects can be fine-tuned by the use of chemical synthesis to create novel 
peptidomimetics. This involves minor structural modifications of synthetic AMP analogues allowing 
repeated optimization of antibacterial activity, while making it possible to limit undesirable side-
effects. One of the main purposes of this thesis was to establish how peptide structure and 
antibacterial activity are correlated, and additionally to determine if mechanistic differences could 
explain resulting changes in activity.  
 
All work in this thesis was done using a series of α-peptide/β-peptoid chimeras designed and 
synthesized at the Faculty of Pharmaceutical Sciences, Copenhagen University. These compounds 
are distinctive because their design does not allow the compound to form the amphipathic helical 
secondary structure observed for several other synthetic analogues. A heterogeneous design allows 
for a higher number of structural modifications and has previously been most studied for α/β-
peptides. For the present work we focused on establishing the antibacterial effect of different α-
amino acid compositions, the presence of chirality in the β-peptoid unit and modifications of peptide 
chain length. Only chain length had a pronounced effect on MIC values since analogues shorter than 
12 residues were virtually inactive. Chimeras that were non-chiral in the β-peptoid unit have been 
reported to form a lower degree of secondary structure than chiral analogues. Our findings indicate 
that the ability to form secondary structures only has a minor effect on activity. This warrants for 
additional studies of how compounds with different levels of chirality interact with the bacterial cell 
membrane. 
 
We studied the antibacterial mechanism of action for selected chimeras. In line with others we found 
that the chimeras permeabilize the membrane leading to leakage of intracellular compounds, in our 
case ATP. Whereas most studies have been performed on model membranes, we chose to use viable 
bacterial cells. Importantly, the chimera concentration used for achieving leakage was lower than the 
observed MIC values when bacterial cell numbers are taking into account. This discrepancy suggests 
that i) the cell membrane is damaged but the cells remain viable or ii) that only the cell membranes 
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of a proportion of cells is disrupted. Our findings from using series of chimeras of different length 
(i.e. 8, 12 and 16) residues clearly demonstrated that though some ATP is leaked from cells this does 
not necessarily lead to a loss in number of viable cells. Hence, bacteria may survive despite of 
(minor) damage to the membrane; a conclusion that is important considering the number of studies 
done on peptide activity against model membranes. The length series included both lysine and 
homoarginine in the repeat, and only the analogue with a length of 16 residues caused complete 
depletion of intracellular ATP. This is in line with what has been found previously for α-helical 
peptides, but since we don’t yet know the precise secondary structure of these compounds, a model 
for their conformation during pore formation/disruption is presently lacking. Conversely, two other 
chimeras (30 and 34) with a length of 12 residues and only containing homoarginine as the α-amino 
acid caused a critical degree of membrane disruption for the number of viable cells to decrease. 
Collectively, our results suggest that despite of minor structural differences between the chimeras, 
their interaction with the membrane varies profoundly. 
 
The considerable attention AMPs has received over the last decades stems primarily from the notion 
that resistance development is unlikely. If resistance to these compounds also confers resistance to 
AMPs of the human immune defence, it is important that this claim holds true since it would 
otherwise compromise our ability to resist infections. Nevertheless, several research groups have 
successfully developed resistance towards AMPs and it was therefore important to clarify the 
resistance potential of the α-peptide/β-peptoid chimeras. Accordingly, we demonstrated that 
continuous exposure to one of the synthetic analogues did select for resistance, which was the first 
time resistance towards a peptidomimetic was reported. It can be speculated that it may be less 
desirable to conduct comprehensive studies of potential resistance development for in house 
designed analogues. Importantly, we demonstrated that though resistance to peptidomimetics may 
develop, no cross-resistance was found to a range of membrane-active AMPs. The details of the 
interaction between the bacterial membrane and AMPs/peptidomimetics have been extensively 
debated and several models have been proposed for the interaction which additionally may differ for 
different compounds. Our results illustrate that the resistance mechanism towards peptidomimetics 
does not confer universal protection against other membrane-active AMPs.  
 
Comparing genome sequences of wild type and peptidomimetic resistant mutant, led us to consider a 
SNP in the gene encoding the membrane-bound lytic murein transglycosylase (mltD) as the most 
likely cause for resistance to the chimeras. Consequently, we plan to introduce this SNP into the 
ancestral wild type bacteria to see if this confers a decrease in chimera susceptibility. Since no other 
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studies have successfully developed resistance to peptidomimetics, it is unknown if the mechanism is 
specific for the present peptidomimetics. Resistance mechanisms involving modifications to the cell 
wall thereby causing reduced AMP entry has been reported numerous times. Consequently, it is 
peculiar that we did not observe any cross-resistance to AMPs outside the peptidomimetics library. 
Our findings could suggest that the α-peptide/β-peptoid chimeras in addition to its cell-
permeabilizing activities also have an effect on the peptidoglycan layer. If these compounds have a 
distinct way of interacting or traversing the peptidoglycan layer that differs from that of natural 
AMPs this would explain why resistance does not confer universal protection against AMPs. We 
only investigated chimera resistance development in Escherichia coli and it would be interesting to 
investigate if the mechanisms differ for other bacteria. A similar study has been performed recently 
for Staphylococcus epidermidis, but a single apparent resistance mechanism was not found (Y. Liu, 
personal communication). Interestingly, this study indicated that two distinct SNP profiles develop 
when the bacteria are exposed to one of two different chimeras. Hence, the development of 
resistance may be different for compounds with minor structural differences, which is in direct line 
with what we have found to occur for membrane activity. These observations have led us to 
hypothesize that resistance development may be circumvented through structural modifications of 
the present scaffold, which we plan to pursuit in future years. Hence, different structures will be 
probed for their ability to induce resistance leading to repeated optimization of promising structures. 
If resistance development can be prevented completely, this will increase the therapeutic potential of 
peptidomimetics considerably.  
 
The findings in this thesis have demonstrated how structure affects the antibacterial activity and 
mechanism of action of peptidomimetics. In addition, we showed that resistance may develop, which 
cautions against the indiscriminate use of these compounds. We strongly recommend that 
comprehensive studies of potential resistance development should be an integrated part of the 
characterisation of novel peptidomimetics.  This can be concluded even though we observed that 
resistant isolates were in fact more sensitive to (immune) factors present in human plasma. We need 
to conduct further studies to provide an explanation for these results, before we can determine the 
effect resistance may have on the human immune system.  Collectively, our results do not discourage 
the development of peptidomimetics as potentially useful antibacterial agents. The great potential of 
these compounds is based on the possibility to optimize their properties through structural 
modification. Hence, AMPs and synthetic analogues thereof in particular, can still be considered 
promising future antibacterials.   
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Abstract
Background: Characterization and use of antimicrobial peptides (AMPs) requires that their mode of action is
determined. The interaction of membrane-active peptides with their target is often established using model
membranes, however, the actual permeabilization of live bacterial cells and subsequent killing is usually not tested.
In this report, six a-peptide/b-peptoid chimeras were examined for the effect of amino acid/peptoid substitutions
and chain length on the membrane perturbation and subsequent killing of food-borne and clinical bacterial
isolates.
Results: All six AMP analogues inhibited growth of twelve food-borne and clinical bacterial strains including
Extended Spectrum Beta-Lactamase-producing Escherichia coli. In general, the Minimum Inhibitory Concentrations
(MIC) against Gram-positive and -negative bacteria were similar, ranging from 1 to 5 μM. The type of cationic
amino acid only had a minor effect on MIC values, whereas chain length had a profound influence on activity. All
chimeras were less active against Serratia marcescens (MICs above 46 μM). The chimeras were bactericidal and
induced leakage of ATP from Staphylococcus aureus and S. marcescens with similar time of onset and reduction in
the number of viable cells. EDTA pre-treatment of S. marcescens and E. coli followed by treatment with chimeras
resulted in pronounced killing indicating that disintegration of the Gram-negative outer membrane eliminated
innate differences in susceptibility. Chimera chain length did not influence the degree of ATP leakage, but the
amount of intracellular ATP remaining in the cell after treatment was influenced by chimera length with the
longest analogue causing complete depletion of intracellular ATP. Hence some chimeras caused a complete
disruption of the membrane, and this was parallel by the largest reduction in number of viable bacteria.
Conclusion: We found that chain length but not type of cationic amino acid influenced the antibacterial activity
of a series of synthetic a-peptide/b-peptoid chimeras. The synthetic chimeras exert their killing effect by
permeabilization of the bacterial cell envelope, and the outer membrane may act as a barrier in Gram-negative
bacteria. The tolerance of S. marcescens to chimeras may be due to differences in the composition of the
lipopolysaccharide layer also responsible for its resistance to polymyxin B.
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Background
Antimicrobial peptides (AMPs) are host defence molecules
that constitute an essential part of the innate immune sys-
tem among all classes of life [1]. Most AMPs permit the
host to resist bacterial infections by direct killing of invad-
ing bacteria or other microorganisms, however, many
AMPs are also immuno-modulatory and thus enhance the
host defence against pathogens [2-5].
In addition to their natural role in combating infections,
AMPs are recognized as promising alternatives to conven-
tional antibiotics for which development of resistance has
become an ever-increasing concern [6-8]. Peptide based
drugs are often hampered by a rapid in vivo degradation,
however, this may be circumvented by stabilizing natural
AMPs by single-site substitutions or by designing novel
synthetic analogues with an altered backbone that confers
complete stability to the compounds. Careful investigation
of structure-activity relationships may eventually allow
design of optimised antimicrobial compounds with high
activity and minimal side effects [9-15].
Many AMPs fold into an amphipathic structure, and it
is believed that this topology enables pore formation or
disintegration of bacterial cell membranes leading to bac-
terial cell death. The amphipathic properties usually
include cationic patches that promote interaction with
the anionic bacterial membrane as well as hydrophobic
patches that favor integration into the membrane. Since
this is the most common mode of action for AMPs there
has been an intense focus on their ability to adapt an
amphipathic conformation [16,17]. In particular, design
of peptides with a high propensity to fold into a helical
amphipathic conformation has attracted considerable
interest [13,18-20].
We have previously described a synthetic approach for
design of a-peptide/b-peptoid chimeras possessing a
design with alternating N-alkylated b-alanine (b-peptoid)
and a-amino acid units (Figure 1). In addition, prelimin-
ary investigations showed that such peptidomimetics
constitute a novel subclass of proteolytically stable anti-
microbial compounds [21-23]. This design displays chiral
unnatural b-peptoid residues that appear to contribute
with structure-promoting effects and lipophilicity, while
strongly cationic properties and intramolecular hydrogen
bonding capacity are introduced via the a-amino acids
lysine and/or homoarginine [24]. The precise secondary
structure of these chimeras still remains to be elucidated,
nevertheless, circular dichroism (CD) spectroscopy
clearly indicates the presence of some degree of second-
ary structure [22,23]. Interestingly, a higher degree of
secondary structure was found for analogues containing
chiral side chains in the b-peptoid units (i.e. compounds
2 and 3 in Figure 1) as compared to chimeras with achiral
b-peptoid residues (i.e. compound 1 in Figure 1) [22], but
the effect of this on antibacterial activity remains largely
unresolved [23].
The membrane-destabilizing effects of the chimeras
have only been investigated in model liposomes pre-
pared from phosphatidylcholine, a phospholipid found
Figure 1 Chemical structure of the six a-peptide/b-peptoid
chimeras
Hein-Kristensen et al. BMC Microbiology 2011, 11:144
http://www.biomedcentral.com/1471-2180/11/144
Page 2 of 12
predominantly in eukaryotic cells, and several of the chi-
meras permeabilized such liposomal membranes [24].
Most studies on membrane activity of antimicrobial
peptides have in fact been performed on model mem-
branes [25-28] while the effects on cell membranes of
viable bacteria have often not been tested. Also, the
effect of membrane permeabilization on killing of bac-
teria has not been tested [27].
Here, we test the antibacterial effect of six chimeras
against a spectrum of bacterial strains that include several
important clinical and food-borne pathogens. The main
purpose was to examine how the type of cationic amino
acid and sequence length affected the antibacterial activity
and to correlate this to a potential membrane-related
mode of action in viable bacteria.
Part of this work was presented at the 50th InterScience
Conference on Antimicrobial Agents and Chemotherapy
in Boston 12-15th of September 2010.
Methods
Bacterial strains and culture conditions
Initial activity experiments were carried out with twelve
strains from seven bacterial species representing com-
mon laboratory strains and clinical strains derived from
both food-borne and nosocomial infections (Table 1).
Stock cultures were stored at -80°C in 4% (w/v) glycerol,
0.5% (w/v) glucose, 2% (w/v) skimmed milk powder and
3% (w/v) tryptone soy powder. All experiments were
carried out with bacteria incubated for one night (i.e.
approximately 18 hours) at 37°C. Experiments were per-
formed in cation-adjusted Mueller Hinton II broth
(MHB) (Becton Dickinson 212322) adjusted to pH 7.4
or Tryptone Soy Broth (TSB) (Oxoid CM0129) for the
ATP leakage assays. Brain Heart Infusion (BHI)
(CM1135) with agar (VWR 20768.292) 1.5% as gelling
agent was used throughout for colony plating.
Peptide synthesis and selection
a-Peptide/b-peptoid chimeras consisting of alternating
repeats of natural cationic a-amino acids and synthetic
lipophilic b-peptoid residues were prepared by solid-phase
synthesis as previously described [21,22]. Six chimeras
were investigated in this study. The possible differences in
sensitivity of different bacterial species were evaluated by
testing the analogues 1, 2 and 3, distinguished by different
degrees of chirality and type of cationic amino acid. Addi-
tionally, the mixed series 4a, 4b and 4c, differing only in
the chain length, was used for evaluating the effect of this
on antimicrobial activity (Figure 1). Compounds 1, 2 and 3
have been described previously [23,24,29], while the series
4a, 4b and 4c were synthesized using the already estab-
lished synthesis protocols involving known dimeric
building blocks [21,22]. The identity of the primary pepti-
domimetic sequences 4a, 4b and 4c were confirmed by
high-resolution MS (Bruker MicroTOF-Q LC mass spec-
trometer equipped with an electrospray ionization source):
compound 4a, (m/z) [M+4H]4+ obsd. = 339.9727 (calcd. =
339.9719, ΔM 2.3 ppm); compound 4b, (m/z) [M+5H]5+
obsd. = 402.0614 (calcd. = 402.0608, ΔM 1.4 ppm); com-
pound 4c, (m/z) [M+6H]6+ obsd. = 443.2880 (calcd. =
443.2879, ΔM 0.2 ppm). Peptides were solubilized to
a stock of 10 mg/mL in sterile MilliQ water and stored
at -20°C.
Determination of Minimum Inhibitory Concentration (MIC)
and Minimum Bactericidal Concentration (MBC)
The Minimum Inhibitory Concentration (MIC) of the
chimeras was determined against the spectrum of bac-
teria using the microdilution method according to
guidelines of the Clinical and Laboratory Standards
Institute (CLSI) [30]. Chimera 1:2 serial dilutions were
prepared from 1,024 μg/mL stock solutions to give a
final range of 512-0.5 μg/mL in the wells. This corre-
sponds to a final range of 144 to 0.14 μM for the heavi-
est chimera (i.e. chimera 4c) and of 282 to 0.27 μM for
the lightest chimera (i.e. chimera 4a). Colonies grown
overnight (i.e. approximately 18 hours) on BHI agar
were suspended in 0.9% saline to give a turbidity of 0.13
at OD546 (approximately 1 × 10
8 CFU/mL), and then
diluted in MHB pH 7.4 to a final concentration of 5 ×
105 CFU/mL in each well. Following CLSI guidelines the
media for testing of Listeria monocytogenes strains were
supplemented with 2.5% lysed horse blood. Polypropy-
lene plates (Nunc 442587) were used to minimize pep-
tide binding and incubation time was 18-20 hours at
37°C. MIC was determined in a minimum of two tech-
nical replicates as the lowest concentration of the
Table 1 Origin and reference of bacterial strains used in
the present study
Origin Ref
S. aureus 8325-4 Wildtype [59]
K. pneumoniae ATCC 13883 Human, clinical -
S. marcescens ATCC 8100 Human, clinical -
E. coli ATCC 25922 Wildtype -
E. coli MG1655 K-12 F- lambda- [60]
E. coli AAS-EC-009 Human, clinical a
E.coli AAS-EC-010 Human, clinical a
L. monocytogenes 4446 Human, clinical [61]
L. monocytogenes N53-1 Food processing [62]
L. monocytogenes EGD Wildtype b
V. vulnificus ATCCT Human, clinical -
V. parahaemolyticus ATCCT Human, clinical -
Susceptibility testing were carried out with a selection of twelve different
bacterial strains comprising common laboratory strains and clinical strains
derived from food-borne pathogens as well as pathogens responsible for
nosocomial infections. a ESBL-producing clinical samples from Danish patients
in 2007; b This strain was kindly provided by Werner Goebel, University of
Würzburg.
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peptide analogue where no visible growth was found.
The Minimum Bactericidal Concentration (MBC) was
determined by plating 10 μL of the suspension from the
first three wells without growth on BHI agar and incu-
bating these for 24 hours at 37°C. MBC was the lowest
concentration at which a 99.9% reduction in CFU/mL
was observed. Activity is expressed in μmol/L to enable
a direct comparison of analogues with different length
(= size).
Killing kinetics of Staphylococcus aureus and Serratia
marcescens
In vitro time-kill curves for chimera 1, 2 and 3 were
determined against S. aureus 8325 (MIC μM: chimera 1
5.9; chimera 2 2.8; chimera 3 18.7) and Serratia marces-
cens ATCC 8100 (MIC μM: chimera 1 46.8; chimera 2
45.5; chimera 3 150.0). These two bacterial strains
represent organisms susceptible and tolerant to the chi-
meras, respectively. The bactericidal effect of the three
chimeras was tested at MIC in two independent experi-
ments; additionally the effect of chimera 2 was tested at
¼ and 1/2 times MIC. In brief, a suspension prepared
from fresh overnight colonies as described above was
transferred to 2 mL PBS or cation-adjusted MHB with
chimera added (from a 10 × MIC solution) to give a
similar bacterial cell density as employed in the MIC
determination; the resulting suspension was then incu-
bated at 37°C, 300 rpm. Samples for colony determina-
tion were taken at 0, 1, 2, 4, 6 and 8 hours after
addition and transferred to a ten-fold dilution row.
Colony counts were determined after incubation for
24 hours at 37°C.
ATP leakage assay
Pore formation as caused by peptide addition was deter-
mined by measuring ATP leakage from the bacterial cell
using a bioluminescence assay [31]. The assay was used
to estimate differences between sub-typical chimeras 1, 2
and 3 on S. aureus and S. marcescens and to evaluate the
effect of chain length of mixed type chimeras 4a, 4b and
4c on S. aureus. In brief, bacteria were grown in TSB at
37°C for 24 hours and then re-inoculated in TSB at 37°C
for 6-8 hours until an absorbance at 546 nm of 2.5 for
S. aureus and 2.0 for S. marcescens and then harvested
(10 min at 2,000 × g). The bacteria were grown to a high
absorbance since a high concentration of bacteria was
necessary in order to get a measurable response in the
ATP leakage assay. Cells were washed once in 50 mM
potassium phosphate buffer (pH 7.0) and once in 50 mM
HEPES buffer (pH 7.0), before the pellet was resuspended
in HEPES buffer to an OD546 ~ 10, and then stored on
ice. Before chimera addition bacteria were pre-incubated
with 0.2% (w/v) glucose to energize the cells. In general
a chimera dose of 1000 μg/mL (corresponding to
280-552 μM for all chimeras) was used for all assays;
however, for determining dose response curves additional
doses of 100 (28-55 μM), 250 (71-137 μM) and 500
(140-276 μM) μg/mL were tested, and only the immedi-
ate release was noted. Total ATP and extracellular ATP
were determined with a luminometer (Pharmacia Biotech
Novaspec II Visible Spectrophotometer). Intracellular
volumes [32] of S. aureus and S. marcescens (0.85 μm3
and 1.7 μm3, respectively) were subtracted from the total
volume before calculating the extracellular ATP concen-
tration; the intracellular ATP concentration could then
be calculated from this and the total ATP. ATP leakage
kinetics was determined on a bacterial suspension pre-
pared as above. Samples were taken at time 0, 5, 10, 20,
30 and 60 minutes and viable counts determined. Both
the ATP leakage assay and killing kinetics performed
under the same assay conditions were performed in two
independent experiments.
Results
Based on our previously published work on a-peptide/
b-peptoid chimeras [23,24,29] we selected six com-
pounds for the present study. Our main purpose was to
examine the influence of the type of cationic amino
acid and chain length on antibacterial activity and speci-
ficity. Also we aimed at elucidating the mechanism of
action against live bacterial cells and determine if this
(membrane perturbation) was influenced by the chimera
structural characteristics. We measured ATP leakage
from chimera-treated cells as an indication of mem-
brane pertubation. Comparing the ATP leakage with
time-kill studies allowed us to establish if there was a
direct correlation between permeabilization of the mem-
brane and killing of bacterial cells.
MIC and MBC against clinical and food-borne pathogens
Twelve strains representing seven bacterial species were
tested for their susceptibility to the peptide analogues. The
analogues exhibited a broad-spectrum activity with no dis-
tinct differences between Gram-positive and -negative
bacteria (Table 2). Five of the six chimeras had a strong
antibacterial effect with MIC values below 5 μM. Impor-
tant food-borne pathogens were included in the suscept-
ibility assay panel. Thus, three L. monocytogenes strains
representing both a clinical lineage 1 strain (strain 4446)
and a persistent lineage 2 strain from a food-processing
plant (strain N53-1) as well as clinical isolates of V. vulnifi-
cus and V. parahaemolyticus were examined.
The MIC values of chimeras 1, 2 and 3 were similar,
indicating that the b-peptoid side chain chirality (i.e. 1 vs.
2) had no effect on antibacterial activity and that the 12-
meric homoarginine (hArg) based sequence 2 was likely
equalled by the longer 16-meric lysine-containing analo-
gue 3. Generally, low MIC values were found for these
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three compounds, however, the activity of chimera 3 was
slightly lower than for chimera 1 and 2 against some
of the bacteria i.e. S. aureus, K. pneumoniae and S.
marcescens.
Chimeras 4a, 4b and 4c all have a 1:1 mixture of Lys and
hArg residues, but differ in length (8-16 residues), and this
had a marked effect on their antibacterial activity. The pat-
tern was the same against all bacterial strains tested. The
longest of the three, chimera 4c, was the most active com-
pound with MIC values of 1.1-2.2 μM against the food-
borne pathogens L. monocytogenes and Vibro spp. Chimera
4c was also active against the clinical strains of E. coli,
S. aureus and K. pneumoniae with MIC values in the
range of 2.2-9.0 μM (Table 2). Chimera 4b, with a length
of 12 residues, was less antibacterial with MIC values
approximately 2-3 times higher than those of the 16-mer
4c (Table 2). Chimera 4a being only half the length of chi-
mera 4c was the least antibacterial as the MIC values were
15-70 times higher than those of chimera 4c (Table 2).
Thus, the relative increase in activity was much larger for
elongation with a third repeating unit (i.e. from 8-mer 4a
to 12-mer 4b), than the further elongation of 4b with a
fourth repeating unit to afford 4c, revealing the minimally
required length of an active AMP analogue to be approxi-
mately 12 residues.
Two Extended Spectrum Beta-Lactamase (ESBL)-pro-
ducing E. coli clinical isolates (AAS-EC-009 and AAS-
EC-010) were included to determine if this antibiotic
resistance affected chimera sensitivity. However, the
chimeras were as effective against these strains as
against non-ESBL strains indicating that resistance
mechanisms conferring resistance to conventional anti-
biotics do not diminish the activity of the present pep-
tidomimetics. Interestingly, S. marcescens, which is
known to be intrinsically resistant to other antimicro-
bial peptides, was tolerant to all six chimeras (MICs
above 46 μM; Table 2), and it most likely possesses
resistance mechanisms that are different from those
present in the two multi-resistant E. coli strains.
All six chimeras had a Minimum Bactericidal Concen-
tration (MBC) equal to or double the MIC. The high
similarity between the MIC and MBC values indicates
that the chimeras exhibit a bactericidal mode of action.
Killing kinetics in two bacteria with different susceptibility
S. marcescens was the only bacterial strain tested that was
tolerant to the a-peptide/b-peptoid chimeras. The strain
is the only one considered intrinsically resistant to the
polymyxin group of AMPs, and this could explain its
resistance to our peptidomimetics. If so, this would indi-
cate that a very similar resistance mechanism was
responsible for the observed decrease in susceptibility.
Therefore we performed a comparative mechanistic
study that also included S. aureus and E. coli as suscepti-
ble reference strains.
We exposed S. aureus and S. marcescens to peptidomi-
metics 1, 2 and 3 at three different concentrations in
MHB as well as at their MIC concentration in PBS buffer
in order to determine whether these chimeras were only
active against growing bacterial cells. S. marcescens was
killed rapidly by chimera 2 (Figure 2A), and the lethal
effect was clearly concentration-dependent (Figure 2C).
In contrast, S. aureus was killed more slowly and with a
less pronounced effect of dose (Figure 2B and 2D). Treat-
ment of S. marcescens with chimera 2 at its MIC caused a
2 log decrease in the number of viable bacteria within the
first hour after which cell numbers declined over the
next 5 hours. When the bacteria were treated with the
chimera in PBS, the killing occurred very rapidly and no
viable cells remained after the first hour. When S. aureus
was treated with chimera 2 at the MIC in MHB, the
number of viable cells did not decrease until after 6
Table 2 Minimum Inhibitory Concentration (μM) of the six a-peptide/b-peptoid chimeras in the present study
Chimera 1 Chimera 2 Chimera 3 Chimera 4a Chimera 4b Chimera 4c
S. aureus 8325 5.9 2.8 18.7 141.2 23.8 4.5
K. pneumoniae ATCC 13883 1.5 2.8 37.5 282.4 23.8 9.0
S. marcescens ATCC 8100 46.8 45.5 150.0 > 282.4 190.3 71.8
E. coli ATCC 25922 1.5 2.8 9.4 141.2 3.0 2.2
E. coli MG1655 1.5 2.8 4.7 141.2 5.9 2.2
E. coli AAS-EC-009 1.5 2.8 9.4 141.2 11.9 4.5
E.coli AAS-EC-010 1.5 1.4 9.4 141.2 3.0 2.2
L. monocytogenes 4446 2.9 1.4 1.1 70.6 3.0 1.1
L. monocytogenes N53-1 2.9 2.8 1.1 70.6 5.9 1.1
L. monocytogenes EGD 1.5 2.8 1.1 70.6 3.0 1.1
V. vulnificus ATCCT 1.5 1.4 2.3 35.3 3.0 2.2
V. parahaemolyticus ATCCT 1.5 1.4 2.3 70.6 3.0 1.1
Minimum Inhibitory Concentration of the six peptidomimetics in this study against the spectrum of bacteria expressed in μM. Values were obtained from a
minimum of two independent trials. The Minimum Bactericidal Concentration (MBC) was in all assays equal to or a maximum of one two-fold higher than the
MIC value indicating a bactericidal mode of action.
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hours, however, when treated in PBS, viable cell numbers
decreased with log 2 after 4 hours (Figure 2B). Even
though a slightly decreased growth rate was observed for
S. aureus upon treatment with concentrations below
MIC as compared to the control, a concentration close to
the MIC value was needed to completely inhibit growth
of the culture (Figure 2D). In comparison, as low as ¼
MIC resulted in a reduction in cell number of S. marces-
cens (Figure 2C) revealing a more pronounced concentra-
tion-dependent killing for this bacterium.
Since the MIC value found for S. marcescens was consid-
erably higher than that seen for S. aureus, we performed
time-kill on E. coli, which exhibited a similar susceptibility
in terms of MIC to that of S. aureus, to test if the rapid
lethal effect against S. marcescens was due to the higher
concentrations of peptidomimetics (E. coli ATCC 25922
MIC μM: chimera 1 1.5; chimera 2 2.8; chimera 3 9.4).
However, a rapid killing effect was also found for this bac-
terial species (data not shown) ruling out that the elevated
concentrations solely could be responsible for the high
killing rate seen for S. marcescens.
Membrane perturbation effects in two bacteria with
different sensitivity
Killing kinetics often reflect the mode of action, and we
hypothesized that differences between S. aureus and S.
marcescens regarding their sensitivity and time-kill
might be due to different modes of interaction with the
peptidomimetics. Therefore, an ATP bioluminescence
assay was employed to determine (i) whether cell envel-
ope perturbation was involved in the antibacterial effect,
and (ii) if so, whether the organisms differed in the
degree of ATP leakage.
Chimera 1, 2 and 3 caused leakage of ATP from both S.
aureus and S. marcescens, but all three peptidomimetics
gave rise to an ATP leakage from S. aureus that was sub-
stantially larger than that from S. marcescens (see Figure
3 for results with chimera 1). The intracellular ATP con-
centration rapidly approached zero for both bacteria
within the first few minutes, whereas the extracellular
ATP concentration increased more rapidly during the
first minutes for S. aureus (~20 μM) than for S. marces-
cens (~5 μM). To examine if this could be due to the fact
Figure 2 Killing kinetics of chimera 2 against S. marcescens (A+C) and S. aureus (B+D) displayed as mean number of viable cells with
standard error of the mean (SEM). The assays were performed in two independent experiments. Time-kill of the chimera was determined at MIC in
MHB (grey solid) and PBS (grey punctuated) and compared to MilliQ-treated control in MHB (black solid) and PBS (black punctuated) for S. marcescens
(A) and S. aureus (B). The effect of chimera concentration on time-kill was determined in MHB at ¼ MIC (dark grey), 1/2 MIC (light grey) and MIC (black
punctuated) and compared with MilliQ-treated control (black solid) for S. marcescens and (C) and S. aureus (D).
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that the two bacteria were treated with the same dose
despite their very different MIC values, we determined
their dose response curves. For both bacteria a minimum
chimera dose of 500 μg/mL (i.e. 145-180 μM) was needed
to obtain the maximum immediate response (data not
shown) ruling out that the rapid release of ATP from
S. aureus seen in Figure 3A is due to a higher concentra-
tion/MIC ratio than employed for S. marcescens.
To investigate if the degree of ATP leakage from the
bacterial cell corresponded to the simultaneous decrease
in the number of viable cells (i.e. if S. marcescens cells on
the basis of their elevated MIC were in fact able to sur-
vive even after a moderate ATP leakage) we determined
time-kill under exactly the same conditions as the ATP
bioluminescence assay had been performed. Irrespective
of which of the three chimeras that were used, both bac-
teria were reduced 2-3 log from an initial value of log
~9.5 per mL within the first 20 minutes before the ATP
leakage tailored off and no further decrease in viable
count was seen for up to 60 minutes (not shown). This
indicates that the degree of ATP leakage from the two
bacteria (i.e. the concentration of the extracellular ATP)
does not reflect differences in viability. No reduction in
the number of viable bacteria was seen for the control
(not shown), and the intracellular concentration of ATP
did not change (Figure 3A and 3B).
Although there was no systematic difference in the
MIC values between Gram-positive and -negative bac-
teria, we speculated that the Gram-negative outer mem-
brane could act as a barrier to the penetration of AMPs,
since polymyxin B resistance in S. marcescens has been
linked to induced changes in the amount and composi-
tion of lipopolysaccharide (LPS) in the outer membrane
[33]. Moreover, similar resistance-conferring membrane
alterations have also been seen for other bacteria in
response to polymyxin B treatment [34-36]. Accordingly,
we studied how a membrane-destabilizing pre-treatment
of S. marcescens, E. coli and S. aureus with the divalent
metal cation-chelating agent EDTA would affect the kill-
ing caused by chimera 1. In these experiments we used a
non-lethal 0.5 mM concentration of EDTA together with
the non-lethal 1.5 μM concentration of the tested AMP
analogue. A slight reduction in the number of viable cells
corresponding to 0.5 log was seen for S. aureus when
treated with chimera 1 alone while E. coli and S. marces-
cens were reduced with 1.5 log (data not shown). No dis-
cernable difference in the number of viable cells
remaining was observed between S. aureus treated suc-
cessively with EDTA and peptidomimetic and S. aureus
treated only with the peptidomimetic. In contrast, cell
numbers of both S. marcescens and E. coli were reduced
with 4-5 log from an initial value of log ~5.5 within the
first 4 hours (not shown) upon treatment with a sub-
lethal EDTA concentration together with the chimera.
This indicates that the intact outer membrane indeed
appears to act as a protective barrier against the antibac-
terial chimeras.
The effect of chimera chain length on membrane
perturbation activity
Peptidomimetics 4a, 4b and 4c consist of the same repeat-
ing unit of four residues (Figure 1; n = 2, 3 and 4, respec-
tively), and thus differ only in length. The MIC values
increased dramatically when going from 8-mer (4a) to 12-
mer (4b) while further elongation to 16-mer (4c) only led
to a slight enhancement in potency (Table 2). Hence, we
were intrigued to establish whether mechanistic differ-
ences could explain this strong correlation.
Figure 3 Chimera-induced ATP leakage in S. aureus (A) and S. marcescens (B) after treatment with 1000 μg/mL chimera. The assays
were performed in two independent experiments. Mean (SEM) intracellular (IC, solid line) and extracellular (EC, punctuated line) ATP
concentration for S. aureus cells (figure A, grey lines) and S. marcescens cells (figure B, grey lines) treated with chimera 1 compared to MilliQ-
treated control (black lines).
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We determined ATP leakage from S. aureus when trea-
ted with chimeras 4a, 4b and 4c to evaluate the effect of
chain length on the extent of pore formation or membrane
disintegration caused by the chimeras. Peptidomimetic-
induced ATP leakage was markedly different for S. aureus
treated with chimera 4a (Figure 4A) as compared to
S. aureus treated with chimera 4c (Figure 4C). The immedi-
ate ATP release was approximately 15 μM for both pepti-
domimetics; however, the intracellular ATP concentration
remained at approx. 5 μM, when the bacterial cells were
treated with the shorter analogue 4a, whereas cells treated
with chimera 4c were immediately depleted of intracellular
ATP. Since the leakage was continuous it seemed that the
cells were able to maintain the ATP production. S. aureus
cells treated with the intermediate length 12-meric chimera
4b had the same leakage pattern as induced by chimera 4a.
Dose-response profiles were also determined (as already
described in the previous section), and despite differences
in MIC values between chimeras 4a and 4c, both reached
the immediate maximum ATP release at 500 μg/mL (i.e.
276 μM and 140 μM, respectively). Likewise, the observed
ATP release was similar immediately upon treatment with
either chimera 4a or 4c, and again cells treated with chi-
mera 4a were able to maintain a low intracellular level of
ATP.
The fact that some ATP remained in the cell after
treatment with chimera 4a could point to an incomplete
disruption of the bacterial cell membrane as compared to
bacterial cells treated with chimera 4c. To determine if
an intracellular ATP concentration of 5 μM had a physio-
logical effect and would allow the bacterial cells to sur-
vive, time-kill was again performed under exactly the
same conditions as used in the ATP assay to allow com-
parison of ATP leakage with killing kinetics. After treat-
ment with chimera 4c, cell numbers were reduced with 2
log within the first 20 minutes (Figure 4D), however,
Figure 4 The effect of chimera chain length on ATP release from S. aureus after treatment with 1000 μg/mL chimera and the
corresponding change in the number of viable cells after treatment with chimera 4a (A+B) or chimera 4c (C+D). The assays were
performed in two independent experiments. Mean (SEM) intracellular (IC, solid line) and extracellular (EC, punctuated line) ATP concentration for
cells treated with chimera 4a (figure A, grey lines) or 4c (figure C, grey lines) compared to MilliQ-treated control (black lines). Mean (SEM)
number of viable cells after addition of chimera 4a (figure B, grey line) or 4c (figure D, grey line) compared to MilliQ-treated control (black line).
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after treatment with chimera 4a (Figure 4B) or chimera
4b (not shown) no killing was observed. The pool of
intracellular ATP in the peptidomimetic-treated bacterial
cells can therefore, as opposed to the amount of leaked
ATP, be considered as indicative for the number of viable
cells remaining.
Discussion
The aim of this study was to determine the mechanism
of action for a series of peptidomimetics, and specifically
we set out to probe the importance of amino acid com-
position and chain length for antibacterial activity. We
included a strain intrinsically resistant to AMPs, and
addressed whether killing kinetics and AMP mechanism
of action in viable bacteria could provide a mechanistic
explanation for the much lower susceptibility of S. mar-
cescens as compared to the more sensitive bacteria.
We examined the effect of having exclusively lysine or
homoarginine cationic residues as well as of substituting
the chiral b-peptoids with achiral counterparts as repre-
sented by the a-peptide/b-peptoid chimeras 1, 2 and 3
(Table 2). All three peptidomimetics had MIC values of 1-
3 μM against most bacterial strains, which compared to
many natural AMPs is a high activity [14,19,37-39].
Noticeably, a considerably lower activity against S. aureus
and K. pneumoniae was observed for the lysine-containing
chimera 3 (6-13 fold) as compared to the homoarginine-
based chimera 2, while only a slightly lower activity of chi-
mera 3 (2-7 fold) was seen compared to chimera 2 when
tested against E.coli. The reduced chirality in chimera 1
did not give rise to any significant loss of activity as com-
pared to chimera 2. In a preliminary antimicrobial charac-
terization these peptidomimetics were tested against four
common bacteria and a fungus [23], whereas the present
study also included important food-borne pathogens L.
monocytogenes, V. vulnificus and V. parahaemolyticus
against which the chimeras also were active (Table 2).
Additionally we investigated the effect of chain length
on activity by studying a series of three peptidomimetics
(i.e. chimera 4a, 4b and 4c based on the same repeating
unit of four residues), which indicated that the mini-
mally required length for an active peptidomimetic is
around 12 residues (Table 2). It has previously been
reported that 14 amino acids is the minimal sequence
required for an active antimicrobial peptide [25], how-
ever, this and other studies focused on the effect of
length on helicity which implies structural restrictions
in the design to enable it to span the lipid bilayer
[26,40]. Also, it is clearly established that the low activity
earlier reported for the shorter homologues of chimera 3
(e.g. the 12-mer exhibited almost no activity [23]) may
be compensated for by a longer sequence. Chimera 4c
corresponds to the analogue where half of the lysines in
chimera 3 are replaced by homoarginines, and similarly
chimera 4b may be considered an analogue derived
from chimera 2 by exchanging half of the homoargi-
nines with lysines. Comparison of the activities found
for these two pairs indicates that a high content of
homoarginines generally induces a somewhat higher
potency; especially, the activity against S. aureus and
K. pneumoniae is clearly promoted by a prevalence of
guaninido-functionalized residues.
A high activity was also found against two isolates of
ESBL-producing E. coli (AAS-EC-09 and AAS-EC-010)
indicating that resistance towards conventional antibiotics
do not affect the sensitivity towards these peptidomi-
metics, further supporting a different mode of action.
Many AMPs exhibit a cell envelope-perturbing effect
[41-43], and hence their target is different from traditional
antibiotics of which many act by inhibiting cell wall synth-
esis or on intracellular targets [44-46]. Notably, S. marces-
cens was the only bacterial strain that proved tolerant to
the peptidomimetics, and thus must harbour specific resis-
tance mechanisms involving induction of changes in the
cell envelope.
Time-kill experiments showed that S. marcescens was
killed more rapidly than the susceptible strain of S. aur-
eus when treated with chimera 1, 2 or 3 at concentrations
close to their MIC values (Figure 2). Polymyxin B and
other cationic AMPs may at high doses in themselves act
like chelating agents allowing them to penetrate the
outer membrane [47,48], however, a noticeable effect was
also seen against S. marcescens at concentrations lower
that the MIC value (Figure 2C). Rapid killing was also
demonstrated for E. coli exposed to the peptidomimetics,
indicating that this could be a phenomenon associated
with Gram-negative bacteria. Shorter exposure times
caused a significant killing of Gram-negative bacteria
when treated with some a-helical AMPs that act by per-
meabilization of the membrane [37]. Another explanation
for the observed differences in the rate of killing could be
that either the degree or mode of membrane disruption
differs among bacteria i.e. the chimeras may exert their
effect by a combination of several mechanisms. The fact
that cell membranes of different bacteria differs in lipid
composition [49] could influence the interaction between
phospholipids and AMPs. However, there is no unequi-
vocal evidence demonstrating that an AMP may exhibit
different pore-forming properties in different bacteria, as
the proposed co-existence of several disruption modes in
fact still is a topic of debate [50,51].
Many AMPs exert their antibacterial effect by interac-
tions with the bacterial cell membrane [38,41,52] invol-
ving pore formation or membrane disintegration that in
turn causes leakage of the cell contents, which ultimately
leads to cell death. Nevertheless, there is a growing
amount of indirect evidence that the mechanisms of
some very potent AMPs in fact involves an initial period
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of intracellular accumulation prior to the actual bacterial
killing indicating that they act on intracellular targets
[38,53,54]. To further investigate the effect of the present
peptidomimetics on the cell membrane in S. marcescens
and S. aureus and to determine how structural features
of these peptidomimetics might affect the potential mem-
brane-related mode of action we examined their ability to
cause leakage of intracellular compounds e.g. ATP. A
considerable body of data on the leakage of intracellular
compounds has already been obtained by using model
membranes thus confirming that many membrane-active
peptides indeed exert a permeabilizing effect [24-26,28].
These studies have, however, not demonstrated whether
there is a direct kinetic relationship between cell mem-
brane damage and loss of viability, and for this reason we
combined leakage assays with a time-kill experiment
under exactly the same conditions.
Treatment of both S. marcescens and S. aureus with
peptidomimetics 1, 2 and 3 caused leakage of ATP from
the bacterial cells with a similar simultaneous reduction in
the number of viable cells, and therefore we conclude that
even though S. marcescens is tolerant to the peptidomi-
metics their mode of action against this bacterium is simi-
lar to that of S. aureus. Earlier, chimera 3 was investigated
for its ability to induce calcein leakage in unilamellar lipo-
somes mimicking human cell membranes with a positive
response [24], but based on the consistent results in the
present work all three peptidomimetics are likely to per-
meabilize both model and bacterial membranes. Leakage
of intracellular compounds has been determined to be the
mode of action for many AMPs [55-57], but here we have
established this mode of action for a series of peptidomi-
metics. We conclude that variation of the type of cationic
amino acid (i.e. lysine versus homoarginine) did not have
an effect on the mode of action in viable bacteria.
Since S. marcescens was tolerant to all peptidomi-
metics tested, their mode of action must therefore
involve a target that is ultimately changed by resistance
mechanisms in this species. It is well-known that
S. marcescens is tolerant to the polymyxin group of
antimicrobials, and the main hypothesis is that this is
due to inherent changes in the composition of the LPS
of the Gram-negative outer membrane that acts as a
barrier [33]. We demonstrated that the outer mem-
brane also seems to play an important role in the tol-
erance of S. marcescens towards our chimeras as a
combined treatment including the chelating agent
EDTA resulted in a reduction in the number of viable
cells comparable to that seen for a more susceptible
Gram-negative strain of E. coli treated similarly (not
shown). This indicated that the innate differences in
susceptibility between the two Gram-negative species
could be completely eliminated after destabilization of
the outer membrane.
When designing new antimicrobial peptides it is gen-
erally accepted that a minimum length is required in
order for the peptide to span or transverse the cell
membrane. However, the majority of studies have
focused on optimizing the length of AMPs assuming it
to adopt a helical conformation [25,26,40]. By contrast,
due to their design with alternating hydrophobic and
cationic residues our peptidomimetics are not expected
to adopt an amphipathic helical active confirmation, but
rather an extended conformation with some degree of
secondary structure as indicated by analysis of their CD
spectra [22,23]. Recently, it has been shown that neither
global amphipathicity nor regular secondary structure
may be required for short peptides to effectively interact
with bacterial membranes [19,58], but the optimal
length of such peptides has not been rationalized by
mechanistic experiments. Only oligomers with a chain
length above 12 residues, i.e. the 16-meric peptidomi-
metic 4c were able to cause such a substantial leakage
of ATP that the number of viable cells were reduced
(Figure 4C and 4D). We attribute this to the inability of
chimeras 4a and 4b to produce a critical degree of
membrane disruption thus leaving a sufficient level of
intracellular ATP for the cells to survive (Figure 4A and
4B for chimera 4a).
This is to our knowledge the first time that the effect
of chain length has been investigated on the membrane-
perturbing activity of peptidomimetics without a domi-
nant secondary structure. Also, we believe that our
study is the first that directly, in a kinetic fashion, corre-
late membrane permeabilization with actual killing
kinetics.
Previously, the interaction of a-peptide/b-peptides chi-
meras with liposomal model membranes and murine
fibroblast was described [24]. Most recently, we investi-
gated their cytotoxicity and haemolytic activity towards
human HeLa cells and erythrocytes, respectively [23].
Besides confirming that members of this subclass of
peptidomimetics exhibit a broad antimicrobial activity
that includes resistant strains and food-borne pathogens,
the purpose of the present study was to undertake a
more detailed investigation of their mode of action. The
present contribution describes their interaction with
viable bacterial cells, and we found that these antimicro-
bial peptidomimetics have a mode of action involving
the cell membrane. The observed membrane disruption
depends strongly on chain length, and it may be
impeded if the outer membrane in a Gram-negative bac-
terium possesses an innate altered composition.
Conclusion
Several a-peptide/b-peptoid chimeras were bactericidal
against important food-borne and clinical pathogens
with MIC values in the range of 1-5 μM. We examined
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the effect of changing the ratio between amino- and
guanidino-functionalized cationic residues as well as the
influence of chain length on both antibacterial activity
and ATP leakage. Although, minor differences in the
antimicrobial profile of the chimeras may be ascribed to
the degree of chirality and/or type of cationic amino
acids, by far the most pronounced impact stems from
the chain length. Only one bacterial species, S. marces-
cens, was tolerant to the peptidomimetics most likely
due to the composition of its outer membrane; however,
the ATP leakage was as pronounced as seen for more
sensitive bacteria. We conclude that these synthetic anti-
microbial peptidomimetics exert their effect through
permeabilization of the cell membrane, and that this
corresponds to a simultaneous reduction in the number
of viable bacteria with the pool of intracellular ATP
being indicative of viability. This is the first time that a
relationship is established between permeabilization and
killing within a peptidomimetics library.
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ABSTRACT 1 
Antimicrobial peptides (AMPs) and synthetic analogues thereof target conserved structures of 2 
bacterial cell membranes and consensus has been that resistance is unlikely to evolve. Hence, such 3 
compounds are considered promising alternatives to conventional antibiotics. The purpose of the 4 
present study was to assess the potential of a novel α-peptide/β-peptoid peptidomimetic to induce 5 
resistance in a clinical isolate of Escherichia coli. 6 
 7 
In a continuous re-inoculation culturing, E. coli ATCC 25922 was exposed to a synthetic α-8 
peptide/β-peptoid chimera (10 lineages), polymyxin B (10 lineages), or MilliQ water (4 lineages). 9 
The concentration was increased in ten steps from 1/16 MIC (Minimum Inhibitory Concentration for 10 
chimera: 8 µg/mL; polymyxin B: 1 µg/mL) to 32×MIC encompassing ~500 generations. All 10 11 
lineages exposed to the chimera adapted to 32×MIC while 8 out of 10 of the polymyxin B-exposed 12 
lineages adapted to the highest concentration. All adapted lineages were tested for MICs. All 13 
lineages exposed to 32×MIC of either the chimera or polymyxin B had a significantly increased MIC 14 
to the respective compound (MIC for chimera-exposed lineages: 128-256 µg/mL; polymyxin B-15 
exposed lineages: 32 µg/mL). Five transfers in unsupplemented media did not abolish resistance 16 
indicating that this is heritable.  No cross-resistance was found between chimeras and conventional 17 
antibiotics, and cross-resistance between the chimera- and polymyxin B-adapted lineages was low 18 
indicating separate mechanisms of resistance. Isolates obtained by plating lineage populations 19 
differed in their MIC against the chimera revealing heterogeneous populations (MIC: 16-256 20 
µg/mL). These isolates showed no cross-resistance against a panel of membrane-active AMPs, but 21 
cross-resistance was found to two similar peptidomimetics. 22 
 23 
Whole-genome sequencing identified four identical single-nucleotide-polymorphisms (SNPs) in all 24 
six highly chimera-resistant isolates (from two lineages). One SNP was in the gene encoding the 25 
3 
 
membrane-bound lytic murein transglycosylase D (mltD), and we hypothesise that alterations in the 1 
peptidoglycan layer was the cause of chimera resistance, however, further studies are required to 2 
elucidate the mechanism by which this SNP confers chimera resistance.  3 
4 
 
INTRODUCTION 1 
Resistance of human bacterial pathogens to conventional antibiotics has increased drastically 2 
worldwide within the last decades (Boucher et al., 2009). This has led to an intense search for safer 3 
alternatives for which resistance is less likely to evolve (Fischbach and Walsh, 2009;Peschel and 4 
Sahl, 2006). These include novel natural compounds with antimicrobial activity (Porsby et al., 2011), 5 
inhibitors of quorum sensing (Bjarnsholt et al., 2010;Quave et al., 2011), and antimicrobial peptides 6 
(AMPs) (Hancock and Sahl, 2006;Yeung et al., 2011). The latter group comprises host defence 7 
molecules constituting part of the innate immune defence in all higher forms of life, where they 8 
display both direct antimicrobial activity and a broad range of immuno-modulating effects (Bowdish 9 
et al., 2005;Gallo and Nizet, 2003;Brown and Hancock, 2006). Development of resistance to these 10 
peptides is considered unlikely due to their co-existence with bacteria during the long period of 11 
evolution, and moreover their preferred target is the ”Achilles´ heel” of bacterial cells i.e. their 12 
distinct membrane structure (Zasloff, 2002). Consequently, there has been increased focus on the 13 
characterization of natural AMPs (Mygind et al., 2005;Park et al., 2011) and on semi-synthetic (Zhu 14 
et al., 2006;Lim et al., 2005;Srinivas et al., 2010) and synthetic analogues (Chen et al., 15 
2005;Chongsiriwatana et al., 2008;Radzishevsky et al., 2007), as well as on the development of 16 
these leads into future antibacterials against human bacterial infections.  17 
 18 
Exposure to antimicrobials can result in resistance, which generally can be divided into two types, 19 
i.e. mutational or adaptive resistance. While the former is considered stable and arises after 20 
mutations or acquisition of a genetic element the latter term describes an auto-regulated phenomenon 21 
characterised by rapid induction of resistance in the presence of the drug followed by reversal to the 22 
sensitive phenotype when drug is absent (Skiada et al., 2011). The outer membrane of Gram-23 
negative bacteria acts as a semi-permeable barrier mediating decreased sensitivity to antimicrobial 24 
compounds (Hancock, 1997). In addition to this, AMP-induced stress has in some species been 25 
5 
 
shown to activate innate two-component systems leading to further modifications of the cell 1 
envelope thereby decreasing the negative charge or permeability of this barrier (Fernandez et al., 2 
2010;Cheng et al., 2010;Weatherspoon-Griffin et al., 2011;Gunn, 2008;Sallum and Chen, 2008). 3 
However, the observed decrease in susceptibility is most often eliminated once the AMP is removed, 4 
and it is therefore considered a tolerance induction rather than resistance caused by genetic 5 
alterations.  6 
 7 
Since AMPs and their analogues mimic  structures that are part of the innate immune defence in 8 
humans, development of resistance towards such compounds could potentially compromise our 9 
innate immune defence (Bell and Gouyon, 2003). Therefore it is important to consider the likelihood 10 
and potential consequences of emergence of AMP-resistant strains before these compounds are to be 11 
used for systemic infections (Bell and Gouyon, 2003;Perron et al., 2006). Only very few studies have 12 
dealt with this problem, and in most published work, the possible AMP-induced mutation 13 
frequencies have been compared to the much higher mutation frequencies usually observed for 14 
conventional antibiotics. In general, earlier experiments have been short-time studies (Zaknoon et al., 15 
2009;Steinberg et al., 1997). A single comprehensive study, focusing on continuous selection to the 16 
magainin-analogue pexiganan, showed that prolonged exposure to an AMP indeed may result in 17 
heritable resistance (Perron et al., 2006) despite the common opinion that resistance towards AMPs 18 
is unlikely to evolve. The study unequivocally shows that this issue calls for an increased focus in 19 
AMP development programs. 20 
 21 
We have previously described a synthetic approach towards peptidomimetics exhibiting 22 
antimicrobial properties, and in the present study we investigate α-peptide/β-peptoid chimeras 23 
possessing a design with alternating N-alkylated β-alanine (β-peptoid) and α-amino acid units 24 
(Bonke et al., 2008;Olsen et al., 2007). Previously, we have demonstrated that these compounds are 25 
6 
 
active against a range of nosocomial and food-borne pathogenic bacteria cell lysis, and we have also 1 
shown that the length of the peptide has a marked influence on activity (Olsen et al., 2010;Hein-2 
Kristensen et al., 2011). Here, we investigate the risk of resistance development in a human 3 
pathogenic bacterium as this is a key parameter required when assessing the therapeutic potential of 4 
AMPs and their analogues. 5 
 6 
 7 
MATERIALS AND METHODS 8 
Bacterial strain and culture conditions. All experiments were performed with Escherichia coli 9 
ATCC 25922. Stock cultures of the wild type strain and lineage isolates were stored at –80oC in 4 % 10 
(w/v) glycerol, 0.5 % (w/v) glucose, 2 % (w/v) skimmed milk powder and 3 % (w/v) tryptone soy 11 
powder. Lineage populations were frozen at –80oC in 50 % (w/v) glycerol. All experiments were 12 
performed at 37oC. Experiments were carried out in cation-adjusted Mueller Hinton II broth (MHB) 13 
(Becton Dickinson 212322) adjusted to pH 7.4 or 1 % (w/v) peptone (Becton Dickinson 211677) for 14 
MIC determination of natural AMPs. Brain Heart Infusion (BHI) (CM1135) with agar (VWR 15 
20768.292) 1.5 % as gelling agent was used throughout for colony plating. 16 
Chimera synthesis, antibiotics and natural AMPs. α-peptide/β-peptoid chimera 1, 2 and 3 17 
consisting of alternating repeats of cationic natural α-L-amino acids and synthetic lipophilic β-18 
peptoid residues were synthesized by solid-phase synthesis as previously described (Bonke et al., 19 
2008;Olsen et al., 2007). Polymyxin B (P4932), protamine (P4020), gentamicin (G3632), ampicillin 20 
(A9518) and erythromycin (E6376) were purchased from Sigma Aldrich.  21 
KR-12 (Wang, 2008), IsCTp (Lim et al., 2005), PEP-1-K (Zhu et al., 2006) and Melittin were 22 
prepared by automated microwave (MW)-assisted solid-phase Fmoc-based synthesis on a CEM 23 
Liberty microwave peptide synthesizer using a Rink amide resin (loading: 1.0 mmol/g). Fmoc 24 
deprotection was performed with 20 % piperidine-DMF at 75°C (30 sec followed by 180 sec), while 25 
7 
 
coupling was performed by using the appropriate Fmoc-protected building block (5.0 eq) with DIC 1 
(5 eq.) and HOBt (5 eq.) in DMF at 75°C for 15 min. Capping was applied after every fourth 2 
coupling with Ac2O-DIPEA-NMP (1:2:3) at 65°C (30 sec, repeated once). Final deprotection of the 3 
N-terminus was followed by cleavage and simultaneously side chain deprotection with TFA-TIS-4 
H2O (95:2.5:2.5; 3 mL) for 60 min. The filtrate was collected and the resin was eluted with DCM (2 5 
mL) and TFA (2× 2 mL). The combined filtrates were conc. in vacuo, and then co-evaporated with 6 
toluene (3×). The crude product was triturated with Et2O, dissolved in MeCN-H2O (50:50) 7 
containing 0.1 % TFA, and then purified by preparative HPLC. Finally the product was dissolved in 8 
water (1 mL) and lyophilized. Analytical HPLC was carried out on a Phenomenex Luna C18 (2) (3 9 
μm) column (150×4.60 mm) using binary mixtures of eluent A (H2O-MeCN-TFA 95:5:0.1) and 10 
eluent B (H2O- MeCN-TFA 5:95:0.1) for elution with a flow rate of 0.8 mL/min by using a linear 11 
gradient of 10-60 % B during 30 min. Peptides were detected with UV at λ = 220 nm. Preparative 12 
HPLC was performed on a Luna C18 (2) (5 μm) column (250 × 21.20 mm) with an Agilent 1100 LC 13 
system with a multiple-wavelength UV detector. Elution was performed with a linear gradient of 10-14 
40 % during 20 min at a flow rate of 20 mL/min. Peptides were detected with UV at λ =220 nm. LC-15 
HRMS was performed with a Phenomenex Luna C18 (2) (3 μm) column (150×4.6 mm) using binary 16 
mixtures of eluent C (H2O-MeCN-HCOOH 95:5:0.1) and D (H2O-MeCN-HCOOH 5:95:0.1). 17 
Elution was performed with a linear gradient of 10-60 % D during 30 min at a flow rate of 0.5 18 
mL/min. HRMS spectra were obtained using a Bruker MicrOTOF-Q II Quadropol MS detector. 19 
Analyt. HPLC (>97 % purity at 220 nm) retention times (RT): RT = 16.85 min for KR-12; RT = 20 
28.75 min for mellitin; RT = 17.74 min for IsCTp; RT = 17.79 min for Pep-1-K. 21 
Chimeras and natural AMPs were solubilised to a stock of 10 mg/mL in sterile MilliQ water and 22 
stored at -20oC. Polymyxin B was solubilised to a stock of 10 mg/mL in sterile MilliQ water, filter-23 
sterilized and stored at 5oC. Protamine was solubilised to a concentration of 1024 µg/mL in sterile 24 
MilliQ water and used immediately. Gentamicin and ampicillin were solubilised to a stock of 25 25 
8 
 
mg/mL in sterile MilliQ water, filter-sterilized and stored at 5oC and -80oC, respectively. 1 
Erythromycin was solubilised to a stock of 10 mg/mL in 96 % ethanol and prepared fresh for each 2 
experiment. 3 
Continuous selection experiment. Continuous selection of resistance was performed for chimera 1 4 
(Figure 1) and for the clinically used polymyxin B. A bacterial suspension of a single colony of E. 5 
coli ATCC 25922 was re-inoculated (10 µl) five times in unsupplemented MHB (990 µl). It was then 6 
re-inoculated in MHB supplemented with chimera 1 (ten lineages) or polymyxin B (ten lineages), 7 
and after ten re-inoculations at constant chimera or polymyxin B concentration, the concentrations 8 
were doubled. The starting concentration was 1/16 of the Minimum Inhibitory Concentration, MIC 9 
(i.e. 0.5 µg/mL and 0.0625 µg/mL, respectively), and this was increased to 32×MIC during the 10 
course of the experiment. Four lineages grown in MHB with MilliQ water were included as control. 11 
Re-inoculations were performed twice a day, but were reduced to once a day when growth was 12 
slower as assessed by turbidity of the cultures. The total number of passages (supplemented with 13 
AMP) was 77 times encompassing ~500 generations. For each increase in concentration the lineages 14 
were preserved as freezing stocks. Ten colony isolates were randomly selected from each lineage 15 
population at 32×MIC and preserved as freezing stocks. 16 
Determination of MIC. MIC was determined by using the micro-dilution method according to 17 
guidelines of the Clinical and Laboratory Standards Institute (The Clinical and Laboratory Standards 18 
Institute (CLSI), 2006). Chimera and erythromycin 1:2 serial dilutions were prepared from 1024 19 
µg/mL stock solutions to give a final range of 512-0.5 µg/mL in the wells. Ampicillin 1:2 serial 20 
dilutions were prepared from a 256 µg/mL stock solution to give a final range of 128-0.13 µg/mL in 21 
the wells. Polymyxin B and gentamicin 1:2 serial dilutions were prepared from a 64 µg/mL stock 22 
solution to give a final range of 32-0.03 µg/mL in the wells. Also, 1:2 serial dilutions of the AMPs 23 
KR-12, IsCTp, Melittin and PEP-1-K were prepared from a 64 µg/mL stock solution to give a final 24 
9 
 
range of 32-0.03 µg/mL in the wells; however this was performed in 1 % peptone instead of in MHB 1 
since activity was drastically diminished in the latter (not shown).  2 
The populations were tested for their susceptibility towards chimera 1, polymyxin B, gentamicin and 3 
ampicillin. Isolates selected from these populations were additionally tested against chimera 1, 4 
polymyxin B, erythromycin and the reference AMPs. To estimate the level of cross-resistance to 5 
related peptidomimetics, MIC determinations were performed for chimeras 2 and 3 (Figure 1) 6 
towards selected isolates. The bacterial suspensions were grown overnight in MHB at 37oC for 7 
determination of the population MIC, or individual isolates were grown overnight on non-selective 8 
BHI agar at 37oC. MIC determination performed on the wild type strain using re-suspended colonies, 9 
as well as on a culture grown overnight in broth, showed that pre-growth in broth had minimal effect 10 
on the MIC results. In order  to determine the population MIC, the respective compound (chimera 1 11 
or polymyxin B) was added to a concentration corresponding to 32×MIC to maintain the selection 12 
pressure of the freezer-revived lineages, and MIC determination performed on the outgrown 13 
population (i.e. ~109 CFU/mL). In all experiments, bacterial cells were suspended in 0.9 % saline to 14 
give a turbidity of 0.13 at OD546 (approximately 1 × 108 CFU/mL) and diluted in MHB pH 7.4 to a 15 
final concentration of 5 × 105 CFU/mL in each well. Polypropylene plates (Nunc 442587) were used 16 
to minimize peptide binding, and the incubation time was 18-20 hours at 37oC. Incubation time was 17 
additionally extended up to 44 hours for the individual isolates due to a potential effect of growth 18 
rate on the outcome, but no effect was seen of this (not shown). MIC was found in a minimum of two 19 
technical (population MIC) or biological (isolate MIC) replicates as the lowest concentration of the 20 
AMP or antibiotic where no visible growth was found. 21 
Stability of resistance. Frozen stocks were reconditioned in unsupplemented MHB media for five 22 
transfers (~35 generations) at 37oC. The heritability of resistance was established through MIC 23 
determination of bacterial populations as described above. 24 
10 
 
Fitness cost. To evaluate whether resistance altered the growth properties of the mutant isolates, we 1 
determined the growth rate of three isolates from lineage 2 (i.e. 2-7, 2-9 and 2-10) in 2 
unsupplemented MHB and MHB supplemented with chimera 1 at sub-MIC concentrations 1 (i.e. 4 3 
and 8 µg/mL). Optical density readings were obtained at 570 nm in 10-12 minute increments on 4 
cultures grown at 37oC over 24 hours (unsupplemented MHB) or 72 hours (supplemented MHB) 5 
using the automated Bioscreen C system (Labsystems, Helsinki, Finland). Growth rates were found 6 
using linear regression on ln(initial CFU/mL) vs. detection time (i.e. the time until a 0.5 unit increase 7 
in absorbance was reached) for inoculum sizes ranging from 102-107 CFU/mL (Dalgaard and 8 
Koutsoumanis, 2001). Data were analysed in GraphPad Prism version 4.03 using One-Way ANOVA 9 
followed by Dunnett’s Test to correct for multiple testing. Control groups were E. coli ATCC 25922 10 
(absence of chimera) or isolates grown in unsupplemented media (presence of chimera). Significance 11 
levels were in all tests set at p < 0.05. All experiments were done in duplicate on at least two 12 
independent days.  13 
Whole-genome sequencing. A total of fourteen isolates from chimera-exposed lineages were chosen 14 
for whole-genome sequencing. We chose six high-level resistant isolates from lineage 2 (numbers 4, 15 
6, 7, 9 and 10) and lineage 7 (number 7), three low-level resistant isolates from lineage 5 (number 6, 16 
8 and 9) and five isolates with wild type MIC from lineage 4 (number 4 and 6), lineage 5 (numbers 2, 17 
and 4) and lineage 7 (number 9).  For comparison we chose one isolate from control 2 (number 3) 18 
and two isolates from control 1 (numbers 3 and 5). The genome sequence of the ancestral wild type 19 
E. coli ATCC 25922 has not previously been published and was therefore included as reference. 20 
Genomic DNA was extracted from each sample by using phenol:chloroform:isoamyl alcohol and 21 
then precipitated with isopropanol. Samples were RNAse treated before quantification and quality 22 
analysis using 1 % agarose gel electrophoresis, NanoDrop Spectrophotometer (Saveen Werner, 23 
Sweden) and Qubit 2.0 Analyser (Invitrogen, United Kingdom). Libraries of 500 bp were used for 24 
100 bp paired-end sequencing of genomes using the Illumina sequencing technology on a HiSeq2000 25 
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with a minimum coverage of 100 (Beijing Genomics Institute, Hong Kong, China). E. coli ATCC 1 
25922 was de novo assembled into contigs using the CLCbio Genomics Workbench (Aarhus, 2 
Denmark) resulting in 135 contigs comprising 5,116,439 bp. Using this procedure the 17 isolates 3 
were mapped with the 135 contigs as a reference with a minimum coverage of 100 and single-4 
nucleotide-polymorphism (SNPs) were then detected. 5 
 6 
 7 
RESULTS 8 
The aim of this study was to investigate the development and spectrum of resistance in a clinical 9 
isolate of Escherichia coli following exposure to an α-peptide/β-peptoid chimera. Additionally, we 10 
were interested in elucidating the mechanism underlying the observed resistance. 11 
Continuous selection towards AMP resistance. Escherichia coli ATCC 25922 was continuously 12 
re-cultured from a concentration of 1/16 of the wild type MIC until a concentration of 32 times the 13 
wild type MIC of either chimera 1 (i.e. 256 µg/mL) or polymyxin B (i.e. 32 µg/mL) was reached 14 
encompassing ~500 generations. All ten lineages supplemented with chimera was eventually 15 
outgrown at 32×MIC; for lineages supplemented with polymyxin B this was the case for eight out of 16 
ten (Figure 2). It is evident that growth was affected at an earlier stage for the polymyxin B-17 
supplemented lineages, i.e. growth was inhibited for all strains already at ¼ MIC where two lineages 18 
failed to grow further; for the chimera-supplemented growth was not visibly inhibited until a 19 
concentration at or above the MIC (Figure 2). Only once was the concentration decreased for a 20 
lineage supplemented with chimera (i.e. lineage 8) due to lack of growth at 32×MIC. After two 21 
additional passages at 16×MIC the lineage successfully grew at 32×MIC. 22 
The four controls were transferred into fresh unsupplemented media simultaneously with the transfer 23 
of the two other groups of lineages. At the time point corresponding to 4×MIC of the supplemented 24 
lineages (i.e. 32 µg/mL for the chimera and 4 µg/mL for polymyxin B) we investigated the ability of 25 
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these controls to grow in the presence of the same concentration as the supplemented lineages. Two 1 
controls supplemented with chimera at 4×MIC failed to grow, but one of the two controls 2 
supplemented with 4×MIC of polymyxin B became outgrown. Growth was retained for three 3 
additional passages at the same concentration of polymyxin B indicating that the spontaneous 4 
mutation rate for polymyxin B may be higher than that of chimera 1.  5 
Population MIC after selection. MIC was determined for the selective AMP against revived 6 
outgrown cultures at 32×MIC of all lineages in the two groups (Table 1). Only five out of ten of the 7 
freezing stocks of the chimera-supplemented lineages could be re-cultured in chimera-supplemented 8 
media, though all of the eight polymyxin B-supplemented freezing stocks fully outgrew. We ascribe 9 
this to stress induced by freezing in some lineages as the cultures subsequently grew in 10 
unsupplemented substrate and retained resistance. A dramatic increase in MIC was seen for both the 11 
chimera- and the polymyxin B-supplemented lineages showing that resistance had developed against 12 
the selective agent (Table 1). For the five chimera-supplemented lineages, MIC against chimera 1 13 
was increased to 128-512 µg/mL from an initial level of 8 µg/mL for the wild-type corresponding to 14 
a 16- to 64-fold increase. The eight polymyxin B-supplemented lineages all had a MIC value at 32 15 
µg/mL against polymyxin B, i.e. a 32-fold increase in MIC as compared to the wild-type strain. The 16 
four controls only showed minor increases in MIC compared to the wild type. 17 
We determined potential cross-resistance to the other selective agent (i.e. chimera 1 vs. polymyxin 18 
B) and to an aminoglycoside (gentamicin) and a cell wall-active antibiotic (ampicillin). No cross-19 
resistance was found against the two conventional antibiotics for any of the lineages (not shown). 20 
Some cross-resistance was found against polymyxin B for some of the chimera-supplemented 21 
lineages (2- to 16-fold increase in MIC compared to wild type, not shown), and against chimera 1 for 22 
the polymyxin B-supplemented lineages (2- to 8-fold increase in MIC as compared to the wild type, 23 
not shown). 24 
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Stability of resistance. To establish if the acquired resistance was heritable we revived all lineages 1 
in unsupplemented media and cultured them for five passages (corresponding to ~35 generations) in 2 
the absence of the compound applied for selection. All ten lineages tolerant to the chimera could now 3 
successfully be revived. Again we performed MIC determinations against both selective agents for 4 
all lineages. The lineages exposed to the chimera displayed high levels of resistance against this 5 
compound even after growth in unsupplemented media confirming the heritability of resistance 6 
(Table 1). The ten lineages displayed MIC values against chimera 1 between 32 µg/mL (4×MIC) and 7 
256 µg/mL (32×MIC); the lowest being lineage no. 10 which showed a strong decrease in the MIC 8 
value compared to the initial level of 256-512 µg/mL indicating that this lineage may be less stable 9 
than the others. Similarly, the MIC for polymyxin B against the polymyxin B-exposed lineages 10 
remained high upon culturing for five passages in unsupplemented media (Table 1). The low level of 11 
cross-resistance seen in the two groups of lineages against chimera 1 and polymyxin B, respectively, 12 
was lost after removal of the selection pressure, and became similar to that of the controls (not 13 
shown). 14 
Isolate MIC after selection. From each of the lineages cultured at 32×MIC, ten individual isolates 15 
were randomly selected from plating the population on non-selective plates. We chose to focus 16 
specifically on the isolates from two of these lineages; lineage no. 2 which had a population MIC of 17 
256 µg/mL, was quickly outgrown in supplemented media and displayed various colony 18 
morphologies (normal as well as larger more light colonies) and lineage no. 5, which had a 19 
population MIC of 128 µg/mL, appeared to have a reduced growth rate and looked homogenous 20 
when plated. To this end, it seemed likely that different genetic events had occurred in these two 21 
populations, and that this may be reflected in the resistance profiles of the isolates from the two 22 
populations. In order to establish whether heterogeneity was a general trend in all lineages, two 23 
randomly selected isolates from lineage 4 (4-4 and 4-6) and lineage 7 (7-7 and 7-9) were included in 24 
the further investigation. 25 
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We determined the MIC against chimera 1 for the twenty isolates from lineage 2 and 5 (Figure 3). 1 
Both populations were heterogeneous displaying large differences in MIC values of individual 2 
isolates. The ten isolates from lineage 2 displayed MIC values within the range 8-128 µ/mL (Figure 3 
3). Two of the ten isolates appeared to be particularly unstable; in three biological replicates isolates 4 
2-3 exhibited MIC values of 8, 16 and 64 µg/mL, while the MIC values for isolate 2-8 were 16, 64 5 
and 128 µg/mL for the three biological replicates. Remarkably, from lineage 5, seven out of ten 6 
isolates had the same MIC value as the wild type (i.e. 8 µg/mL) while none of the other three isolates 7 
displayed the same MIC as the whole population i.e. 128 µ/mL (Figure 3). Overall, this population 8 
was evidently less resistant (or stable) than lineage 2. Differences in colony morphology were not 9 
reflected in a significantly altered MIC value. Additionally, individual colonies were verified as E. 10 
coli by 16S rRNA sequencing as well as by a range of standard phenotypic tests. Interestingly, the 11 
two isolates from lineage 4 had the same MIC value as the wild type E. coli. Moreover, the MIC 12 
value of one of the isolates from lineage 7 (i.e. 7-9) was the same as that found for the wild type, 13 
whereas the other isolate (7-7) was highly resistant (MIC = 64 µg/mL). Therefore it appears that it is 14 
a general trend that the vast majority of cells have a lower MIC than the population as a whole and 15 
that a large degree of heterogeneity exists within the lineage populations. 16 
Cross-resistance. Since AMPs are found widely in nature, the potential of cross-resistance to natural 17 
AMPs constitutes an important issue to clarify. Therefore we determined MIC values against 18 
polymyxin B (bacterial), protamine (salmon), KR-12 (a short analogue of the human cathelicidin LL-19 
37), IsCTp (scorpion), Pep-1-K (viral) and mellitin (honey bee venom) for all twenty isolates from 20 
lineages 2 and 5. We did not find increased MIC values for any of these as compared to the wild type 21 
(not shown). Next, the level of cross-resistance towards the related chimera 2 (Figure 1) was 22 
addressed. We found high levels of resistance against this chimeras for all resistant isolates, whereas 23 
isolates with wild type MIC towards chimera 1 also had considerably lower MIC values towards this 24 
chimera (Figure 4). Furthermore, MIC determination for a third chimera (i.e. chimera 3, Figure 1) 25 
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against the three most resistant isolates from lineage 2 gave MIC levels that were 8 times higher than 1 
seen for the wild type (i.e. 4 µg/mL vs. 32 µg/mL). The evaluation of cross-resistance against 2 
different groups of antimicrobials including conventional antibiotics, natural AMPs and 3 
peptidomimetics confirmed that the developed resistance was specific for these peptidomimetics.  4 
Fitness cost. Another interesting issue was to determine whether acquisition of resistance had altered 5 
the growth properties of the resistant isolates. Thus, the growth rates of the twenty isolates from 6 
lineages 2 and 5 were compared with that of the wild type strain in the absence of the selective 7 
chimera. None of the twenty isolates displayed a significant change in growth rate compared to E. 8 
coli ATCC 25922 (p > 0.05 for all). Likewise, no correlation was seen between MIC of the isolates 9 
(Figure 3) and their growth rates. We also determined the growth rate of the three most resistant 10 
isolates found, namely isolates 2-7, 2-9 and 2-10 in the presence of sub-lethal concentrations of 11 
chimera 1. Despite the high MIC value (128 µg/mL for all three isolates) a pronounced effect on 12 
growth was seen even at very low concentrations of chimera 1. The growth rate of all three isolates 13 
were significantly reduced at a chimera concentration of 8 µg/mL corresponding to the wild type 14 
MIC or 1/16 of the isolate MIC (2-7: p<0.01; 2-9: p<0.05; 2-10: p<0.01). Remarkably a significantly 15 
reduced growth rate was also seen for two of the isolates (2-7: p < 0.01 and 2-10:  p < 0.05) at a 16 
concentration of 4 µg/mL i.e. 1/32 of the MIC of the isolate.  17 
Whole-genome sequencing. Fourteen isolates exposed to chimera 1 and three isolates cultured with 18 
MilliQ water as well as the ancestral wild type were whole-genome sequenced. The wild type (E. 19 
coli ATCC 25922) was de novo assembled creating 135 contigs encompassing 5.12 MB. The 135 20 
contigs of the ancestral strain then served as a reference for indentifying SNPs in the evolved 21 
isolates. The sequenced isolates were divided into three groups based on their susceptibility towards 22 
chimera 1: (i) isolates with wild type MIC (8 µg/mL), (ii) isolates with low levels of resistance (4-8 23 
×wild type MIC), and (iii) isolates that were highly resistant (8-16 ×wild type MIC) (Table 2). We 24 
identified four SNPs, which were present in the six highly resistant isolates (i.e. with MIC 8-16 times 25 
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above wild type MIC) from lineages 2 and 7, but not in isolates with low or intermediate levels of 1 
resistance or in the controls not exposed to chimera 1. Using BLAST it was determined that the four 2 
SNPs were located in genes encoding a hypothetical protein, a putative outer membrane transporter, 3 
a macrolide transporter and the membrane-bound lytic murein transglycosylase D (mltD), 4 
respectively. No change was seen in the susceptibility of the five isolates to the macrolide 5 
erythromycin as compared to the wild type (not shown). The SNP in the mltD gene caused a change 6 
of amino acid 55 from proline (nonpolar) to glutamine (polar), but the effect of this on the secondary 7 
structure of the protein is unknown (Bateman and Bycroft, 2000). No consistent pattern was seen in 8 
the presence of SNPs in the three isolates displaying low levels of resistance to chimera 1 (5-6, 5-8, 9 
5-9, Figure 3).  10 
 11 
 12 
DISCUSSION 13 
In this study it was demonstrated that Escherichia coli may develop resistance during continuous 14 
exposure to increasing concentrations of an α-peptide/β-peptoid peptidomimetic (Table 1) and that 15 
this was observed in all of ten lineages. To our knowledge this is the first time heritable resistance 16 
has been developed to a synthetic AMP analogue (i.e. a peptidomimetic). We have previously shown 17 
that these peptidomimetics are membrane-active (Hein-Kristensen et al., 2011). For long, it was 18 
believed that AMP resistance development was unlikely since these compounds target the bacterial 19 
Achilles’ heel i.e. the plasma membrane structure (Zasloff, 2002). Hence, though these 20 
peptidomimetics indeed target the structural features of the bacterial membrane, the investigated 21 
wild-type strain of E. coli developed a mechanism of resistance that apparently circumvents the 22 
membrane-activity of the peptidomimetics. A few studies have shown that resistance may develop 23 
towards other AMPs. The most comprehensive of these studies was performed with pexiganan, an 24 
analogue of the natural AMP magainin against Pseudomonas fluorescens and E.coli (Perron et al., 25 
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2006). The authors demonstrated high levels of heritable resistance in both bacteria showing that 1 
resistance mechanisms may evolve as a result of a continuous selection pressure exerted by a single 2 
compound. Other studies have not found AMP resistance as a result of continuous selection with 3 
natural or synthetic AMPs (Farrell et al., 2011;Zaknoon et al., 2009;Steinberg et al., 1997), however, 4 
these studies were performed with sub-inhibitory concentrations of the AMP without any attempts at 5 
increasing the concentration. We speculate that the development of resistance shown by Perron et.al. 6 
(2006) and demonstrated in the present study might be due to the gradual 2-fold increments in the 7 
concentration starting from a very low level (1/16 of MIC) of the AMP used for selection. 8 
 9 
E. coli bacteria possess a large mutational reservoir for increased resistance to antibiotics (Girgis et 10 
al., 2009). SNP detection in the sequenced genomes revealed an average number of 500 SNPs in 11 
each isolate as compared to the ancestral wild type (not shown), i.e. statistically one SNP occurs per 12 
generation indicating a very high mutation rate. The differences observed in the level of resistance 13 
and stability (Table 1) indicate that distinct mutational events may have taken place between and 14 
within the lineages. We have shown that the MIC values for the chimera varied profoundly between 15 
individual isolates from lineages 2 and 5 (Figure 3) as well as from lineage 7. It is interesting that we 16 
did not find any isolates displaying the population MIC of either lineage 2 or 5; we hypothesize that 17 
this could be due to: (i) lack of stability of the population, or (ii) presence of low proportions of 18 
highly resistant isolates. In the development of resistance to antibiotics, bacterial charity (i.e. 19 
production of indole) has been proposed to confer protection to less resistant clones in a 20 
heterogeneous population (Lee et al., 2010). Also, it is  possible that epigenetic events such as 21 
changes in gene expression may provide temporary protection of the entire population (Adam et al., 22 
2008). 23 
 24 
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Since earlier studies had indicated moderate mutation rates for polymyxins (Rahaman et al., 1 
1998;Falagas et al., 2010), we selected for polymyxin B resistance in parallel experiments. Thus, we 2 
found indications of a higher mutation rate for polymyxin B than that of chimera 1 as spontaneous 3 
growth of one of the controls at 4×MIC was only seen for the former (not shown). No cross-4 
resistance was seen between chimera 1 and polymyxin B, independently of which compound had 5 
been used as the selective agent, demonstrating that different mechanisms must confer resistance 6 
against these compounds. Resistance to polymyxins has been demonstrated several times to be 7 
related to modification of the bacterial outer membrane, in particular of the lipopolysaccharide (LPS) 8 
layer (Rahaman et al., 1998;Nummila et al., 1995;Zhou et al., 2001). Such modifications are most 9 
often mediated by two-component systems, which have been widely studied for their role in 10 
resistance to AMPs (Cheng et al., 2010;Fernandez et al., 2010;Weatherspoon-Griffin et al., 2011). 11 
However, two-component systems are associated with adaptive (inducible) resistance, but as 12 
resistance to polymyxin B in our case proved heritable in unsupplemented media, two-component 13 
systems are unlikely to be responsible for the development of resistance to polymyxin B in the 14 
present study.  15 
 16 
Similarly, resistance to chimera 1 was heritable indicating that tolerance involving two-component 17 
systems are not responsible for conferring resistance against chimera 1 in the resistant isolates. To 18 
investigate the resistance mechanism, we tested for cross-resistance to conventional antibiotics and 19 
natural AMPs. Resistance to aminoglycosides may be mediated by LPS modifications (Rahaman et 20 
al., 1998), but we could not demonstrate any cross-resistance to this type of antibiotics. Similarly, no 21 
change was seen in the susceptibility of the isolates to β-lactams. Importantly, we found no evidence 22 
of cross-resistance to a range of natural and semi-synthetic AMPs indicating that the resistance 23 
mechanism for membrane-active AMPs is not universal. However, pronounced cross-resistance was 24 
seen to other peptidomimetics with the same scaffold (e.g. 2 and 3), i.e. cross resistance was 25 
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demonstrated to a chimera where: (i) homoarginine was replaced by lysine and extra repeating units 1 
were added (i.e. 16-meric 2 vs. 12-meric 1), and (ii) the structure was non-chiral (i.e. 3) as opposed 2 
to the chiral structure of chimera 1 (Figure 1). Especially, cross-resistance to the latter chimera is 3 
interesting since the extent of chirality influences the secondary structure of the compound, which 4 
generally is believed to have a marked impact on the mechanism of action of membrane-active 5 
AMPs and  peptidomimetics (Deslouches et al., 2005).    6 
 7 
Whole-genome sequencing of resistant isolates revealed that resistance possibly was mediated by a 8 
SNP in the gene encoding the MltD protein, a membrane-bound lytic murein transglycosylase 9 
responsible for peptidoglycan reorganization. This SNP causes a change in amino acid 55 of the 10 
protein from proline (a nonpolar amino acid) to glutamine (a polar amino acid), and it is possible that 11 
this changes the secondary structure and thereby the activity of MltD. A study in Vibrio anguillarum 12 
has shown that inactivation of the mltD gene results in resistance to conventional antibiotics (Xu et 13 
al., 2011). Since we found this SNP in six isolates from two different lineages, it appears not to be 14 
deleterious to the bacteria. Additionally, the potential modification of the cell envelope does not 15 
seem to entail a fitness cost in resistant isolates since we found no change in the growth rate of the 16 
isolates as compared to the ancestral wild-type strain. However, in a separate study we have found 17 
evidence that resistant isolates have an increased susceptibility to the innate antibacterial action of 18 
human blood plasma (Hein-Kristensen et al., 2012). Further studies are needed to confirm that this 19 
SNP in the gene encoding mltD is responsible for the observed resistance to the peptidomimetics.  20 
 21 
In conclusion, we found that E. coli may develop heritable resistance during continuous selection to 22 
an α-peptide/β-peptoid peptidomimetic, which we believe is the first time this has been demonstrated 23 
for a backbone-modified AMP analogue. Cross-resistance was demonstrated to other compounds 24 
belonging to the same peptidomimetic subclass indicating that cross-resistance most likely is 25 
20 
 
correlated with the scaffold. Importantly, the mechanism of resistance appear to be closely linked to 1 
changes in the organization of the peptidoglycan layer due to a common mutation in the gene 2 
encoding the MltD protein in all highly resistant isolates.  3 
 4 
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Figure 1. The structure of chimera 1 used for continuous culturing of Escherichia coli and the structure of 
chimeras 2 and 3 to which cross-resistance was demonstrated. 
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Figure 2. Continuous selection exerted by chimera 1 (A), or by polymyxin B (B) leads to tolerance in E. coli. All lineages exposed to the peptidomimetic were 
cultured up to 32×MIC (A); for lineages selected against polymyxin B this was eight out of ten (the last two were not able to grow above ¼ MIC  i.e. 0.25 µg/mL).  
Punctuated lines indicate wild type MIC of the selective agents (8 µg/mL and 1 µg/mL, respectively). 
 
29 
 
Table 1. Minimum Inhibitory Concentration (µg/mL) 
 Chimera 1 (chimera-exposed lineages)  Polymyxin B (polymyxin B-exposed lineages) 
Lineage number After selection Stability  After selection Stability 
1 n.a. 128-256  n.a. n.a. 
2 256 256  32 32 
3 n.a. 128  32 32 
4 256 128  32 32 
5 64-128 128  32 32 
6 n.a. 64-128  32 32 
7 128 128  n.a. n.a. 
8 n.a. 32-64  32 32 
9 n.a. 128  32 32 
10 256 32  32 32 
Control 1 32 16-32  8 0.5 
Control 2 8 8  1 0.5-1 
E. coli ATCC 25922 8  1 
Table 1. Minimum Inhibitory Concentration (µg/mL) of the cultured lineages against the two selective agents, chimera 1 and polymyxin B. MIC values were determined for 
exposed lineages while keeping the selection pressure as well as  after the selection pressure had been removed for ~ 35 generations (i.e. stability). MIC values are based on 
two technical duplicates. All exposed lineages displayed increased MIC values compared to the ancestral E. coli strain, and resistance was heritable for all but one lineage. 
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Figure 3. Minimum Inhibitory Concentration (MIC) for chimera 1 against population isolates of lineage 2 (A) and 
lineage 5 (B). Bars indicate biological replicates; MIC for all isolates was determined twice, a third replicate was 
performed for isolates 2-3 and 2-8 due to large variations in results. Susceptibility to chimera 1 varies widely within 
the populations. Solid line: population MIC; punctuated line: wild type MIC (8 µg/mL). 
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Figure 4. Association between Minimum Inhibitory Concentration (MIC) for chimera 1 and chimera 2 
against lineage 2 (black circles) and lineage 5 (white circles). E. coli ATCC 25922 MIC is highlighted 
with an asterisk (i.e. MIC values of 8 µg/mL and 64 µg/mL for chimera 1 and 2, respectively). This data 
point is shared with six of the ten isolates from lineage 5. All values based on two biological replicates; 
the mean value is displayed when results varied. 
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Table 2. Levels of resistance in sequenced isolates grouped by MIC values 
Wild type MIC 
(8 µg/mL)  
Low levels of resistance 
(4-8 × wild type MIC)  
High  levels of resistance 
(8-16 × wild type MIC) 
4-4  5-6  2-4 
4-6  5-8  2-6 
5-4  5-9  2-7 
5-6    2-9 
7-9    2-10 
    7-7 
Table 2. Levels of resistance in the three groups of sequenced isolates. MIC was determined in a 
minimum of two biological replicates according to CLSI guidelines. Isolates were grouped based on 
the average of these determinations.  Only the six highly resistant isolates contained a SNP in the gene 
encoding MltD. 
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ABSTRACT 1 
Cationic antimicrobial peptides (AMPs) are considered promising leads for novel antibiotics, 2 
however, their activity may be compromised under physiologically relevant conditions due to 3 
inherent instability towards proteolytic degradation. The purpose of the present study was to 4 
determine the activity of a series of stable α-peptide/β-peptoid peptidomimetics against Escherichia 5 
coli in the presence of human blood plasma and relevant immune effector molecules. We also 6 
addressed if acquired bacterial resistance towards the chimeras might compromise plasma 7 
antibacterial activity. 8 
 9 
The Minimum Inhibitory Concentration (MIC) of an α-peptide/β-peptoid chimera against a clinical 10 
strain of E.coli decreased from 4 µg/mL in MHB media to 0.125-1 µg/mL with the addition of 50 % 11 
blood plasma. Similarly, the Minimum Bactericidal Concentration (MBC) decreased 4-fold in the 12 
presence of 50 % blood plasma. To elucidate the cause of this enhanced antibacterial activity, the 13 
interaction between the chimera and effector molecules of the immune system was examined. No 14 
effect (synergy or antagonism) was found between the chimera and immune effector molecules (a 15 
shortened LL-37 analogue, lysozyme, or hydrogen peroxide), however, the enhancement of 16 
antibacterial activity observed in blood plasma was abolished following heat-induced inactivation of 17 
the complement system. Chimera-resistant mutants of E.coli, exhibiting a MIC 8 times above the 18 
MIC of a wild-type strain, were highly susceptible to plasma antibacterial activity and were killed 19 
when blood plasma concentrations exceeded ~30 %. Additionally, chimera MIC of the resistant 20 
mutants returned to wild-type level upon addition of 25 % plasma. 21 
 22 
The enhancement of chimera antibacterial activity in a physiological environment and the increased 23 
susceptibility to blood plasma following acquisition of resistance significantly increases the 24 
therapeutic potential of these compounds.25 
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INTRODUCTION 1 
The number of new classes of antimicrobials released for clinical use has been extremely limited 2 
since the golden-age of antibiotics in the 1930-1960s (Fischbach and Walsh, 2009). Only four new 3 
classes of antibiotics have been introduced within the last decade, instead most novel antibacterial 4 
drugs are designed through modification of existing scaffolds (Jabes, 2011;Livermore, 2011). 5 
Furthermore, treatment of infectious diseases has been hampered by the rapid emergence of bacterial 6 
resistance to such varieties of antibiotics soon after their introduction, and it seems that in spite of 7 
low mutation rates resistance to all classes of conventional antibiotics will inevitability evolve over 8 
time (Theuretzbacher, 2011). One strategy to win this evolutionary battle involves the use of the very 9 
widespread class of naturally occurring antimicrobial peptides (AMPs). However, AMPs must in 10 
general be developed into compounds suitable for therapeutic use (Hancock and Sahl, 2006). These 11 
short, cationic compounds form part of the innate immune defence among all classes of life, where 12 
they display direct antimicrobial activities as well as immuno-modulatory properties (Zasloff, 13 
2002;Nijnik and Hancock, 2009;Easton et al., 2009). The co-evolution of AMPs and bacteria has 14 
obviously avoided development of resistance, and have thus made the structural properties and 15 
diversity of these compounds very interesting research objectives (Peschel and Sahl, 16 
2006;Woolhouse et al., 2002). Yet, concerns have been raised that systemic therapeutic use of AMPs 17 
might disrupt this delicate balance allowing bacteria to develop resistance, and thereby compromise 18 
our own immune defence (Bell and Gouyon, 2003).  19 
 20 
One of the great obstacles in the further advancement of lead AMPs is the transition from in vitro 21 
activity to efficacy in animal models because of the sensitivity of many AMPs to biological 22 
environments (Deslouches et al., 2005). Biological relevant conditions may lead to a decrease or 23 
complete loss of activity of otherwise promising compounds making these unsuitable for systemic 24 
use (Sabath, 1978;Otvos and Cudic, 2007;O'Neill and Chopra, 2004;Powell et al., 1993). The 25 
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activity of AMPs is especially sensitive to the saline conditions present in plasma. In particular 1 
divalent cations compete with the peptide for bindings sites on the negatively charged bacterial 2 
surface (Deslouches et al., 2005). Moreover, AMPs are susceptible to degradation by serum 3 
proteases (Knappe et al., 2010), and for these reasons many AMPs have only been developed as 4 
topical agents. A simple model for determining the potential in vivo activity involves biological 5 
evaluation in the presence of human blood plasma, which may be obtained from freshly drawn blood 6 
by removal of red and white blood cells. Therefore it contains the same components as whole blood 7 
as opposed to blood serum. Plasma contains both factors known to facilitate the growth of bacteria 8 
(i.e. vitamins, amino acids etc.) as well as factors of the immune defence promoting killing or 9 
inhibition of bacteria (e.g. complement, lysozyme, antibodies and AMPs), and hence blood plasma 10 
exhibits an innate antibacterial effect (Taylor, 1983). However, some bacterial strains are resistant to 11 
plasma and are therefore not efficiently cleared from the blood by natural immune processes.  12 
 13 
The soluble components of the immune system (i.e. complement, antibodies and AMPs) may act 14 
synergistically with antimicrobial therapeutics, and such interaction has been demonstrated for both 15 
AMPs and antibiotics (Dutcher et al., 1978;Deslouches et al., 2005;Vaara and Vaara, 1983). 16 
Although the exact mechanisms are not known it appears that the combined effects lead to disruption 17 
of the permeability barrier of the outer membrane of Gram-negative bacteria thereby enabling 18 
immune factors and antibacterial drugs to reach their targets more readily (Dutcher et al., 19 
1978;Yeaman et al., 2002). Synergy as well as negative interactions (i.e. antagonism) between 20 
antimicrobial drugs and human AMPs have been reported by numerous investigators (Mishra et al., 21 
2011;Jones et al., 2008;Zahner et al., 2010;Kristian et al., 2007;Xiong et al., 1999).  22 
 23 
Previously, we have described the synthesis of an array of α-peptide/β-peptoid chimeras designed 24 
with alternating N-alkylated β-alanine (β-peptoid) and α-amino acid residues (Bonke et al., 25 
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2008;Olsen et al., 2007). The structure-activity relationship against food borne and nosocomial 1 
bacterial pathogens was investigated, and the cell envelope was shown to be the primary target of the 2 
chimeras (Hein-Kristensen et al., 2011). The ultimate aim is to test and use these chimeras in vivo, 3 
and the present study concerns determination of activity of a single α-peptide/β-peptoid chimera in a 4 
simulated in vivo system as an initial step in this development process. We used a clinical strain of 5 
Escherichia coli that is one of the principal test strains for determining antimicrobial activity (The 6 
Clinical and Laboratory Standards Institute (CLSI), 2006). Also, this strain produces hemolysin 7 
making it relevant to test in a model for potential activity in blood. Additionally, we used three 8 
chimera-resistant mutants of E.coli to determine whether the acquisition of heritable resistance 9 
affected the tolerance of the bacteria to innate immune factors present in blood. 10 
 11 
 12 
MATERIALS AND METHODS 13 
Bacterial strains and culture conditions and human blood plasma. All experiments were 14 
performed with Escherichia coli ATCC 25922 or isolates derived from this strain. Stock cultures 15 
were stored at –80oC in 4 % (w/v) glycerol, 0.5 % (w/v) glucose, 2 % (w/v) skimmed milk powder 16 
and 3 % (w/v) tryptone soy powder. Unless otherwise stated experiments were carried out with 17 
bacteria incubated for one night (i.e. approximately 18 hours) at 37oC. Experiments were performed 18 
in cation-adjusted Mueller Hinton II broth (MHB) (Becton Dickinson 212322) adjusted to pH 7.4. 19 
Brain Heart Infusion (BHI) (CM1135) with agar (VWR 20768.292) 1.5 % as gelling agent was used 20 
for colony plating. Human blood plasma was obtained from two healthy individuals by 21 
centrifugation of freshly drawn blood for 10 minutes at 4000×g. Sodium citrate was used as 22 
anticoagulant. Blood plasma was stored at −20oC in 2 mL aliquots, whereby multiple freeze-thaw 23 
cycles was avoided. 24 
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Chimera synthesis. A library of α-peptide/β-peptoid peptidomimetics consisting of alternating 1 
repeats of natural cationic α-amino acids and synthetic lipophilic β-peptoid residues was synthesized 2 
by solid-phase synthesis as previously described (Bonke et al., 2008;Olsen et al., 2007). From this 3 
library a single compound i.e. chimera 1 was chosen for all experiments, Figure 1. The chimera was 4 
solubilised to a stock concentration of 10 mg/mL in MilliQ water and stored at -20oC. 5 
Growth of wild type bacteria in human blood plasma. The ability of E. coli ATCC 25922 to grow 6 
in human plasma was investigated in a spectrum of 25-50 % plasma (based on preliminary 7 
experiments). A volume of 50 µl 100 % plasma, plasma diluted with MHB pH 7.4 to 2 × assay 8 
concentration or pure MHB as control was added to each well of a polypropylene microtiter plate 9 
(Nunc 442587). Colonies grown on BHI agar overnight (i.e. approximately 18 hours) were 10 
suspended in 0.9 % saline to give a turbidity of 0.13 at OD546 (approximately 1 × 108 CFU/mL), and 11 
then diluted in MHB pH 7.4 to a final concentration of 5 × 105 CFU/mL in each well. Growth was 12 
assessed after 18-20 hours at 37oC. Experiments were performed on at least two independent days for 13 
each blood donor. E.coli formed a dense slime precipitate when grown in plasma. To test whether 14 
extracellular DNA could be a component of this, the slime pellets were transferred to a new 15 
microtiter-plate and DNase treated. 50 µl 20× or 100× DNase (Sigma Aldrich D5319) diluted in 0.9 16 
% saline were added, and the plates were incubated at 37oC for up to 20 hours.  17 
Determination of chimera Minimum Inhibitory Concentration (MIC) with/without blood 18 
plasma. MIC was determined using the micro-dilution method according to guidelines of the 19 
Clinical and Laboratory Standards Institute (CLSI) (The Clinical and Laboratory Standards Institute 20 
(CLSI), 2006). Chimera 1:2 serial dilutions in MHB pH 7.4 were prepared from a 32 µg/mL stock 21 
solution to give a final range of 0.016-16 µg/mL in the wells. Bacterial suspensions were prepared as 22 
described above to give a final bacterial density of 5 × 105 CFU/mL in each well. Polypropylene 23 
plates (Nunc 442587) were used to minimize peptide binding, and the incubation time was 18-20 24 
hours at 37oC. MIC was determined in a minimum of two biological replicates as the lowest 25 
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concentration of the peptide analogue where no visible growth was found. The Minimum 1 
Bactericidal Concentration (MBC) was determined by plating 10 µL of the suspension from the first 2 
three wells without growth on BHI agar and incubating these for 24 hours at 37oC. MBC was the 3 
lowest concentration at which a 99.9 % reduction in CFU/mL was observed. 4 
To determine whether chimera activity was affected by human blood plasma, we compared the 5 
activity (i.e. MIC) in MHB with the activity in MHB supplemented with 50 % plasma. We chose this 6 
amount of plasma because 50 % is the natural proportion of plasma in human blood, and because 7 
growth of E. coli was not diminished by the addition of 50 % plasma. For MIC determination in 50 8 
% plasma, we used the standard protocol, but made the chimera 1:2 serial dilutions in 100 % plasma 9 
instead of MHB. In each experiment a row of MHB 1:2 serial dilutions were included as control. 10 
MBC determination was performed as described above. Experiments were performed in at least two 11 
independent experiments for each blood donor. Additionally, we performed the MIC determination 12 
in 50 % plasma on a shaken culture (300 rpm) since preliminary experiments indicated that stagnant 13 
growth in plasma could protect against peptide activity. For this, chimera was added in a 14 
concentration of 8, 1, 0.125 or 0 µg/mL to a bacterial suspension at 5 × 105 CFU/mL with/without 50 15 
% plasma for a total volume of 0.5 mL. Cultures were incubated at 37oC, 300 rpm for 20 hours and 16 
MBC was determined as described above. 17 
The presence of plasma strongly reduced chimera MIC, and to determine if plasma had to be present 18 
simultaneously to exert an effect or if pre-incubation with blood plasma also had an influence on 19 
peptide activity, we pre-incubated bacteria in plasma for seven passages (~50 generations). 20 
Preliminary experiments showed no effect on growth at 6.25 %, and we therefore chose this 21 
concentration for the experiments. E. coli ATCC 25922 grown on BHI agar overnight at 37oC was 22 
re-inoculated (10 µl) seven times in MHB (990 µl) supplemented with plasma or MilliQ water as 23 
control with transfer into fresh media once a day. After the last passage, cells were either (i) 24 
harvested and washed three times (0.9 % saline, 2000×g, 10 min) before being re-suspended in 0.9 % 25 
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saline to give a turbidity of 0.13 at OD546 (approximately 1 × 108 CFU/mL), and then diluted in 1 
MHB pH 7.4 to a final concentration of 106 CFU/mL, or (ii) transferred directly into fresh MHB pH 2 
7.4 to a concentration at 106-107 CFU/mL. Time-kill was performed by adding chimera to a final 3 
concentration of ½×MIC (i.e. 2 µg/mL) and incubating the suspension at 37oC, 300 rpm. Samples for 4 
colony determination were taken at 0, 2, 4, 6, 8, 10 and 24 hours after addition and transferred to a 5 
ten-fold dilution row. Colony counts were determined after incubation for 24 hours at 37oC. The 6 
whole experiment was performed twice. 7 
Interaction with innate immune factors. To investigate which compounds in plasma may be 8 
responsible for enhanced antibacterial effect of the chimera, we used the checkerboard method (Yan 9 
and Hancock, 2001) to investigate possible synergy with relevant immune effector molecules. Since 10 
the present chimera has a structure and mode of action that mimic natural AMPs belonging to the 11 
innate immune defence (Hein-Kristensen et al., 2011), where synergy is known a to be prominent 12 
part of the overall activity (Peschel and Sahl, 2006), we focused on a LL-37 analogue i.e. KR-12 13 
(Wang, 2008), hydrogen peroxide, and lysozyme from human neutrophils (Sigma Aldrich L8402) 14 
(Yan and Hancock, 2001). The chimera was serially diluted along the rows of the microtiter plate 15 
and the immune effector molecules diluted along the columns. Chimera 1:2 serial dilutions were 16 
prepared from a 64 µg/mL stock solution to give a final range of 0.25-16 µg/mL in the wells. 17 
Lysozyme 1:2 serial dilutions were prepared from a 256 µg/mL stock solution to give a final range of 18 
1-64 µg/mL in the wells. Hydrogen peroxide 1:2 serial dilutions were prepared from a 32 mM stock 19 
solution to give a final range of 0.13-8 mM in the wells. Also, 1:2 serial dilutions of the natural 20 
peptide KR-12 were prepared from a 64 µg/mL stock solution to give a final range of 0.25-16 µg/mL 21 
in the wells; however this was performed in 1 % (w/v) peptone (Becton Dickinson 211677) instead 22 
of in MHB since activity was drastically diminished in the latter (not shown). For testing synergy 23 
with KR-12 we therefore also diluted the chimera in 1 % peptone, which had no effect on chimera 24 
activity (not shown). The bacterial suspension was prepared as described for standard MIC 25 
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determination. Polypropylene plates (Nunc 442587) were used to minimize peptide binding, and the 1 
incubation time was 18-20 hours at 37oC. Synergy, defined as a reduction in the MIC value of the 2 
chimera in the presence of one of the effector molecules, was investigated in two biological 3 
replicates. 4 
Heat-inactivation of plasma. Human blood plasma contains parts of the complement system, which 5 
can be inactivated by high temperatures (Zinsser and Johnson, 1911;Hazen, 1943). To determine 6 
whether complement enhanced the effect of the chimera, we determined chimera activity in heat-7 
inactivated plasma, and compared this with untreated plasma. Plasma was heat-inactivated by 8 
incubation at 56oC for 15 minutes followed by rapid cooling on ice. MIC of the chimera in the 9 
presence of 50 % heat-inactivated plasma, 50 % untreated plasma or MHB as control was determined 10 
as described above. The assay was performed in two independent experiments. 11 
Effect of bacterial chimera-resistance on the activity of blood plasma. E.coli is capable of 12 
developing heritable resistance to chimeras following continuous selection (Hein-Kristensen et al., 13 
2012). Resistant variants of E.coli were not resistant to other natural or synthetic AMPs, but 14 
increased MICs were seen for compounds with a similar design, indicating that the activity of the 15 
chimeras within the array were influenced by the same resistance mechanism (Hein-Kristensen et al., 16 
2012). The MIC value of the ancestral wild type to chimera 1 is 4 µg/mL whereas it is 32 µg/mL for 17 
resistant isolates (Hein-Kristensen et al., 2012). Since it has been claimed that AMP resistance is a 18 
potential health risk due to impairment of our own immune system, we determined plasma activity 19 
against three resistant isolates and compared this to the effect on the (ancestral) wild type bacteria to 20 
see whether the activity of plasma had been changed following acquisition of resistance.  21 
Three resistant isolates (strains 2-7, 2-9 and 2-10, numbered according to isolation from lineage 2 22 
(Hein-Kristensen et al., 2012)) were revived from freeze storage. The three isolates were grown in 23 
25-50 % blood plasma and 25-50 % heat-inactivated plasma as described above for the wild type. 24 
Experiments were performed on at least two independent days for each blood donor. MIC 25 
10 
 
determination of a short analogue (KR-12) of LL-37, hydrogen peroxide, and lysozyme was 1 
performed in biological duplicates as described above to see whether resistance also conferred 2 
elevated MIC values to immune factors. Lastly, MIC against chimera 1 was determined as described 3 
above in the presence of 25 % plasma (chosen due to lack of growth of the three isolates in 50 % 4 
plasma) to determine if this could decrease or abolish the high MIC values seen for the resistant 5 
isolates. 6 
 7 
 8 
RESULTS 9 
The purpose of this study was to determine whether physiologically relevant compounds (human 10 
blood plasma and human immune factors assumed to be present in this) influenced the activity of an 11 
α-peptide/β-peptoid chimera as compared to the activity seen in conventional laboratory assay media. 12 
Additionally, we wanted to test growth and susceptibility of chimera-resistant E. coli mutants 13 
towards these compounds in order to establish how development of chimera resistance influenced the 14 
sensitivity of bacteria to factors of the innate human immune defence. 15 
Growth of wild type bacteria in human blood plasma. E. coli ATCC 25922 grew well in MHB 16 
supplemented with 25-50 % human blood plasma, but formed visible, large (0.5 mm) pellets when 17 
grown in 25-50 % plasma (Figure 2b). Microscopy revealed a dense 3D matrix of cells clustering 18 
within a slime matrix (Figure 2e). We suspected that eDNA was responsible for the slime/biofilm 19 
matrix, however, the slime pellet showed no signs of disintegration after treatment with DNAse for 20 
20 hours.  21 
Chimera MIC with/without human blood plasma. MIC for chimera 1 in MHB was 4 µg/mL 22 
against E. coli ATCC 25922, which corresponds to the MBC value reported previously (Hein-23 
Kristensen et al., 2011). With 50 % plasma added, the MIC decreased to 0.125-1 µg/mL, i.e., a 4- to 24 
32-fold decrease (Table 1). This decrease in MIC was observed with plasma from two different 25 
11 
 
donors. The change in MIC was less pronounced when the assay was performed in 25 % plasma (i.e., 1 
MIC was only diminished to 1-2 µg/mL) indicating a dose-response effect of plasma on chimera 2 
activity. Though MIC values in plasma differed substantially (most likely reflecting variations in the 3 
plasma composition itself), MBC values never exceeded 1 µg/mL. Hence, compared to chimera 4 
activity in MHB media, where MIC equals MBC, the activity of chimera 1 in 50 % plasma was 5 
bacteriostatic. The same pellet morphology consisting of a dense slime matrix of cells observed 6 
when E. coli was grown in 50 % plasma only was also seen upon addition of sub-inhibitory 7 
concentrations of chimera (Figure 2a).  8 
The slime pellet was only observed when E. coli was grown with plasma under stagnant conditions. 9 
To determine whether the slime pellet influenced the bactericidal activity of chimera 1, we 10 
determined MIC on a shaken culture. Due to limited amounts of chimera only three concentrations 11 
were used in MHB media with or without 50 % plasma. At 8 µg/mL (2×MIC) no growth was seen in 12 
MHB with or without plasma added. At 1 and 0.125 µg/mL, growth was only seen in MHB without 13 
plasma added.  Colony counts of tubes with 1 or 0.125 µg/mL of chimera in 50 % plasma revealed 14 
bacterial densities that were very close to inoculation levels indicating that bacterial growth had only 15 
been inhibited. Microscopy revealed normal single motile cells. Since the tolerance to the chimera 16 
was decreased under both stagnant and shaking growth conditions, and no slime pellet was observed 17 
in the latter, this phenomenon does not appear to be the cause of the observed increase in tolerance 18 
towards chimera 1.  19 
To determine whether the decrease in MIC in the presence of plasma was due to a synergistic 20 
activity between chimera and plasma, or a direct effect of plasma that caused enhanced susceptibility 21 
to the following treatment, we pre-incubated E. coli for 7 days (i.e. 50 generations) in MHB 22 
supplemented with 6.25 % plasma, and then performed time-kill using a concentration of ½×MIC. 23 
No change was seen in chimera inhibition of cells pre-incubated in plasma compared to cells pre-24 
12 
 
incubated in MilliQ water (not shown), neither at inoculum levels of 106 nor 107 CFU/mL (not 1 
shown).  2 
Effect of plasma components on chimera activity. The checkerboard method was used to test for 3 
synergy between chimera 1 and immune effector molecules: the LL-37 analogue KR-12, hydrogen 4 
peroxide, and lysozyme. However, neither of these compounds changed the MIC of the chimera (not 5 
shown). 6 
We hypothesised that complement activity in plasma could be the cause of increased sensitivity to 7 
chimera 1, and therefore we inactivated complement by heating (Hazen, 1943). Heat treatment 8 
completely abolished the effect of plasma on chimera activity (Table 1). The MIC of chimera 1 9 
against E. coli is 4 µg/mL when determined in MHB, but in 50 % plasma the MIC value decreased to 10 
0.125-1 µg/mL. In the presence of 50 % heat-inactivated plasma, the MIC value was 8 µg/mL (Table 11 
1). The development of the slimy pellet seen in 50 % normal plasma was not observed for E. coli 12 
grown in 50 % heat-inactivated plasma  13 
Effect of chimera resistance on the activity of blood plasma. Similarly to the ancestral wild type 14 
E. coli, from which the three resistant isolates had been developed, the resistant isolates were grown 15 
in a range of 25-50 % plasma. While the wild type grew well and formed a visible pellet at 50 % 16 
plasma concentration, the resistant isolates were not able to grow at plasma concentrations above 30 17 
%. At concentrations where the isolates were able to grow, a dense slime matrix of cells was formed, 18 
though less pronounced than for the wild type (Figure 2b versus 2d). Colony counts of cells 19 
recovered from wells with high plasma concentrations gave none or a very low number of surviving 20 
cells showing that high concentrations of plasma was bactericidal to the chimera-resistant isolates. 21 
When plasma was heat-treated as described above the mutants grew well in 50 % plasma similar to 22 
the wild type. Additionally, no changes were seen in the MIC of KR-12, hydrogen peroxide or 23 
lysozyme following acquisition of chimera resistance. Lastly, MIC determination was performed 24 
13 
 
against the three isolates in 25 % plasma to see whether the presence of plasma counteracted the 1 
mechanism of resistance. In 25 % plasma the MIC value of chimera 1 against the wild type E. coli 2 
was only marginally affected i.e. MIC was decreased from 4 µg/mL in MHB media to 1-2 µg/mL. 3 
However, MIC determined against the three resistant isolates decreased from 32 µg/mL in MHB 4 
media to 1 µg/mL in 25 % plasma. Hence, the presence of plasma was found to abolish the acquired 5 
resistance to chimera 1.   6 
 7 
 8 
DISCUSSION 9 
One of the major obstacles in using cationic AMPs as antimicrobial agents is their inactivation under 10 
physiologically relevant conditions. This inactivation may be caused by binding of the cationic 11 
AMPs to blood components (e.g. serum albumin) (Deslouches et al., 2005), degradation by proteases 12 
(Jenssen and Aspmo, 2008), or obstruction of bacterial membrane binding sites by divalent cations of 13 
dissolved salts (Friedrich et al., 1999). Since all of these processes may take place during circulation 14 
in the bloodstream, determination of the peptide activity in blood plasma provides a suitable simple 15 
model for in vivo systemic use of AMPs and peptidomimetics. 16 
 17 
We found that blood plasma potentiated chimera activity (Table 1) to a surprisingly high extent. The 18 
bacteriolytic activities of plasma are well-known (Taylor, 1983), however, microscopy revealed that 19 
E. coli cells were alive within the slime matrix formed during growth without shaking. We speculate 20 
that the matrix may be formed by the contents of lysed cells thereby protecting the other cells from 21 
plasma. Possibly, this might lead to a decreased initial cell number, which in turn then affects the 22 
MIC value. However, the notion that the slime matrix provides protection against the chimera is not 23 
likely since a similar result was obtained under shaken incubation conditions, where the slime matrix 24 
was not formed.  25 
14 
 
Synergy between chimera 1 and plasma components offers an alternative explanation for the 1 
increased activity of chimera 1 in the presence of plasma. Previously, we have shown  that α-2 
peptide/β-peptoid chimeras target the cell membrane and leads to leakage of intracellular contents 3 
(Hein-Kristensen et al., 2011). Many immune factors present in plasma (i.e. AMPs, lysozyme, 4 
complement) have a similar effect on the cell envelope though the exact mechanisms vary between 5 
different factors (Levy, 2000). In the present investigation we did not find evidence of synergy 6 
between the chimera and KR-12, lysozyme or hydrogen peroxide  (not shown) although synergy 7 
between antibacterial drugs and human AMPs has previously been shown (Mishra et al., 2011;Jones 8 
et al., 2008;Xiong et al., 1999). This is interesting since the cathelicidin LL-37 and lysozyme are 9 
both present in the blood at a concentration in the µg/mL range (Taylor, 1983;Zahner et al., 2010), 10 
and synergy could therefore have explained the observed decrease in MIC. However, heat-11 
inactivation of plasma, a method commonly used for eliminating complement activity (Hazen, 1943), 12 
rendered the plasma inefficient in reducing the MIC value of the chimera (Table 1). The bactericidal 13 
activity of the complement system stems from the formation of the membrane-attack-complex 14 
(MAC) that efficiently lyses intruding bacteria (Taylor, 1983;Kondos et al., 2010). Synergy between 15 
the complement system and AMPs (Yeaman et al., 2002;Fierer and Finley, 1979) or antibiotics 16 
(Darveau and Cunningham, 1990;Dutcher et al., 1978;Schweinle and Nishiyasu, 1992) has been 17 
reported, but it is not known whether this is due to the compounds acting in concert or sequentially. 18 
We did not find any effect of pre-exposure to plasma on the killing activity of chimera with low 19 
concentrations (6.25 %) of plasma, although sequentially enhanced activity of plasma and antibiotics 20 
has been shown by others (Dutcher et al., 1978). This indicates that the chimera and plasma 21 
components potentially act in concert, however, we have not tested the effect of opposite order (i.e. 22 
the effect of pre-exposure to chimera on subsequent plasma activity) so it is possible that chimera 23 
could prime the bacteria for complement activity, which has been demonstrated for antibiotics 24 
(Alexander et al., 1980;Taylor et al., 1981;Schweinle and Nishiyasu, 1992). In line with this, serum 25 
15 
 
has been shown to potentiate the post-antibiotic effect (Davidson et al., 1991). Furthermore, cationic 1 
AMPs similar to these chimeras, possess an ability to traverse the outer membrane of Gram-negative 2 
bacteria, and some studies have shown that this may lead to disintegration of the outer membrane 3 
structure even at low doses (Epand et al., 2008;Vaara and Vaara, 1983). If the integrity of the outer 4 
membrane is compromised due to chimera activity, this would facilitate insertion of MAC into the 5 
plasma membrane, providing a potential mechanistic explanation for the observed decrease in 6 
chimera MIC. Further studies are needed to validate the role of the complement system in the 7 
observed increase in chimera activity in the presence of blood plasma.  8 
  9 
One potential problem in using AMP peptidomimetics against systemic infections is that resistance 10 
to these compounds could potentially compromise our own immune defence since these compounds 11 
mimic the structure of our own defence peptides (Bell and Gouyon, 2003). We investigated this by 12 
using a resistant mutant of the same E. coli strain to determine whether acquisition of resistance 13 
influences the activity of innate immune factors present in the blood. Surprisingly, the growth of the 14 
three chimera-resistant isolates 2-7, 2-9 and 2-10 was significantly hampered in the presence of 15 
plasma. Hence, the acquisition of resistance to an AMP peptidomimetic in fact renders the bacteria 16 
more susceptible to at least the soluble components of the innate immune defence in blood plasma. 17 
The mechanism of resistance of these isolates is likely a single-nucleotide-polymorphism (SNP) in 18 
the gene for the membrane-bound lytic murein transglycosylase D (mltD) (Hein-Kristensen et al., 19 
2012), which is involved in reorganization of the peptidoglycan layer (Xu et al., 2011). We 20 
hypothesize that changes in the structure of the outer membrane confer an increased susceptibility to 21 
yet unknown membrane-acting plasma components. Inactivation of complement by heat treatment 22 
eliminated the bactericidal activity of plasma against the three chimera-resistant isolates. It is 23 
possible that changes in the organization of the peptidoglycan layer due to changes in the mltD 24 
protein leads to easier access of complement components and subsequent MAC insertion into the 25 
16 
 
plasma membrane. We were also interested in investigating chimera activity towards the resistant 1 
isolates in the presence of plasma. Interestingly, chimera resistance was abolished in the presence of 2 
25 % plasma, suggesting that the activity of plasma components renders the resistance mechanism 3 
against chimera activity ineffective. Plasma potentiation against resistant strains has been 4 
demonstrated for antibiotics (Odio et al., 1984). We suspect that the mechanisms behind this are 5 
similar to that for the chimera-susceptible strain.  6 
 7 
In conclusion, chimera activity was significantly increased when determined in a physiological 8 
environment, and under these conditions the resistance mechanism of chimera-resistant isolates was 9 
rendered ineffective. These results add further support to the therapeutic potential of the 10 
peptidomimetics and to AMPs in general. 11 
 12 
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Figure 1. Structure of chimera 1 
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Figure 2. Formation of slime matrix after stagnant growth of Escherichia coli ATCC 25922 (a and b), or one of 
the resistant isolates (c and d) with chimera 1 (a and c) or without chimera 1 (b and d). A more dense slime 
matrix was formed after addition of chimera 1, in particular for the resistant isolate (d). Light microscopy at 10× 
magnification showed release of contents after puncture of the slime matrix (e); 100× magnification clearly 
identified the contents as E. coli cells 
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Table 1. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration 
(MBC) of chimera 1 against E. coli grown in the presence/absence of human blood plasma 
Growth conditions MIC (µg/mL) MBC (µg/mL) 
MHB (stagnant) 4 4 
50 % plasma (stagnant) 0.125-1 1 
50 % inactivated plasma (stagnant) 8 8 
MHB (shaken) 8 8 
50 % plasma (shaken) 0.125 > 1 
Table 1. Minimum Inhibitory Concentration and Minimum Bactericidal Concentration against E. coli ATCC 
25922 in MHB media with/without 50 % human blood plasma under stagnant and shaken incubation 
conditions. Values were obtained from a minimum of two independent tests with two blood donors. Plasma was 
inactivated by heat treatment for 15 min at 56oC. 
 1 
